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ABSTRACT 
 
THE DEVELOPMENT, CHARACTERIZATION AND IMPLEMENTATION OF 
A REACTIVE OXYGEN SPECIES-RESPONSIVE RATIOMETRIC 
BIOLUMINESCENT REPORTER AND ITS USE AS A SENSOR FOR 
PROGRAMMED CELL DEATH 
 
 
Julie Czupryna 
 
Advisor:  Andrew Tsourkas, Ph.D. 
 
The process of programmed cell death (PCD) is a prevalent area of scientific research and 
is characterized by a highly complex proteolytic cascade.  PCD is involved in 
development, homeostasis and the immune response.  Further, unregulated PCD has been 
implicated in various, often, devastating pathologies including cancer, autoimmune 
diseases and neurodegenerative disorders.  The importance of PCD in human health and 
disease has led to the widespread utilization of genetically encoded reporters for the non-
invasive imaging of PCD in vitro and in vivo; however, it is currently not well understood 
whether the reporters themselves are susceptible to inactivation and/or degradation during 
PCD.  Molecular reporters that do exhibit an unexpected sensitivity to their environment 
could lead to ambiguous findings and/or inaccurate conclusions.  Interestingly, we have 
found that the commonly used bioluminescent reporter protein, Firefly Luciferase (fLuc), 
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exhibits a rapid loss in activity in cells undergoing PCD.  In contrast, a variant of Renilla 
Luciferase, RLuc8, demonstrated quite stable activity under the same conditions.  
Following extensive inhibition analyses, it was determined that reactive oxygen species 
(ROS), particularly hydrogen peroxide (H2O2), play a large role in the disparity between 
fLuc and RLuc8 activity, in cells undergoing PCD.  ROS are natural byproducts of 
oxygen metabolism that are normally regulated by antioxidants; if the balance between 
ROS and antioxidants becomes skewed, cells can enter a state of ‘oxidative stress.’  It has 
been reported that many cases of PCD are associated with elevated levels of ROS.  
Consistent with these reports, when fLuc and RLuc8 were intracellularly coexpressed, it 
was found that the bioluminescence ratio, RLuc8:fLuc, served as a useful metric to report 
on caspase-dependent and –independent PCD in vitro and in vivo in an ROS-mediated 
manner.  It is envisioned that this ratiometric reporter could have widespread impact on 
research endeavors involving the aforementioned maladies, including therapeutic 
development and evaluation. 
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Chapter 1: Introduction to bioluminescence imaging, 
programmed cell death and reactive oxygen species 
1.1 Introduction 
 Complete understanding of physiology and disease states requires the capability 
to monitor specific cellular and molecular phenomena over biologically relevant time 
scales.  Molecular imaging technologies provide investigators with the ability to non-
invasively examine a wide variety of biological processes, both in vitro and in animal 
models.  Bioluminescence imaging (BLI) is a molecular imaging modality wherein 
luciferase enzymes oxidize a substrate to produce light.  Attributes of BLI include high 
sensitivity, cost-effectiveness, simplicity, virtually non-existent background signals, high-
throughput screening potential and ability to acquire temporal information in cells and in 
live animal models.  While safety concerns regarding transgene expression preclude BLI 
usage in humans, it remains a powerful tool for pre-clinical in vivo imaging studies.   
Luciferases and their substrates have been engineered to report on gene 
expression levels, promoter activity and various other molecular processes, including 
programmed cell death (PCD), which is known as an exquisitely regulated ‘cell suicide’ 
mechanism.  PCD is the primary contributor to the removal of excessive and damaged 
cells and plays a role in development, aging and the immune response.  However, many 
pathologies can result from unregulated PCD including cancer, Alzheimer’s disease and 
autoimmune disorders.  Thus, the ability to monitor aberrant PCD could have widespread 
impact on the development of therapeutics for diseases characterized by this process.   
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We have found that in cells undergoing PCD, the activity of wild-type Firefly 
Luciferase (fLuc) is rapidly lost, and under the same conditions the activity of a Renilla 
Luciferase variant (RLuc8) remains relatively stable (Chapter 3).  Investigation into the 
mechanism behind this disparity suggested that reactive oxygen species (ROS), 
particularly hydrogen peroxide (H2O2), play a dominant role (Chapter 4).  Therefore it 
was hypothesized that when fLuc and RLuc8 were coexpressed in cells, their activity 
differential could be used in a ratiometric manner (i.e. RLuc8:fLuc) to relay information 
on intracellular ROS levels.  It is well established that certain chemotherapeutic agents 
can generate ROS in their induction of cell death and that ROS often serve as mediators 
in caspase-dependent and –independent pathways.  Consistent with these findings, we 
have found that levels of intracellular H2O2 increased in multiple cell types treated with a 
variety of PCD inducers and that this increase correlated well with RLuc8:fLuc ratios 
(Chapter 5 and Chapter 6). The implementation of the ratiometric reporter in murine 
models demonstrated that it was capable of detecting PCD in drug-treated tumors and 
that this detection was related to intratumoral ROS levels (Chapter 7).  In this chapter, 
extensive background is provided on BLI, PCD and ROS. 
1.2 Background 
1.2.1 Bioluminescence Imaging 
1.2.1a Overview 
In order to obtain comprehensive knowledge regarding normal and pathological 
physiology, it is important for biological processes related to these states to be monitored 
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in real-time and over biologically relevant time scales.  Molecular imaging techniques 
can facilitate the ability of investigators to non-invasively scrutinize the spatiotemporal 
dynamics of specific biological processes without sacrificing cells or animals (see (1) for 
extensive review).  The field of molecular imaging encompasses many modalities 
including magnetic resonance imaging (MRI), optical imaging, signal photon emission 
spectroscopy (SPECT), ultrasound, and positron emission tomography (PET). 
Bioluminescence imaging (BLI) is an optical molecular imaging modality that harnesses 
the light produced during enzyme (luciferase)-mediated oxidation of a substrate (e.g. 
luciferin or coelenterazine) when the enzyme is expressed in cells, tissues or animals (see 
(2) for review).  BLI has been utilized in studies examining tumor growth and 
metastasis(3), gene therapy(4), cell tracking(5), infection progression(6), gene 
expression(7) and toxicology(8), among others. 
1.2.1b Types of luciferases and their substrates 
 Various types of luciferases have been identified across diverse phyla; however, 
only a few of these have been characterized sufficiently for mammalian use.  Even 
though structures, sizes, substrates and emission wavelengths of these enzymes are quite 
varied, their mechanisms of light production are generally similar:  during the oxidation 
of luciferin or coelenterazine by luciferase, an excited intermediate is generated and upon 
its relaxation to ground state, it emits a photon of light(9).  The most commonly used 
luciferases and key attributes are highlighted in Table 1.1. 
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Table 1.1.  Common luciferases and selected characteristics.  Adapted from (2). 
Luciferase Luciferin 
Peak 
emission 
(nm) 
Size 
(kDa) 
Comments Reference(s) 
Firefly 
(fLuc) 
D-luciferin 612 61 Codon-optimized for 
mammalian 
expression; requires 
ATP 
(10) 
Click beetle 
red (cbRed) 
D-luciferin 611 61 Requires ATP (10, 11) 
Click beetle 
green 
(cbGreen) 
D-luciferin 544 61 Requires ATP (10, 11) 
Renilla 
reniformis 
(RLuc) 
Coelenterazine 480 36 Does not require 
ATP; codon-
optimized for 
mammalian 
expression 
(9, 11, 12) 
Gaussia 
princes 
(gLuc) 
Coelenterazine 480 36 Does not require 
ATP; naturally 
secreted from cells 
(12) 
 
The luciferases from Firefly (fLuc) and Renilla reniformis (RLuc) are two of the 
most widely used bioluminescent proteins in current research.  Fluc emits light at ~600 
nm making it more suitable for in vivo imaging compared with the ~480 nm light emitted 
by RLuc, as fLuc photons are less absorbed by animal tissue.  To produce light, fLuc 
must react with its substrate, luciferin, in the presence of ATP, oxygen and magnesium.  
RLuc requires its substrate, coelenterazine, and oxygen to produce light.  The emission 
spectra of the luciferases are depicted in Figure 1.1.   
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Despite the low emission wavelength of RLuc, both fLuc and RLuc are 
commonly used together in both cell culture(13) and in vivo(14), with RLuc often serving 
as a transfection control for studies involving fLuc under the control of a specific 
promoter, and vice verse.  The distinct substrates of these enzymes also allow for their 
use in this manner since after washing or clearance of the substrate for the first enzyme 
examined, a second substrate may be administered to specifically examine the second 
enzyme (see Table I). An alternative to washing/clearance involves using spectral 
separation to distinguish the signal from each protein.  Each luciferase emits at a different 
wavelength of light; thus if the imaging equipment possesses emission filters appropriate 
for each enzyme, substrates can be administered at the same time, and each signal can be 
spectrally separated. 
1.2.1c BLI: general considerations 
There are many advantages of utilizing BLI as a molecular imaging modality.  
Since bioluminescent proteins are genetically encoded, once validated, they can be 
employed in a range of vectors to investigate a wide variety of intracellular pathways(15-
17).  A study using BLI to examine intracellular pathways involved heat shock proteins 
(HSPs), which are proteins utilized in cellular heat shock response.  Heat shock response 
Figure 1.1.  Emission spectra of various bioluminescent proteins.  Adapted from (10). 
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occurs in cells undergoing thermal and other stresses and can abrogate resulting cellular 
damage and programmed cell death (see (18) for review).  This group used transgenic 
mice expressing fLuc under the control of an HSP promoter to assess spatiotemporal 
patterns of HSP70 expression after thermal stress induced by laser irradiation(17).  BLI 
has been used to investigate many other promoters in addition to HSP, including β-
catenin promoters(19), insulin promoters(20), ubiquitin promoters(21) and hepatitis B 
virus promoters(22).  
BLI has been used in conjunction with positron emission tomography (PET) to 
examine tumor hypoxia and related molecular events (15).  Tumor hypoxia was 
monitored using a hypoxia-sensitive PET tracer, followed by investigation of hypoxia 
inducible factor (HIF), a transcription factor that helps tumor cells adapt to low oxygen 
environments(23), using BLI.  Specifically, a fusion protein of HIF-1α-luciferase was 
monitored to assess the stability of HIF-1α, the subunit of HIF that is a target for 
degradation under normoxic conditions and stabilization under hypoxic conditions(24).  
In the same study, the gene encoding fLuc was placed downstream of a hypoxia response 
element (HRE) promoter to monitor HIF-driven gene expression. 
The optical properties of some bioluminescent proteins allow for depths of up to a 
few centimeters to be imaged in vivo(25, 26).  The emission wavelength of fLuc is ~600 
nm, making it less likely than fluorescent light to be attenuated in animal tissue.  Tumor 
cells expressing fLuc have been imaged in rat colon(25) and mouse lungs(26), illustrating 
the potential of BLI to image beyond superficial depths in vivo.  Also, the intrinsically 
low bioluminescence of tissues allows for greater signal-to-background ratios compared 
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to fluorescence.  For example, when using fluorescence imaging, the autofluorescence of 
tissues causes unwanted background signal, effectively reducing this ratio.   
In addition to its cost-effectiveness, robustness and simplicity, BLI has recently 
proven to be quite useful in high-throughput screening assays(27-29).  For example, 
malignant cells expressing fLuc were co-cultured with non-fLuc stromal cells and this co-
culture was screened with anti-neoplastic candidates(27).  Here, it was possible to 
specifically identify the effects of the compounds on malignant cells in an environment 
more representative of in vivo conditions as tumor-stroma interactions play key roles in 
tumor biology(30, 31).  This ability to distinguish between cancerous and normal cells 
using this method holds an advantage over traditional viability assays (discussed later) 
where the high background of the stromal cells could skew information on malignant cell 
viability. 
However, like any imaging modality, BLI possesses certain disadvantages that 
should be considered before its use in study design.  Safety concerns preclude genetically 
encoded reporters (including bioluminescent proteins) from being used in humans, with 
the exception of gene therapy.  Additionally, while the multi-centimeter depth penetration 
of bioluminescent proteins is greater than that of fluorescent molecular reporters, it 
nonetheless limits their in vivo application to small rodents.  Another consideration 
regarding BLI is the potential for the proteins themselves to interfere with intracellular 
processes and possible phenotypic changes.  Notably, it has been shown that colon cancer 
cells expressing fLuc were unable to grow into tumors in immunocompetent rats as 
opposed to parental colon cancer cells(32); it was hypothesized that the high expression 
levels of fLuc created unwanted immunogenecity and/or altered growth rates.  Finally, 
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issues with substrate administration include altered substrate catalysis and 
pharmacokinetics due to disease states and cellular transporters, respectively.  The tumor 
microenvironment is often hypoxic, and since the fLuc-luciferin reaction is oxygen 
dependent, this reaction may be impeded and resulting light output diminished.  
Additionally, the cellular membrane pumps ABCG2(29) and MDR1 P-glycoprotein(33) 
have been shown to transport luciferin and coelenterazine, respectively, out of cells, 
potentially hindering light output of the bioluminescent enzymes.  Taken together, these 
issues can lead to inaccurate findings and ambiguous conclusions. 
1.2.2 Programmed Cell Death 
1.2.2a Overview 
 Programmed cell death (PCD) is a major contributor to the removal of excessive 
and damaged cells through an exquisitely regulated ‘cell suicide’ mechanism and is an 
essential process that is involved in development(34), aging(35), homeostasis(36) and the 
immune response(37).  Apoptosis, or Type I PCD, is mechanistically characterized by a 
proteolytic cascade involving cysteine-aspartic proteases (caspases)(38); these caspases 
can be distinguished by the specific amino acid sequences wherein they cleave(39).  
Many types of caspases can be activated during apoptosis, however, the activation of 
caspase-3, an effector caspase, is required to complete the process (40); this necessity 
makes caspase-3 an often utilized target in studies assessing PCD.  Additional 
characteristics of apoptosis include membrane blebbing, chromatin condensation, and 
nuclear fragmentation and the process ends with phagocytic engulfment of the dead cell 
and debris(36). 
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While apoptosis has been thoroughly characterized and is generally accepted as 
the most prevalent form of PCD, a number of alternative cell death pathways have been 
identified and are referred to as ‘caspase-independent cell death pathways’.  These 
pathways serve many purposes in vivo including embryonic removal of interdigital 
webs(41), the death of chondrocytes controlling bone growth(42), and the negative 
selection of lymphocytes(34, 35).    
One form of caspase-independent PCD involves the mitochondria.  Under certain 
stimuli the mitochondria release the apoptosis-inducing factor (AIF) from the 
intermembrane space(43); AIF enters the nucleus and eventually causes the degradation 
of chromatin into large (50 kb) chromatin fragments, in contrast to the oligonucleosomal 
DNA fragments that are formed when certain DNase’s are activated by caspases(43, 44).  
The exact mechanism behind chromatin degradation by AIF remains unknown.  Another 
mitochondrial-related PCD mechanism involves signaling from the tumor necrosis factor 
receptor 1 resulting in mitochondrial production of reactive oxygen species (ROS) and 
necrosis-like PCD(40). 
Autophagy, or type II PCD, is a type of caspase-independent cell death that 
mechanistically manifests cellular metabolism through the cell’s own lysosomal 
machinery (see (45) for review).  In cells undergoing type II PCD, autophagic vesicles 
are formed to engulf various cytoplasmic components and these vesicles subsequently 
fuse with lysosomes to form autophagolysosomes.  Various digestive enzymes are 
present in the lysosomal machinery, including aspartate, zinc and cysteine proteases 
(cathepsins), which are responsible for macromolecule breakdown.  Autophagy can play 
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multiple roles as it can be a method for cells to adapt to cellular stresses and avoid 
apoptosis, or it can be an alternative method of PCD if apoptosis is inhibited(46). 
Figure 1.2 illustrates pathways involved in both caspase-dependent and caspase-
independent cell death.  Caspase-dependent PCD can result from various onslaughts; 
however, regardless of induction method, this process is characterized by the activation 
of initiator caspases (e.g., caspases-2 and –8), eventually leading to the activation of 
effector caspases (e.g., caspase-3).  Various stimuli can also induce caspase-independent 
PCD, however this type of cell death is usually characterized by increased proteolysis.  
ROS production and DNA damage can play prominent roles as well. 
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Given the myriad processes in which PCD is involved, it is not surprising that 
unregulated PCD can result in various devastating pathologies, including autoimmune 
diseases, neurodegenerative disorders, and cancer (see (48) for review).  Table 1.2 lists 
conditions that may result from either increased or inhibited PCD.  Accordingly, many 
sensors have been developed to monitor and image PCD both in vitro and in vivo with the 
Figure 1.2.  Illustration of caspase-dependent and caspase-independent PCD pathways. Reprinted with 
permission from (47). 
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impression that these sensors will aid in the development and evaluation of therapeutics 
designed to combat the many ailments associated with unregulated PCD.   
 
Table 1.2.  Pathogenic conditions related to PCD. 
 Condition Reference(s) 
Cancer 
Carcinomas with p53 mutations 
Hormone-dependent tumors 
Breast 
Prostate 
 
(49, 50) 
 
(51) 
(52) 
Autoimmune diseases 
    Lupus 
 
(53) 
P
C
D
 i
n
h
ib
it
io
n
 
Viral Infection 
Poxviruses 
Adenoviruses 
 
(54) 
(55, 56) 
AIDS (49-51) 
Neurodegenerative disorders 
Alzheimer’s disease 
Huntington’s disease 
 
(52-54) 
(55, 56) 
In
cr
ea
se
d
 P
C
D
 
Ischemic Injury 
Myocardial Infarction 
Stroke 
 
 
(57, 58) 
(57, 59) 
 
1.2.2b Current Sensors for Apoptosis 
Over the past decade, a large number of probes have been specifically developed 
for assessing apoptosis in cell culture and animal model studies.  Since apoptosis occurs 
via a complex signaling cascade that is tightly regulated, these probes have been designed 
to take advantage of a number of different molecular targets to identify apoptosis.  Some 
of the most commonly used agents involve measuring the level of caspase activity.  
These probes can generally be categorized as fluorogenic peptide probes, fluorescent 
molecular reporters, or bioluminescent reporters.  However, not all sensors for apoptosis 
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rely on caspase activity.  Phosphatidylserine (PS) targeting agents are designed to detect 
PS phospholipids that have flipped from the inner-leaflet to the outer-leaflet of 
membranes of cells undergoing apoptosis.  Also, various commercial sensors are 
available to detect DNA fragmentation levels, dead-cell proteases and enzymes related to 
cellular viability.  The following subsections will expand upon each of these types of 
sensors. 
Fluorogenic Peptide Probes 
Fluorogenic peptide probes for caspases are typically comprised of a peptidic 
protease substrate, e.g. a caspase recognition motif, intervening between two 
fluorophores or a fluorophore and a quencher(57-63).  Peptidic cleavage by the target 
enzyme separates the fluorescent/quenching moieties and the subsequent change in the 
fluorescent emission spectrum is used to indicate enzymatic activity.  Figure 1.3 
represents a schematic of fluorogenic peptide probes for caspase-3; a quencher is attached 
to a fluorophore via a DEVD amino acid linkage, effectively quenching the fluorescence 
of the excited fluorophore.  After caspase-3 cleavage of DEVD (its recognition 
sequence), the quencher is removed and the fluorophore emission is restored. 
 
 
 
 14 
While fluorogenic peptide probes represent an important breakthrough in caspase 
activation detection, their sensitivity can be less than ideal, due to incomplete quenching 
before cleavage or spectral overlap of the two fluorophores in fluorescence resonance 
energy transfer (FRET)-based assays.  Additional problems are manifested in vivo where 
autofluorescence of the living subject and/or pharmaceuticals can further reduce 
sensitivity.  As both caspase activity and the biodistribution/pharmacokinetics of these 
probes affect the fluorescence intensity over time, imaging the temporal dynamics of 
apoptosis using these sensors can be challenging.  Finally, cytoplasmic delivery of these 
probes can present additional issues as they may become non-specifically trapped and 
degraded in the lysosomes. 
 
Figure 1.3.  Schematic of a fluorogenic peptide probe for caspase-3.  A fluorophore is conjugated to a 
quenching molecule via the DEVD amino acid sequence.  Thus when excited, the fluorophore’s emission is 
quenched.  However upon caspase-3 mediated cleavage of its target sequence, DEVD, the quencher is 
released and the fluorophore emits light. 
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Fluorescent Molecular Reporters 
 Another category of fluorescent imaging sensors for apoptosis consists of 
fluorescent molecular reporters (64-66).  These probes are defined by two fluorescent 
proteins with overlapping emission-excitation wavelengths that are linked by a protease-
specific recognition sequence.  For example, the emission spectrum of cyan fluorescent 
protein (CFP) significantly overlaps the excitation spectrum of yellow fluorescent protein 
(YFP).  When these two proteins are in close proximity (i.e., connected by the amino acid 
sequence DEVD), the excitation of CFP results in emission from YFP, as a result of 
FRET.  This phenomenon is depicted in Figure 1.4A.  The tethering of YFP to CFP with 
DEVD effectively creates an activatable sensor for caspase-3; with increasing caspase-3 
activation, the DEVD sequence is cleaved, the proteins separate, YFP emission decreases 
and CFP emission increases with CFP excitation(66).  A summary of this mechanism is 
illustrated in Figure 1.4B.   
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Fluorescent molecular reporters are genetically encoded, thus their synthesis costs 
are typically less than fluorogenic peptide probes.  Another advantage of these reporters 
is their constitutive expression reduces their chances of lysosomal degradation and 
endosomal entrapment, two concerns of fluorogenic peptide probes.  However 
fluorescent molecular reporters still suffer from similar background and autofluorescence 
issues, especially given the dearth of highly fluorescent near-infrared (NIR) molecular 
reporters available.  It should be noted that very recently, an NIR fluorophore has been 
developed that could allow for much improvement on these sensors in regards to in vivo 
imaging capability(67). 
Figure 1.4.  Schematic of FRET and its use in a reporter for caspase-3 activity.  (A) In an activatable 
reporter for caspase-3 activity, CFP and YFP are fused together via the DEVD sequence, resulting in 
FRET.  (B) Upon caspase-3 activation, its target DEVD sequence is cleaved, and CFP emission increases 
as the distance between the fluorophores increases (i.e., FRET is no longer occurring). 
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Bioluminescent Reporters 
 To avoid sensitivity issues commonly associated with fluorogenic sensors, several 
groups have recently employed bioluminescent caspase reporter systems for PCD 
detection.  One of these sensors utilized a recombinant Firefly luciferase (fLuc) reporter 
protein that was flanked on both sides by an estrogen receptor regulatory domain protein 
(ER)(68).  The presence of these two large ER proteins (35 kDa each) effectively 
silenced the enzymatic activity of fLuc by ~90%.  Additionally, a DEVD sequence was 
included between fLuc and each ER protein, which allowed for caspase-3 mediated 
removal of the silencing ER domains and thus restoration of fLuc activity.  An 
illustration of this sensor is shown in Figure 1.5. 
Figure 1.5.  Schematic of ER-fLuc-ER sensor for caspase-3.  Under normal cellular conditions, the large 
ER proteins flank the fLuc protein via DEVD linkages, hindering its enzymatic activity.  When caspase-3 is 
activated in PCD inducing conditions, the DEVD sequences are cleaved, the ER proteins are released and 
fLuc activity is restored. 
 18 
A number of drawbacks to this design exist, including that two proteolytic events 
are required to completely restore luciferase activity, the protease cleavage sites may be 
inaccessible due to the large flanking ER proteins, and that the usage of ER proteins 
themselves, which are endogenously expressed in mammalian cells, could provoke overly 
complex intracellular localization/dynamics, potentially leading to alternative proteolytic 
pathways and ambiguous bioluminescent signals.  Furthermore, it should be noted that 
although the fLuc bioluminescence increases with increasing caspase-3 activity, this may 
be abrogated by accelerated degradation of functional enzyme under apoptotic 
conditions, as observed in this thesis. 
 Another bioluminescent approach for imaging apoptosis via caspase-3 activation 
in vivo made use of a split fLuc reporter strategy (69). In this sensor, fLuc is expressed in 
two parts, NH2- and COOH-terminal sections, rendering it functionally inactive.  When 
the two halves are brought into close enough proximity, enzymatic activity is restored, 
producing a bioluminescent signal in the presence of proper substrate.  In the apoptotic 
probe design, small, yet strongly interacting, peptides and the DEVD sequence were 
incorporated to create a caspase-3 activatable sensor(70).  Specifically, strongly 
interacting peptides, peptide A and peptide B (71, 72), were fused to the N- and C-
terminal halves of fLuc, respectively, creating ANLuc and BCLuc (Figure 1.6).  These 
fusions are positioned sequentially with and intervening DEVD sequence.  Under 
apoptotic conditions, active caspase-3 cleaves at the DEVD site, which allows peptide A 
and peptide B to interact, effectively bringing the fLuc halves into favorable proximity, 
and the bioluminescence activity of fLuc is restored.   
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Although this probe exhibits improvements over previous split reporter 
technologies, where drawbacks can include high-background and non-ideal signal-to-
noise ratios (73), the requirement of two explicit events (i.e., DEVD cleavage and 
peptideA-peptideB interaction) to generate a functionally indicator of cell death, and the 
potential for an accelerated rate of enzyme degradation in cells undergoing PCD may 
present unforeseen difficulties in the utilization of this sensor. 
Figure 1.6.  Schematic of split fLuc reporter for caspase-3.  Under normal conditions, the NH2- and 
COOH-terminal sections of fLuc (NLuc and CLuc, respectively) are attached to small, strongly 
interacting peptides (PePA and PepB) with and intervening DEVD sequence.  Under apoptotic 
conditions, caspase-3 is activated and cleaves the DEVD sequence.  The fLuc fragments are separated 
and PepA and PepB interact to bring the fragments into close enough proximity to reconstitute the 
activity of the fLuc enzyme. 
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 Another activatable bioluminescent sensor for apoptosis that has found success in 
vivo makes use of the DEVD sequence conjugated to aminoluciferin(74, 75).  This 
conjugation renders the luciferin unable to act as a proper substrate for fLuc until the 
peptide sequence is cleaved off upon caspase-3 activation.  This method allowed for the 
detection of caspase-3 in murine tumor models, however some potential limitations must 
be addressed.  First, it has been reported that the DEVD-luciferin is toxic to the 
animals(74, 75), forcing all imaging experiments to be ceased 2 hours after DEVD-
luciferin injection, thus limiting the temporal dynamic range of this sensor significantly.  
Additionally, extraneous background signal due to nonspecific degradation in serum, 
extracellular space, lysosomes and non-apoptotic cells may decrease the sensitivity of this 
approach.  Also, the peptide conjugation may affect the biodistribution and 
pharmacokinetics of the caged aminoluciferin and this reagent can be quite cost-
inefficient. 
 
Phosphatidylserine Targeting Agents 
Phosphatidylserine (PS) is a phospholipid that is typically found in the inner-
leaflet of cell membranes.  In apoptotic cells, PS is often flipped to the outer leaflet of the 
cell membrane(76).  This biological phenomenon has brought about the use of PS as a 
molecular marker for apoptotic cells, most commonly with Annexin V, a naturally 
occurring protein with avid binding affinity for PS(77).  It has been found that apoptotic 
cells can be detected in vivo by labeling Annexin V with various contrast agents, 
including fluorescent dyes(78), iron oxide nanoparticles(79), technetium 99m(80) and 
PET agents(81).  The cost-effectiveness of the fluorescently labeled Annexin V make 
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them an attractive choice for the routine imaging of apoptosis; however autofluorescence 
remains a concern, as does the non-specific localization of the labeled Annexin V agents 
in untreated tumors due to the enhanced permeability and retention (EPR) effect.  
Commercial Sensors for Apoptosis 
 Many commercial sensors have been developed to investigate apoptosis and its 
related molecular processes. The terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay, first developed in 1992(82), detects DNA strand breaks after 
terminal deoxynucleotidyl transferase (TdT) incorporates labeled dUTP at break sites; 
DNA fragmentation is a hallmark of cells undergoing PCD(83).  CytoTox Glo is a 
bioluminescent assay that measures the activity of certain intracellular proteases (dead-
cell proteases) that are released from cells with compromised membranes.  Additionally, 
assays that measure the reduction of various tetrazolium salts, such as MTT(84), 
XTT(85) and WST-1(86), by intracellular dehydrogenases which are active only in living 
cells are commonly used.  However, it is important to note that these reduction assays are 
actually a measure of cell viability as opposed to cell death.  Although all of these assays 
clearly have utility in measuring PCD in cell culture, most of them are not appropriate for 
real-time imaging/detection and/or imaging in animal models of disease.  These 
limitations arise from the need for cell lysis, the use of membrane impermeable 
substrates, and/or the use of green fluorescent dyes, which are generally masked by 
autofluorescence in vivo.    
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1.2.2c Current Sensors for Caspase-Independent PCD 
 While caspase-3 activation is considered a gold standard for identification of cells 
undergoing apoptosis, caspase-independent PCD has recently been attracting attention in 
regards to cancer drug development.  Anticancer drug resistance and tumorigenesis have 
been linked to the ability of certain cancer types to evade caspase activation(87, 88); thus 
it can be envisioned that therapeutics developed to induce caspase-independent PCD 
could have widespread impact.  To date, there exist no molecular imaging sensors to 
specifically monitor caspase-independent PCD in vivo.  Certainly, some of the 
aforementioned assays, namely TUNEL, CytoTox-Glo, MTT, and WST-1 have the 
capability to provide information on caspase-independent cell death, but suffer from the 
same previously mentioned limitations.   
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1.2.3 Reactive Oxygen Species, Oxidative Stress and Cell Death 
1.2.3a Overview 
 Reactive oxygen species (ROS) are natural byproducts of intracellular metabolic 
processes, such as oxidation of xanthine by xanthine oxidase(89), uncoupling of the 
mitochondrial transport chain(90, 91) and oxidation of NADPH by NADPH oxidase(92, 
93), and have been shown to play a role in cell signaling and function(94-96).  For 
example, it has been shown that the growth factors tumor necrosis factor alpha (TNF 
alpha) and basic fibroblast growth factor (bFGF) induce increases in ROS production in 
chondrocytes(97).  The ROS production seen here can stimulate the expression of early 
response genes (e.g., c-fos and c-jun), which play roles in cell proliferation and 
differentiation.  Types of ROS include the hydroxyl radical (
•
OH), the superoxide radical 
(O2
•-
), hydrogen peroxide (H2O2) and the peroxynitrite anion (ONOO
-
).  In a balanced 
cellular state, the level of ROS is typically controlled by various antioxidants that are 
either expressed in cells (e.g. glutathione(98), superoxide dismutase(99) and 
catalase(100)) or supplied through diet (e.g. vitamin E(101) and β-carotene(102)).  When 
unnecessary excesses of ROS are present, cells enter a state of ‘oxidative stress,’ wherein 
various cellular components can be damaged, including DNA(103), RNA(104), 
proteins(101-104) and lipids(105).  Pathological conditions that have been linked to 
oxidative stress include atherosclerosis(106), cancer(107), cystic fibrosis(108), type-2 
diabetes(109) and Alzheimer’s disease(110).   
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1.2.3b Protein modification, damage and degradation by ROS 
While ROS-mediated damage of DNA, RNA and lipids are significant topics for 
discussion, the body of work included in this thesis focuses on the effects of oxidative 
stress on proteins.  A summary of common ROS and mechanisms of protein oxidation is 
provided in Figure 1.7 and these mechanisms are described in more detail in subsequent 
sections. 
 
Superoxide 
Superoxide (O2
•-
) is the primary free radical formed within the cell by the 
reduction of molecular oxygen and it can act as either an oxidant or reductant.  The 
mitochondria produce a large fraction of this radical (see (111) for review) due to their 
consumption of oxygen to produce energy for the cell.  However, O2
•-
 is not particularly 
reactive in biological systems and does not itself cause much oxidative damage(112), 
Figure 1.7.  Schematic representing potential pathways for intracellular protein modification and/or 
degradation. 
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rather it serves as a precursor to other oxidizing agents.  The principal reaction of O2
•-
 is 
to react with itself to produce H2O2 and oxygen (O2), a reaction known as dismutation.  
Superoxide dismutation can be spontaneous or can be catalyzed by superoxide dismutase 
(SOD, (99)).  Additionally, O2
•-
 is important in the production of the highly reactive 
hydroxyl radical (
•
OH).  In this process, O2
•-
 reduces 
 
metal ions (e.g. Fe
3+
  Fe
2+
) by 
donating one electron, and these metal ions then act as catalysts to convert H2O2 into 
•
OH. 
 
Hydrogen Peroxide 
Hydrogen peroxide (H2O2) is a natural byproduct of oxygen metabolism and is 
necessary for the function of many enzymes in the intracellular environment (e.g. protein 
tyrosine phosphatases and the lipid phosphatase PTEN)(113).  An important attribute of 
H2O2 is that it is small enough to pass through cell membranes and thus cannot be 
excluded from cells.  H2O2 is a powerful oxidizing agent that can directly and indirectly 
modify many amino acids (see (114) for review), often creating hydroxyl- or carbonyl-
derivatives.  While the effect of protein oxidation can vary, it has been shown in some 
cases that oxidation can destabilize a protein’s native structure and result in the 
impairment of protein function and activity loss(115, 116).  Loss of secondary structure 
has also been shown to enhance the rate of protein degradation by the 20S 
proteasome(117).  In contrast, the presence of oxidized amino acids alone does not seem 
to be a signal for degradation even though in vitro studies have suggested that proteins 
oxidized by H2O2 may be more susceptible to proteolytic attack(118).  It should also be 
noted that in the presence of peroxidase (e.g. myeloperoxidase, lactoperoxidase and 
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cyclooxygenase) H2O2 can also produce tyrosyl radicals, which can subsequently 
dimerize to form dityrosine, which can further lead to protein cross-linking and 
aggregation(119-121). 
 
Hydroxyl Radical 
The hydroxyl radical (
•
OH) is generally considered to be the most powerful 
oxidizing species in biological systems, and similarly to H2O2, can also pass through 
membranes and thus cannot be kept out of cells.  The oxidative attack of protein 
backbones is initiated by the 
•
OH-dependent abstraction of the α-hydrogen atom of an 
amino acid residue to form a carbon-centered radical(122).  Here, the 
•
OH may be 
created by the radiolysis of water or the metal-catalyzed cleavage of H2O2.  In biological 
systems, the majority of 
•
OH radicals are produced when iron or copper react with H2O2, 
commonly referred to as the Fenton reaction. 
 Once a carbon-centered radical is formed, it can give rise to protein cross-links, 
peptide-bond cleavage (via diamide or α-amidation pathways), or direct oxidation of 
amino acids(122).  The direct oxidation of lysine, arginine, proline and threonine residues 
may result in the formation of carbonyl derivatives (e.g. semialdehydes)(121, 122).  
Alternatively, carbonyl groups may be introduced into proteins by reactions with 
aldehydes produced during lipid peroxidation(123) or with other reactive carbonyls 
generated by the reduction or oxidation of carbohydrates(109).  Lipid peroxidation 
products can diffuse across membranes, thus allowing amino acids and proteins relatively 
far from the initial site of peroxidation product formation to be modified(124).  
Interestingly, protein carbonylation as a result of lipid-derived aldehydes is more 
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prevalent than carbonylation from direct amino acid oxidation(125).  The degradation of 
carbonylated proteins typically occurs via the 20S proteasome; however, the 26S 
proteasome has also been shown to play a role in the degradation of oxidatively modified 
proteins(126, 127). 
 Besides the direct effect of 
•
OH on proteins, they may also damage and 
destabilize lysosomal membranes, causing the subsequent release of moderate amounts of 
lysosomal hydrolytic enzymes into the cytosol(128, 129).  The release of some of these 
enzymes, namely cathepsins, has been implicated in PCD(130, 131).  Recently, it has 
been suggested that an intralysosomal pool of redox-active iron is also released upon 
lysosomal permeabilization, which can lead to the further production of 
•
OH if reacted 
with intracellular H2O2(132).   
 
Peroxynitrite  
Peroxynitrite (ONOO-) is formed as a result of the reaction between O2
•-
 and 
nitric oxide (NO)(133).  ONOO- can be cytotoxic through various mechanisms including 
initiating lipid peroxidation(134), ssDNA cleavage(135) and glutathione depletion(136).  
Methionine and cysteine residues are especially vulnerable to oxidation by ONOO-, 
however tyrosine and tryptophan residues are also selective targets for nitration(122).  
Tyrosine nitration is particularly damaging to cells because it can interfere with protein 
phosphorylation, thus compromising intracellular signal transduction networks(122, 137).  
As with previously mentioned ROS, mild ONOO- modification leads to the selective 
recognition and degradation of proteins by the proteasome(138). 
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1.2.3c Common Probes for Imaging ROS/Oxidative Stress 
Leuco dyes and fluorescein derivatives 
There currently exist a number of activatable fluorescent probes for detecting 
ROS.  Many of these sensors fall under the category of non-fluorescent leuco dyes, i.e. 
‘dihydro’ derivatives of fluorescein, rhodamine and other dyes that are oxidized back to 
the parent dye by some ROS.  Even though these probes have been used to detect 
oxidative activity in cells and tissue, their oxidation sometimes does not easily 
discriminate between the various types of ROS.  It has been reported that 
dihydrodichlorofluorescein (H2DCF) and dihydrorhodamine 123 (DHR) only react with 
intracellular H2O2 in reactions mediated by peroxidase, cytochrome c or Fe
2+
, rather than 
with H2O2 alone (139-141).  Additionally, it has been reported that DHR can also be 
rapidly oxidized by ONOO-(142).  It has been shown that dihydroethidium (DHE) and, 
more recently, the mitochondrial-targeted derivative of DHE, MitoSOX Red, can provide 
a more specific signal for superoxide(143, 144); however, the need for these dyes to be 
excited with a wavelength of 494-510 nm likely prevents their usage in animal models. 
 While not as commonly utilized as H2DCF, aminophenyl fluorescein (APF) and 
hydroxyphenyl fluorescein (HPF) tend to show much more specific reactivity and greater 
resistance to light-induced oxidation than leuco dyes(145).  Until reaction with 
•
OH or 
ONOO-, these fluorescein derivatives are essentially non-fluorescent.  Also, since APF 
also reacts with the hypochlorite anion (-OCl), it is possible to use APF and HPF 
concomitantly to selectively detect –OCl(145), an ROS not only well-known in 
neutrophil killing of bacteria, but also in microvascular damage caused by platelet-
activating factor(146).  As with the leuco dyes, the excitation wavelengths of these 
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fluorescein derivatives (494 nm) likely limit their usage to in vitro assays.  Table 1.3 
summarizes the leuco dyes and fluorescein derivatives for ROS detection.   
 
Table 1.3.  Summary of leuco dyes and fluorescein derivatives for ROS detection. 
Reporter ROS Detected λEx/λEm (nm) 
H2DCF H2O2 494/518 
DHR H2O2 505/534 
DHE O2
•-
 510/595 
MitoSox Red O2
•-
 510/580 
APF •OH, ONOO-, -OCl 494/518 
HPF •OH, ONOO- 494/518 
 
Luminol and lucigenin 
Luminol and lucigenin are chemiluminescent compounds that have been used to 
report the presence of ROS(147-149).  However, a problematic characteristic of these 
sensors is the requirement of two steps for light emission(150, 151).  First, either luminol 
must be oxidized by 
•
OH(152), ONOO-(153), or peroxidase/H2O2(154) or lucigenin must 
be reduced by xanthine oxidase(150), the mitochondrial electron transport chain(155) or 
NADPH oxidase present in phagocytes(156).  Then, the resulting radicals must react with 
O2
•-
 to generate a light-emitting product.  The intermediate radicals present complicating 
issues as they can themselves reduce oxygen to O2
•-
.  Therefore, luminol and lucigenin 
can be both sources and detectors of O2
•-
, which can obviously lead to ambiguous results.  
Despite these complications, luminol was recently reported to be a successful method to 
image myeloperoxidase activity in animal models(157). 
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Electron Spin Resonance 
Electron spin resonance (ESR) spectroscopy is an imaging technique for species 
that have one or more unpaired electrons, analogous to the spins of atomic nuclei in 
nuclear magnetic resonance.  Theoretically ESR can be used to image ROS in living 
subjects, however ROS generally do not accumulate enough to be detected(158).  To 
overcome this issue, ROS ‘traps’ have been developed to intercept reactive/unstable 
radicals and react with them to form stable radicals that can thus be detected by ESR(159, 
160).  While initially promising, ROS traps suffer from numerous drawbacks including 
loss of the ESR signal by enzymatic and/or molecular reductions, potential toxicity from 
the high concentration of traps needed to generate an ESR signal and perturbations of the 
traps on normal physiological function(158). 
 
Luciferase-based sensors 
The commercial assay GSH-Glo (Promega) is the only luciferase-based assay 
designed to investigate oxidative stress; it detects intracellular glutathione (GSH) levels, 
which generally tend to decrease in the presence of reactive species.  This assay involves 
the cleavage of an inactive luciferin derivative by GSH to render the native form of 
luciferin.  The luciferase provided in the assay can then catalyze the luciferin and produce 
a bioluminescent signal.  However there are currently no established luciferase-based 
sensors designed to directly detect ROS.  If achieved, luciferase-based sensors could offer 
many advantageous attributes including cost-effectiveness, high sensitivity, simplicity 
and ability to garner temporal information in cells and animal models.  Given that current 
ROS imaging techniques are quite limited in their ability to provide information in vivo, 
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it is expected that a luciferase-based sensor would provide unique insight into the role of 
ROS in disease progression and in response to therapy under natural biological 
conditions.  Furthermore, the ability to image ROS in animal models would most 
certainly be expected to facilitate the development and evaluation of new therapeutics, 
assist with the development of strategies to improve the efficacy of current therapeutics, 
or limit the unwanted side effects of current therapeutic agents. 
1.2.4 The Role of ROS/Oxidative Stress in PCD 
 It is well established that certain chemotherapeutic agents, such as 
rituximab(161), bortezomib(162) and adaphostin(163), among others(164-166), generate 
ROS in their induction of malignant cell death.  However, there is growing evidence that 
ROS may be involved in the regulation of both apoptotic and non-apoptotic (caspase-
independent) cell death pathways(167, 168).  Recent studies have suggested that various 
cell death triggers can lead to the direct production of ROS or enhanced mitochondrial 
outer membrane permeability (MOMP(169, 170)).  The direct production of ROS can 
induce lysosomal membrane permeabilization and the subsequent release of lysosomal 
enzymes can either induce MOMP or cause lysosomal degradation-mediated autophagic 
cell death(171, 172).  If MOMP is induced, cytochrome c and other pro-apoptotic factors 
are released into the cytosol; additionally, NADH dehydrogenase and reduced enzyme 
Q10 divert electrons from the electron transport system to oxygen, and O2
•-
 are 
formed(169, 170).  Illustration of these processes can be seen in Figure 1.1.  These 
findings suggest that there is substantial interplay between apoptotic and non-apoptotic 
cell death signaling, and that ROS play significant roles within each mechanism(168).  It 
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is envisioned that ROS/oxidative stress can be used as robust, versatile markers for the 
various morphologically distinct pathways of cell death. 
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Chapter 2: Proposed Strategy and Experimental Methods 
2.1 Proposed Strategy 
Studies in our lab have shown that HeLa cells transiently expressing Firefly 
Luciferase (fLuc) or Renilla Luciferase (RLuc) exhibited severely diminished 
bioluminescence when treated with a PCD-inducing drug.  However, when stable 
mutant variants of luciferase were utilized, bioluminescence measurements were less 
sensitive to these treatment conditions.  Based on these observations, it was 
hypothesized that the bioluminescent ratio (stable luciferase activity:wild-type 
luciferase activity) could be used to report on the extent of intracellular stress associated 
with PCD, inducing agents or other environmental factors.  A schematic of this 
hypothesis is illustrated in Figure 2.1; bioluminescence from the stable luciferase 
variant remains relatively constant over a range of drug dosages/treatment time while 
wild-type luciferase bioluminescence declines(Figure 2.1A).  The ratio of stable:wild-
type luciferase activity thus increases over drug dosage or time course, accordingly 
(Figure 2.1B).  Coexpression of the mutant and wild-type luciferases would ultimately 
create a Ratiometric Bioluminescent sensor (RBS) for cellular stress and PCD.  
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When considering which luciferases to incorporate into the RBS, it is necessary 
that the bioluminescence from each of the proteins can be distinguished.  This can be 
accomplished by selecting stable and wild-type luciferase variants that catalyze different 
substrates, e.g., luciferin and coelenterazine.  Distinct signals can then be obtained from 
each luciferase by adding one substrate first, measuring the signal, and either washing the 
substrate out (in vitro) or allowing the substrate to clear (in vivo) before addition of the 
second substrate.  An alternative for in vitro assays involves the use of the Dual-Glo 
Luciferase assay from Promega.  This assay utilizes two proprietary solutions: the first 
solution contains the substrate for fLuc and the second solution contains a reagent to 
quench the bioluminescence of fLuc in addition to the substrate for RLuc.   
As an alternative to using two different substrates to distinguish between stable 
and wild-type luciferase variants, luciferase enzymes can also be selected that emit light 
Figure 2.1. Schematic of RBS.  (A) Over increasing time or drug dosage it is expected that the mutant 
luciferase bioluminescence will remain relatively stable while the wild-type luciferase bioluminescence 
will decrease. (B) Over the same time or drug dosage increase, the ratio (mutant bioluminescence:wild-type 
bioluminescence) will increase. 
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at different wavelengths and thus can be differentiated optically.  In this scenario, 
multiple emission filters can be applied during bioluminescence imaging in order to 
obtain specific signals for each luciferase.  For example, the emission wavelength of 
RLuc is 480 nm and the emission wavelength of fLuc is 612; in this case, both substrates 
can be administered during the same imaging session, and optically distinct emission 
filters can be implemented to specifically obtain bioluminescent images from each 
enzyme.  Therefore, it is not necessary to wait for one substrate to clear before the second 
can be administered and imaged. 
 
2.2 Materials and Methods 
2.2.1 Preliminary transient transfection studies 
 The DNA sequence encoding fLuc was PCR amplified from the pGL3-Basic 
vector (Promega, Madison, WI) and inserted into the pCDNA3.1+ vector (Invitrogen, 
Carlsbad, CA) between the BamHI and EcoRI restriction sites, creating fLuc-
pCDNA3.1+.  The fLuc-pCDNA3.1+ vector was modified with 5 amino acid mutations 
(F14R, L35Q, V182K, I232K, F465R) using the QuikChange Multi Site Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions, 
ultimately creating fLuc5.  The phRL-CMV vector (Promega) encoding Renilla 
Luciferase was modified to contain eight amino acid mutations within the RLuc sequence 
(A55T, C124A, S130A, K136R, A143M, M185V, M253L, and S287L) using the 
QuikChange Multi Site Directed Mutagenesis Kit (Stratagene) according to the 
manufacturer’s instructions, ultimately creating RLuc8.  Cells were plated at a density of 
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24,500 cells/well in a 48-well tissue culture plate (BD Biosciences, Franklin Lakes, NJ) 
and transiently transfected with either the fLuc-pCDNA3.1+, phRL-CMV (encoding 
Renilla Luciferase (RLuc)) (Promega), fLuc5 or RLuc8 vectors using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions.  After 24 hours, culture 
medium was replaced and the transfected cells were allowed to recover for another 24 
hours.  Transfected cells were treated with 1 µM Staurosporine (Sigma, St. Louis, MO) 
or PBS (pH 7.4) for indicated time periods.  In certain assays, cells were treated with 20 
µg/mL phenylbenzothiazole (PBT, Sigma) in addition to STS.  At selected time points, 
fLuc, RLuc and fLuc5 measurements were taken using a Dual-Glo Luciferase assay 
system (Promega) according to the manufacturer’s instructions and an Infinite 200 plate 
reader (Tecan, Mannedorf, Switzerland).  To measure caspase-3 activity, the Caspase-3/7 
Glo assay (Promega) was used according to the manufacturer’s instructions and 
bioluminescence measurements were obtained from an Infinite 200 plate reader (Tecan). 
2.2.2 RBS plasmid vector construction 
The internal ribosome entry site (IRES) from the pIRES2-DsRed Express Vector 
(Clontech, Mountain View, CA) was cloned into the pIRES vector (Clontech) using 
restriction enzymes NheI and KpnI (New England Biolabs, Ipswich, MA), creating the 
pIRES12 vector.  The DNA sequence encoding Firefly Luciferase (fLuc) from the pGL3-
Basic vector (Promega) was PCR amplified and inserted into pCDNA3.1+ (Invitrogen) 
between the BamHI and EcoRI restriction sites.  The fLuc sequence was subsequently 
cloned into pIRES12 using the NheI and XbaI restriction sites of fLuc-pCDNA3.1+ and 
the XbaI site of pIRES12.  RLuc8 was cloned into the pIRES12-fLuc vector at the NheI 
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and BglII restriction sites.  The resulting RLuc8-IRES-fLuc sequence was cloned into the 
pLENTI6/V-5 TOPO vector (Invitrogen) per the manufacturer’s instructions to create the 
final vector necessary for the Ratiometric Bioluminescent Sensor (RBS).  The final RBS 
plasmid map is shown in Figure 2.2. 
 
2.2.3 Reverse RBS plasmid vector construction 
The RLuc8 sequence from the phRL-CMV vector (Promega) was PCR amplified 
and cloned into pCDNA3.1+ (Invitrogen) between the BamHI and EcoRI restriction sites, 
creating RLuc8-pCDNA2.1+.  RLuc8 was subsequently cloned into pIRES12 using the 
Figure 2.2. Plasmid map of the RBS.  Image created using PlasMapper (1). 
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NheI and XbaI restriction sites of RLuc8-pCDNA3.1+ and the XbaI site of pIRES12, 
creating pIRES12-RLuc8.  The fLuc sequence was PCR amplified and inserted into 
pCDNA3.1+ between the BamHI and EcoRI restriction sites.  The fLuc sequence from 
the pGL3-Basic vector (Promega) was subsequently cloned into the pIRES12-RLuc8 
vector at the NheI and BglII restriction sites.  The resulting fluc-pIRES-RLuc8 sequence 
was cloned into the pLENTI6/V-5 TOPO vector per the manufacturer’s instructions to 
create the final vector necessary for the reverse RBS. 
2.2.4 Cell culture 
Human cervical carcinoma (HeLa) and human breast adenocarcinoma (MCF7) 
cells (ATCC, Manassas, VA) were grown in Eagle’s Minimum essential medium 
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS, HyClone, 
Logan, UT), 1.5 g/L sodium bicarbonate, 100 U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen).  Human embryonic kidney (293T/17) cells (ATCC) were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech) supplemented with 
10% FBS (Hyclone), 1.5 g/L sodium bicarbonate, 100 U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen).  The genetically modified human embryonic kidney cells 
(293FT, Invitrogen) for generating lentiviral particles were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Mediatech) supplemented with 10% fetal bovine 
serum (FBS, HyClone, Logan, UT), 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 
0.1 mM MEM non-essential amino acids (NEAA), 6 mM L-glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Invitrogen).  Cells that were genetically 
engineered to stably express RBS (described below) also had Blasticidin (Invitrogen) 
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added at a final concentration of 4 µg/mL.  All cells were cultivated in a 37°C humidified 
incubator with 5% CO2. 
 
2.2.5 Lentiviral particle production and stable cell line creation 
RBS lentiviral particles were produced using the Virapower Lentiviral Directional 
TOPO Expression Kit (Invitrogen) according to the manufacturer’s instructions.  Briefly, 
293FT cells were transfected with viral packaging plasmids and the RBS lentiviral vector 
using Lipofectamine 2000 (Invitrogen).  Viral supernatant was harvested 48 hours after 
transfection, concentrated using Peg-it Virus Concentration solution (System 
Biosciences, Mountain View, CA) and the titer was assessed.  Concentrated viral 
particles were added to HeLa, MCF7 and 293T/17 cells, which were subsequently 
selected for stable genomic integration using Blasticidin (Invitrogen), resulting in RBS-
HeLa, RBS-MCF7 and RBS-293T/17 cells. 
 
2.2.6 Cellular stress and inhibition assays 
To induce cellular stress, RBS-cells were treated with various compounds listed in 
Table I.  Stressed and unstressed cells were also incubated with inhibitors that target 
various intracellular protein degradation/modification pathways.  The specific 
compounds/proteins that were utilized as inhibitors and the respective final working 
concentrations are also listed in Table 2.1.  Inhibitors were added to cells for 1 hour prior 
to adding inducers of cellular stress and left in the media for the duration of the treatment.  
Analogous controls were conducted in the absence of stress inducers. 
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Table 2.1. Summary of reagents. 
 
2.2.7 Cellular bioluminescence assays 
Unless otherwise noted, bioluminescence assays were performed 24 hours after 
plating 10,000 RBS-HeLa cells/well in a white-walled 96 well tissue culture plate (BD 
Biosciences).  The Dual-Glo Luciferase Assay System (Promega) was utilized according 
 
Reagent 
Induces/Inhibits 
Manufacturer 
Working                  
Concentration 
Staurosporine (STS) PCD, ROS/- Sigma 0 - 50 µM 
Hydrogen peroxide (H2O2) ROS/- Fisher 0 - 10 mM 
Hypoxanthine (HX) ROS/- Sigma 50 µM 
Xanthine Oxidase (XO) ROS/- Sigma 25 mU/mL 
Doxorubicin (DOX) PCD/- Sigma 1 µM 
Camptothecin (CPT) PCD/- Sigma 10 µM 
Sodium Selenite (SSe) PCD/- MP Biomedicals 0 – 55 µM 
S
tr
es
s 
In
d
u
ce
rs
 
Resveratrol (Res) PCD/- Enzo Life Sciences 0 – 1 mM 
MG-132 -/proteasome Fisher 20 µM 
Epoxomicin -/proteasome Enzo Life Sciences 10 µM 
Lactacystin -/proteasome Sigma 10 µM 
Calpain Inhibitor III -/calpains Calbiochem 100 µM 
Pepstatin A -/cathepsins Enzo Life Sciences 100 µM 
Ammonium Chloride -/autophagy Alfa Aesar 1 mM 
z-vad-fmk -/caspases Sigma 1 µM 
Tiron -/superoxide Sigma 10 mM 
TEMPOL -/superoxide Sigma 10 mM 
MnTMPyp -/superoxide Enzo Life Sciences 100 µM 
Mannitol -/hydroxyl radical Sigma 100 mM 
DFO -/hydroxyl radical Calbiochem 50 µM 
TEPA -/hydroxyl radical Sigma 50 µM 
Catalase -/hydrogen peroxide Sigma 40 U/mL 
Allopurinol -/hydrogen peroxide MP Biomedicals 100 µM 
Acetylsylic Acid (Aspirin) -/hydrogen peroxide Fisher 1 mM 
In
h
ib
it
o
rs
/S
ca
v
en
g
er
s 
Uric Acid -/peroxynitrite Alfa Aesar 1 mM 
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to the manufacturer’s instructions to obtain both fLuc and RLuc8 bioluminescence 
measurements from an Infinite 200 plate reader (Tecan).  In the case of using MnTMPyP 
as an inhibitor, the cell media was removed, cells were gently washed and the media was 
replaced before using the Dual-Glo Luciferase Assay System as it was found that the 
compound interfered with the bioluminescence measurements.  
 
2.2.8 Cellular bioluminescence imaging 
RBS-HeLa cells were plated at a density of 10,000 cells/well in a black-walled 96 
well tissue culture plate (BD Biosciences).  The Dual-Glo Luciferase Assay System 
(Promega) was utilized according to the manufacturer’s instructions in order to obtain 
bioluminescent images in an Omega 16vs imaging system (UltraLum, Claremont, CA).  
It should be noted that the exact position of the 96 well plate was kept constant 
throughout the imaging session in order for accurate ratiometric images to be calculated.   
 
2.2.9 Cellular bioluminescence image analysis 
Image analyses were performed using ImageJ (NIH, Bethesda, MD).  Image 
background was determined by measuring 3 regions of interest (ROIs) surrounding the 
bioluminescent ROI.  After background subtraction, the RLuc8 image was divided by the 
fLuc image using the ‘Math’ command under the ‘Process’ menu tab. 
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2.2.10 Cell death assays 
Caspase Activity:  PCD was induced (as described above) 24 hours after plating 
10,000 cells/well in white-walled 96 well tissue culture plates (BD Biosciences).  After 
indicated treatment times, the Caspase 3/7-Glo Assay (Promega) was performed 
according to the manufacturer’s protocol and bioluminescence measurements were 
obtained from and Infinite 200 plate reader (Tecan).  All values were normalized to 
controls (i.e. pre-treatment values). 
DNA Fragmentation: PCD was induced (as described above) 24 hours after 
plating 300,000 cells/well in 6 well tissue culture plates (BD Biosciences).  After 
indicated treatment times, TUNEL assays for DNA fragmentation were performed using 
the TUNEL/ApoBRDU assay kit (Invitrogen) according to the manufacturer’s protocol.  
Percent DNA fragmentation was determined using flow cytometry on a Guava EasyCyte 
flow cytometer (Guava Technologies, Hayward, CA).  Analysis of flow cytometry data 
was performed using FlowJo software (Treestar, Ashland, OR). 
 
2.2.11 Proteasome inhibition control assay 
RBS-HeLa cells were plated at a density of 10,000 cells/well in a white-walled 
96-well plate (BD Biosciences).  24 hours later, cells were treated with PBS (pH 7.4),  20 
µM MG-132, 10 µM epoxomicin or 10 µM lactacystin for 1 hour.  RBS-HeLa cells were 
then treated with PBS (pH 7.4) or 10 µM Staurosporine (STS) in addition to the 
inhibitors for 24 hours.  Proteasome activity measurements were obtained using the 
 63 
Proteasome-Glo 3-Substrate Cell-Based Assay system (Promega) according to the 
manufacturer’s instructions. 
 
2.2.12 Protease inhibition control assays 
Calpain Inhibitor III:  RBS-HeLa cells were plated at a density of 10,000 
cells/well in a white-walled 96-well plate (BD Biosciences).  24 hours later, cells were 
treated with either PBS (pH 7.4) or 100 µM Calpain Inhibitor III for 1 hour.  PBS (pH 
7.4) or 10 µM STS was subsequently added to the cells, and both compounds remained 
on the cells for 24 hours.  Calpain activity measurements were obtained using the 
Calpain-Glo Protease Assay (Promega) according to the manufacturer’s instructions. 
Pepstatin A:  RBS-HeLa cells were plated at a density of 10,000 cells/well in a 
black-walled 96-well plate (BD Biosciences).  24 hours later, cells were treated with 
either PBS (pH 7.4) or 100 µM pepstatin A for 1 hour, with either PBS (pH 7.4) or 10 
µM STS added for another 24 hours.  Cathepsin activity was assessed using the CV-
Cathepsin B Detection Kit (Enzo Life Sciences) according to the manufacturer’s 
instructions with one exception; after the final wash step, the plate was read on an Infinite 
200 plate reader (Tecan) for fluorescence (550ex/610em), as opposed to microscopy. 
Ammonium Chloride:  In lieu of a control assay for ammonium chloride 
effectively inhibiting lysosome-phagosome fusion, we direct the reader to a seminal 
paper regarding this phenomena in HeLa cells(2).  
 64 
z-vad-fmk:  RBS-HeLa cells were plated at a density of 10,000 cells/well in a 
white-walled 96-well plate (BD Biosciences).  24 hours later, cells were treated with 
either PBS (pH 7.4) or 1 µM z-vad-fmk for 1 hour.  PBS (pH 7.4) or 10 µM STS was 
subsequently added to the cells, and both compounds remained on the cells for 24 hours.  
Caspase activity measurements were obtained using the Caspase-Glo 3/7 Assay 
(Promega) according to the manufacturer’s instructions. 
 
2.2.13 Superoxide (O2
•-
) scavenger control assay 
RBS-HeLa cells were plated at a density of 120,000 cells per well of a 12 well 
tissue culture plate (BD Biosciences).  24 hours later, cells were treated with PBS (pH 
7.4), 10 mM TEMPOL, 10 mM Tiron or 100 µM MnTMPyP for 1 hour.  PBS (pH 7.4) or 
10 µM STS was subsequently added to the cells, and both compounds remained on the 
cells for 24 hours.  Intracellular O2
•-
 levels were then determined by incubating the cells 
in 5 µM dihydroethidium (DHE, Invitrogen) for 30 minutes at 37°C and subjecting them 
to flow cytometry using a Guava EasyCyte (Guava Technologies, Hayward, CA). 
Analysis of flow cytometry data was accomplished using FlowJo software (TreeStar, 
Ashland, OR). 
 
2.2.14 Hydroxyl Radical (
•
OH) scavenger/inhibitor control assay 
RBS-HeLa cells were plated at a density of 120,000 cells per well of a 12 well 
tissue culture plate (BD Biosciences).  24 hours later, the cells were incubated with 10 
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µM hydroxyphenylfluorescein (HPF, Sigma) for 30 minutes at 37°C.  Cells were then 
treated with PBS (pH 7.4), 100 mM Mannitol, 50 µM deferoxamine (DFO), 50 µM 
tetraethylenepentamine (TEPA) or 50 µM DFO plus 50 µM TEPA for 1 hour.  PBS (pH 
7.4) or 10 µM STS was subsequently added to the cells, and all compounds remained on 
the cells for 24 hours.  Intracellular 
•
OH levels were determined by subjecting the cells to 
flow cytometry using a Guava EasyCyte (Guava Technologies).  Analysis of flow 
cytometry data was accomplished using FlowJo software (TreeStar). 
 
2.2.15 Hydrogen peroxide (H2O2)-related inhibitor control assays 
Catalase and Allopurinol: RBS-HeLa cells were plated at a density of 120,000 
cells per well of a 12 well tissue culture plate (BD Biosciences).  24 hours later, the cells 
were incubated with 10 µM CM-H2DCFDA (Invitrogen) for 30 minutes at 37°C.  Cells 
were then treated with PBS (pH 7.4), 50 U/mL catalase or 100 µM allopurinol for one 
hour.  PBS (pH 7.4) or 10 µM STS was subsequently added to the cells, and all 
compounds remained on the cells for 24 hours.  Intracellular H2O2 levels were 
determined by subjecting the cells to flow cytometry using a Guava EasyCyte (Guava 
Technologies).  Analysis of flow cytometry data was accomplished using FlowJo 
software (Treestar). 
Aspirin:  RBS-HeLa cells were plated at a density of 1.2 x 10
6
 cells in 100 mM 
tissue culture dishes (BD Biosciences).  24 hours later, the cells were treated with PBS 
(pH 7.4) or 1 mM aspirin for one hour, followed by PBS (pH 7.4) or 10 µM STS for 24 
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hours.  Cyclooxygenase (COX) activity was determined by using the Cox Activity Assay 
Kit (Cayman Chemical Company, Ann Arbor, MI).   
 
2.2.16 Quantitative real-time PCR (qRT-PCR) 
Cytoplasmic RNA from RBS-HeLa cells cultured under indicated conditions was 
isolated using the High Pure RNA Isolation Kit (Roche, Mannheim, Germany) and 
subsequently reverse-transcribed to single-stranded cDNA using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to each 
manufacturer’s protocol.  Quantitative RT-PCR was performed on an ABI PRISM 7300 
Sequence detection system using FAM-labeled Taqman primer sets for RLuc8, fLuc and 
β-actin (as a control) and the Taqman universal PCR Master Mix (Applied Biosytems) 
according to the manufacturer’s protocol. 
 
2.2.17 Western blot analysis 
Following indicated culture conditions, RBS-HeLa cells were washed 3 times 
with 1x PBS (pH7.4).  Proteins were extracted using RIPA extraction buffer (50 mM Tris 
HCL, pH 7.4, 1% Triton X-100, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA 
and a Complete Mini Protease Inhibitor Cocktail Tablet (Roche)) at 4°C for 30 minutes 
with constant agitation.  Total protein concentrations were measured using a BCA assay 
(Pierce, Rockford, IL).  30 µg of total protein from each sample were heated to 95°C in 
Laemmli Sample buffer containing 2% (v/v) 2-mercaptoethanol (Bio-Rad, Hercules, 
CA).  After a 5 minute cooling period, the samples were quickly centrifuged and the 
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supernatants were immediately run on a 4-15% Tris-HCl gel (Bio-Rad).  Proteins 
separated by electrophoresis were transferred to nitrocellulose membranes in 1X Transfer 
Buffer (Bio-Rad) at 15V for 30 minutes.  Membranes were blocked in Blocking Buffer 
for Fluorescent Western Blotting (Rockland Immunochemicals, Gilbertsville, PA) for 60 
minutes.  The membranes were incubated with anti-fLuc (Sigma), anti-rLuc (Millipore, 
Billerica, MA) or anti-β-actin primary antibodies in blocking buffer overnight.  After 
washing 3 times with TBS-T, the membranes were incubated with either Anti-Mouse IgG 
Antibody IRDye800 conjugated (fLuc, rLuc) or Anti-Rabbit IgG Antibody IRDye800 
conjugated (β-actin) at a 1:10,000 dilution (Rockland Immunochemicals).  The 
fluorescent signal from the membranes was imaged using the Odyssey Infrared Imaging 
System (Li-Cor Biosciences, Lincoln, NE) 
 
2.2.18 Intracellular hydrogen peroxide detection 
Amplex Red:  HeLa cells subjected to various treatment conditions, as indicated, 
were lysed using RIPA buffer and the clarified lysate samples were used in the Amplex 
Red Hydrogen Peroxide/Peroxidase assay kit (Invitrogen) to determine levels of H2O2.  
Results were normalized to total protein content determined by the BCA assay (Pierce). 
CM-H2DCFDA:  Cells were plated at a density of 120,000 cells per well of a 12 
well tissue culture plate (BD Biosciences).  24 hours later, the cells were incubated with 
10 µM CM-H2DCFDA (Invitrogen) for 30 minutes at 37°C.  The reagent was removed, 
the cells were washed with PBS (pH 7.4) and PCD was induced as described above.  
Cells were lifted using a rubber scraper, washed twice with PBS (pH 7.4) and 
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intracellular H2O2 levels were determined by subjecting the cells to flow cytometry using 
a Guava EasyCyte flow cytometer (Guave Technologies).  Analysis of flow cytometry 
data was accomplished using FlowJo software (TreeStar). 
 
2.2.19 RLuc8 and fLuc protein purification 
The DNA sequences encoding RLuc8 and fLuc were PCR amplified and inserted 
into the pHAT 10 and pHAT 11 vectors (Clontech) between the BamHI and EcoRI 
restriction sites.  50 mL of bacterial cultures were inoculated in LB medium containing 
50 µg/mL ampicillin overnight, shaking at 37°C.  Cultures were expanded into 500 mL 
LB medium containing 50 µg/mL ampicillin for 1.5 hours, shaking at 37°C.  Protein 
expression was induced by adding 500 µM IPTG (Fisher Scientific, Pittsburgh, PA) and 
shaking for 5 hours at 37°C.  After centrifugation at 10,000 x g for 5 minutes, cell pellets 
were resuspended in 35 mL wash/extraction buffer (50 mM Phosphate, 300 mM NaCl, 
pH 7.0).  Lysozyme (final concentration of 0.75 mg/mL) and PMSF (final concentration 
of 1 mM) were added and the cells were frozen at -80°C overnight after standing at room 
temperature for 20 minutes.  Lysates were thawed in a 37°C water bath, sonicated and 
centrifuged at 20,0000 x g for 20 minutes.  Clarified cell lysates were applied to a 
purification column loaded with TALON metal affinity resin (Clontech) and washed 
several times with wash/extraction buffer.  The RLuc8 and fLuc proteins were eluted 
from the column using an imidazole gradient (10, 60, 150, 300, 450, 600, 700, 1000 
mM).  Samples from each imidazole concentration were subjected to SDS-PAGE in order 
to identify the most pure protein samples. Aliquots were heated to 95°C in Laemmli 
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sample buffer containing 2% (v/v) 2-mercaptoethanol (Bio-Rad).  After a 5 minute 
cooling period the samples were immediately centrifuged and run on a 4-15% Tris-HCl 
gel (Bio-Rad).  Proteins were visualized using the Simply Blue stain (Invitrogen) and the 
purest samples of each protein (i.e. the samples with the least amount of extraneous 
bands) were further purified on Amicon Ultra Centrifugal Filtration Devices (Millipore, 
Billerica, MA) of appropriate molecular weight cutoffs to remove the imidazole.   
 
2.2.20 In vitro bioluminescence assays on purified proteins 
For the xanthine/xanthine oxidase assay, equivalent concentrations of each protein 
were resuspended in a sample buffer consisting of phosphate buffered saline (PBS, 
Invitrogen), 1 mg/mL bovine serum albumin (BSA, Fisher Scientific) and a Complete 
Mini protease inhibitor cocktail tablet (Roche).  Samples were treated with 50 µM 
hypoxanthine, 25 mU/mL xanthine oxidase (Sigma) or a combination of each and 
incubated at 37°C for indicated time periods.  Luminescence measurements were made 
on an Infinite 200 plate reader (Tecan) following the addition of Dual-Glo reagents 
(Promega).   
For the H2O2 assay, 650 nM of both purified fLuc and RLuc8 proteines were 
used.  Proteins were added to PBS containing a range of H2O2 concentrations (0-10 mM) 
for up to 120 minutes at 37°C.  At indicated times, 10 µL aliquots of each sample were 
subjected to bioluminescence measurements on an Infinite 200 plate reader (Tecan), 
following the addition of Dual-Glo reagents (Promega).   
 70 
2.2.21 SDS-PAGE gels on purified proteins treated with H2O2 
Three protein conditions were used: fLuc alone (650 nM), rLuc alone (650 nM) or 
fLuc and RLuc together (650 nM total protein).  Proteins were added to PBS containing a 
range of H2O2 concentrations (0-10 mM) for up to 120 minutes at 37°C.  At indicated 
times, 10 µL aliquots were removed and heated to 95°C in Laemmli sample buffer 
containing 2% (v/v) 2-mercaptoethanol (Bio-Rad).  After a 5 minute cooling period the 
samples were immediately centrifuged and run on a 4-15% Tris-HCl gel (Bio-Rad).  
Proteins were visualized using the Simply Blue stain (Invitrogen) according to the 
manufacturer’s instructions. 
 
2.2.22 Cellular protein carbonylation detection 
To assay for protein carbonylation, the OxyBlot Protein Carbonlyation Detection 
Kit (Millipore) was used according to the manufacturer’s instructions.  Briefly, RBS-
HeLa cells were treated with PBS or STS for 24 hours.  Proteins were extracted using 
RIPA extraction buffer (50 mM Tris HCL, pH 7.4, 1% Triton X-100, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA and a Complete Mini Protease Inhibitor 
Cocktail Tablet) at 4°C for 30 minutes with constant agitation.  Total protein 
concentrations were measured using a BCA assay and 15 µg of total protein was treated 
with a final concentration of 6% SDS to denature the proteins.  The samples were then 
treated with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups in the 
protein side chains to 2,4-dinitrophenylhydrazone (DNP-hydrazone).  Also, a second set 
of samples was treated with Derivatization-Control solution, to serve as a negative 
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control.  The protein samples were run on a 4-15% Tris-HCl gel (Bio-Rad).  Proteins 
separated by electrophoresis were transferred to nitrocellulose membranes in 1X Transfer 
Buffer (Bio-Rad) at 15V for 30 minutes.  The membrane was blocked in 
blocking/dilution buffer (1%BSA/PBS-T (PBS, pH 7.4, 0.05% Tween-20)) for 1 hour 
and then incubated with rabbit anti-DNP antibody (1:150 dilution in blocking/dilution 
buffer) for one hour.  After rinsing with PBS-T, the membrane was incubated with HRP-
conjugated goat anti-rabbit IgG antibody (1:300 dilution in blocking/dilution buffer) for 
one hour and again rinsed.  The Immun-Star HRP Chemiluminescent kit (Bio-rad) was 
used and the signal was imaged on an Omega 16vs imaging system (UltraLum). 
2.2.23 Purified protein carbonylation detection 
To assay for protein carbonylation, the OxyBlot Protein Carbonylation Detection 
Kit (Millipore) was used according to the manufacturer’s instructions.  Briefly, 650 nM 
of pure fLuc and RLuc8 proteins were treated with PBS or 5 mM H2O2 for 2 hours, 
followed by denaturation with SDS (final concentration: 6%).   The samples were then 
treated with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups in the 
protein side chains to 2,4-dinitrophenylhydrazone (DNP-hydrazone).  The protein 
samples were run on a 4-15% Tris-HCl gel (Bio-Rad).  Proteins separated by 
electrophoresis were transferred to nitrocellulose membranes in 1X Transfer Buffer (Bio-
Rad) at 15V for 30 minutes.  The membrane was blocked in blocking/dilution buffer 
(1%BSA/PBS-T (PBS, pH 7.4, 0.05% Tween-20)) for 1 hour and then incubated with 
rabbit anti-DNP antibody (1:150 dilution in blocking/dilution buffer) for one hour.  After 
rinsing with PBS-T, the membrane was incubated with Anti-Rabbit IgG Antibody 
IRDye800 conjugated (β-actin) at a 1:10,000 dilution (Rockland Immunochemicals).  
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The fluorescent signal from the membranes was imaged using the Odyssey Infrared 
Imaging System (Li-Cor Biosciences, Lincoln, NE). 
2.2.24 Animal imaging 
Five week old female nude mice (Charles River Laboratories International LLC, 
Wilmington, MA) were obtained and given free access to food and water.  All 
experiments conformed to animal care protocols approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Pennsylvania.  For tumor 
induction, 2.5 x 10
6
 RBS-HeLa cells were resuspended in PBS (pH 7.4) and 
subcutaneously implanted in the lower right flank of lightly anesthetized mice (1% 
isoflurane/oxygen mixture).  Once the tumors reached ~ 1 cm in diameter, each group 
was imaged prior to any inhibitor/drug treatment.  Briefly, the animals were i.v. injected 
with 100 µL of 500 µg/mL sterile coelenterazine (NanoLight, Pinetop, AZ) in a 20/20/60 
mixture of USP grade ethanol/propylene glycol/PBS and imaged using an IVIS Lumina II 
(Caliper Life Sciences, Hopkinton, MA) under anesthesia (2.5% isoflurane/oxygen 
mixture).  The substrate was allowed to clear for 3 hours before the animals received an 
i.p. injection of 200 µL of sterile 15 mg/mL luciferin (Biosynth, Itasca, IL) in PBS (pH 
7.4) and imaged using an IVIS Lumina II under anesthesia (2.5% isoflurane/oxygen 
mixture).  Immediately following the second imaging session animals were divided into 4 
groups (PBS/PBS, PBS/STS, Allo/PBS, Allo/STS) and the inhibitor (1 mM Allopurinol) 
or control (PBS, pH 7.4) was intratumorally injected.  After 1 hour, the cell death inducer 
(500 µM STS) or control (PBS, pH 7.4) was intratumorally injected.  All intratumoral 
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injections were of a volume of 25 µL.  24 hours later, the animals were imaged in the 
same manner as stated previously.   
2.2.25 Animal image analysis 
Image analysis was performed using Living Image Software (Caliper Life 
Sciences).  Images were first background subtracted (treating the animal body as the 
background) and automatic (5% threshold) ROIs were generated around each tumor.  
Average bioluminescent counts were recorded and used in the ratio calculations. For each 
group, data was normalized to the day 1 ratio values. 
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Chapter 3: Development of the Ratiometric Bioluminescent 
Sensor (RBS) and its response to cellular stress in HeLa cells 
 
3.1 Abstract 
 The use of bioluminescent proteins as optical reporters for PCD and other cellular 
stress states is advantageous owing to their sensitivity, non-invasiveness, and in vivo 
imaging capability.  However, the possibility of reporter degradation during these 
biological processes must be accounted for.  In this chapter, we show that wild-type 
bioluminescent proteins (luciferases) exhibit a marked decrease in activity in cells 
undergoing PCD and that certain chemical treatments and mutations can rescue activity.  
Wild-type fLuc and a stable variant of RLuc (RLuc8) were incorporated into a 
Ratiometric Bioluminescent Sensor (RBS) and when expressed in HeLa cells, the RBS 
was capable of detecting PCD in a ratiometric manner.  
3.2 Introduction 
 There are many optical sensors designed to image and/or report on programmed 
cell death (PCD).  Many of these sensors are based on the specific proteolytic cleavage of 
the amino acid sequence DEVD by caspase-3, the cysteine-aspartic protease that is 
considered to be absolutely required for apoptotic PCD(1).  Some of these caspase-3 
dependent sensors are fluorescent in nature and typically involve the separation of a 
fluorophore and a quencher or overlapping FRET-pairs after DEVD cleavage by caspase-
3.  The fluorescent molecular reporters(2-4) hold an advantage over fluorogenic peptide 
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probes(5-11) in their synthesis costs and cellular delivery methods; however both 
categories of PCD sensors suffer from drawbacks, including autofluorescence and poor 
light penetration of tissue, making them less than ideal for in vivo applications. 
 To circumvent the issues surrounding fluorescent probes for PCD, several groups 
have recently utilized bioluminescent proteins as optical reporters for PCD.  
Bioluminescent proteins are highly sensitive as they emit no light until a specific 
substrate is present and one of the most prominently used bioluminescent proteins, 
Firefly luciferase (fLuc), emits a wavelength of light (610 nm) that is much less 
attenuated in tissues than many fluorescent molecules, making it a promising candidate 
for in vivo studies.  Generally, these PCD sensors utilize the cleavage of the caspase-3 
recognition sequence, DEVD, as a catalyst for luciferin (substrate) recognition(12, 13), 
removal of steric hindrance(14), or protein fragment complementation(15).   
 While the bioluminescent sensors for PCD seem to be superior to fluorescent 
sensors for in vivo imaging purposes, the design of any genetically encoded or peptidic 
sensor for PCD should take into account the possibility of sensor degradation and 
modification in cells undergoing PCD.  It has been shown that certain proteases (e.g., 
calpains(16, 17) and cathepsins(18, 19)) can be upregulated during PCD, in addition to 
the oxidative modifications that can result from increases in various reactive oxygen 
species (ROS)(20-22).  Thus, information garnered from these types of sensors should be 
highly scrutinized. 
 In this chapter, we show that wild-type luciferases do indeed suffer from activity 
loss in cells undergoing PCD.  Pretreatment with phenylbenzothiazole (PBT), a 
compound shown to prevent the intracellular degradation of fLuc(23), abrogated fLuc 
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activity loss in cells undergoing PCD.  Additionally, certain mutant forms of luciferase 
were analyzed under the same conditions; a fLuc (fLuc5) mutant exhibited slightly more 
activity than wild-type fLuc while an RLuc mutant (RLuc8) retained significant activity 
in cells undergoing PCD.  Based on these observations, RLuc8 and fLuc were 
incorporated into one sensor to explore whether the ratio (RLuc8 bioluminescence:fLuc 
bioluminescence) could be used to report on PCD.  It was found that the Ratiometric 
Bioluminescent Sensor (RBS) was capable of detecting PCD in STS-treated HeLa cells 
over ranges of time and dosage.  
3.3 Results 
In order to investigate the sensitivity of bioluminescent proteins to intracellular 
stresses incurred during PCD, we examined the effects of staurosporine (STS), a PCD-
inducing drug(24) that has also been shown to increase intracellular ROS(25), on HeLa 
cells transiently expressing Firefly and Renilla luciferases (fLuc and RLuc, respectively).  
The normalized bioluminescence measurements of fLuc and RLuc decreased 
significantly over time with 1 µM STS treatment as shown in Figure 3.1.  By 8 hours, 
fLuc activity was reduced by ~85% and RLuc activity was reduced by ~95%. 
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Under the same treatment conditions of 1 µM STS for 24 hours, caspase-3 
activity in HeLa cells increased over the course of 12 hours before reaching a plateau and 
slowly decreasing (Figure 3.2), indicative of PCD.  Caspase-3 activity was clearly 
elevated at time points where fLuc and RLuc bioluminescence was nearly completely 
diminished.  Thus, the use of wild-type luciferases in sensors for PCD must be 
scrutinized carefully since their signals can be nearly completely abrogated before the 
appearance of the apoptotic markers (i.e., caspases) they are supposed to detect. 
 
 
 
 
Figure 3.1. Effect of staurosporine on fLuc and RLuc bioluminescence.  HeLa cells were transiently 
transfected with either fLuc or RLuc vectors and treated with 1 µM staurosporine (STS) for a time period 
of 24 hours.  Bioluminescence measurements were taken at various time points and each point was 
normalized to time 0. 
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To circumvent the issue of diminished bioluminescence during PCD, we 
investigated the potential use of a chemical stabilizer to prevent the loss of fLuc activity.  
Phenylbenzothiazole (PBT) has been shown to prevent the intracellular degradation of 
fLuc(23) when added to cell cultures.  HeLa cells transiently expressing fLuc were 
treated with either 1 µM STS or 1 µM STS + 20 µg/mL PBT for 24 hours.  Figure 3.3 
shows that the bioluminescence of the cells treated with PBT in addition to STS was 
slightly higher and more stable than cells treated with STS alone.   
 
 
 
 
 
Figure 3.2. Caspase-3 activity during a time course of STS treatment.  HeLa cells were treated with 1 
µM STS for 24 hours.  At selected time points, cells were assayed for caspase-3 activity using 
Caspase-3/7 Glo and each point was normalized to time 0. 
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While the in vitro utilization of PBT to stabilize fLuc activity exhibited positive 
results, the use of this chemical may not translate well into in vivo models.  Thus, we 
investigated the potential use of bioluminescent proteins that have been mutated to 
enhance their stability in our PCD sensor.  Table 3.1 summarizes some of these proteins 
and the purported effects of the mutations. 
Table 3.1. Luciferase mutations and their reported effects. 
 
 When HeLa cells were transiently transfected with a vector encoding either wild-
type fLuc or fLuc5 and treated with 1 µM STS for a time course of 24 hours, the 
Figure 3.3. Response of fLuc to STS or STS + PBT treatment.  HeLa cells transiently expressing fLuc 
were treated with either 1 µM STS or 1 µM STS + 20 µg/mL PBT for 24 hours.  Bioluminescence 
measurements were taken at various time points and each point was normalized to time 0. 
Enzyme Mutations Effects Reference 
FLuc5 F14R, L35Q, V182K, I232K, 
F465R 
↑ pH tolerance, 
thermostable up to 45°C 
(26) 
RLuc8 A55T, C124A, S130A, K136R, 
A143M, M185V, M253L, and 
S287L 
200x serum inactivation 
resistance and 4x brighter 
than WT 
(27) 
 81 
normalized bioluminescence from the fLuc5 cells was slightly higher and more stable 
than that of fLuc (Figure 3.4). 
 
 
 
 
 
 
 
 
 
Similarly, when HeLa cells were transiently transfected with a vector encoding 
either wild-type RLuc or RLuc8 and treated with 1 µM STS for a time course of 24 
hours, the normalized bioluminescence from the RLuc8 cells was higher and more stable 
than that of RLuc (Figure 3.5).  RLuc8 clearly exhibits less activity loss than fLuc5, 
therefore it would ultimately be included in our bioluminescent sensor for PCD. 
 
 
 
 
Figure 3.4. Effect of STS on fLuc5 compared to wt fLuc.  HeLa cells were transiently transfected with 
fLuc or fLuc5 and treated with 1 µM STS for a time course of 24 hours.  Bioluminescence 
measurements were taken at various time points and each point was normalized to time 0. 
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We have shown the fLuc and RLuc bioluminescence decreases significantly under 
PCD-inducing conditions while the bioluminescence of PBT/fLuc, fluc5, and RLuc8 
remains more stable.  These observations led us to hypothesize that we could incorporate 
an unstable luciferase and a stable luciferase into one sensor and that the bioluminescent 
ratio (stable bioluminescence:unstable luminescence) could be used to report on the 
extent of intracellular stress associated with PCD.  We chose to incorporate fLuc and 
RLuc8 into this Ratiometric Bioluminescent Sensor, or RBS, for multiple reasons.  
RLuc8 exhibited the highest level of activity/stability under PCD-inducing conditions.  
Also, the emission wavelength of fLuc (~600 nm) makes it more suitable for in vivo 
imaging.  Further, each of these enzymes utilizes a different substrate, effectively 
simplifying the distinction between the bioluminescence of fLuc and RLuc8.  The fLuc 
and RLuc8 coding sequences flank an internal ribosomal entry site (IRES) in the plasmid 
construct, allowing both proteins to be translated from one bicistronic mRNA(28, 29); 
Figure 3.5. Effect of STS on RLuc8 compared to wt RLuc.  HeLa cells were transiently transfected with 
RLuc or RLuc8 and treated with 1 µM STS for a time course of 8 hours.  Bioluminescence measurements 
were taken at various time points and each point was normalized to time 0. 
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this ensures that protein levels (and the thus the ratio) would be unaffected by any 
changes in promoter activity. 
 HeLa cells constitutively expressing the RBS (RBS-HeLa cells) were subjected to 
STS time course and dosage treatments.  As seen in Figure 3.6A, upon treatment with 10 
µM STS, the fLuc bioluminescence decreases while the RLuc8 bioluminescence remains 
relatively stable over the time course of 24 hours.  This can be presented as an increase in 
the RLuc8:fLuc ratio (right-hand axis).  Representative bioluminescent images obtained 
from RBS-HeLa cells under the same conditions are shown in Figure 3.6B.  The resulting 
ratiometric images generated from the RLuc8 and fLuc images exemplify similar trends 
to the ratiometric measurements in Figure 3.6A.  When RBS-HeLa cells were treated 
with a dosage range of STS (0-50 µM) for 6 hours, the RLuc8 bioluminescence remained 
stable, fLuc bioluminescence decreased and the RLuc8:fLuc ratio increased (Figure 
3.6C).  Consistent with these findings, bioluminescent images acquired under the same 
treatment conditions, and the corresponding ratiometric measurements, exhibited similar 
trends (Figure 3.6D).   
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To confirm that the RLuc8:fLuc ratio was independent of cell number, RBS-HeLa 
cells were plated at a range of 0 – 20,000 cells/well and bioluminescence measurements 
of RLuc8 and fLuc were taken 24 hours later.  As shown in figure 3.7A, the RLuc8:fLuc 
ratio remained constant regardless of the cell seeding density.  Additionally, little to no 
increase in the RLuc8:fLuc ratio was observed in cells that were not treated with STS 
Figure 3.6. Response of RBS-HeLa cells to STS.  (A) Bioluminescent measurements of RLuc8 and fLuc 
were acquired at various times during the course of 10 µM STS treatment.  All measurements were 
normalized to values at time 0. The RLuc8:fLuc ratio was subsequently calculated for each time point 
(right axis). (B) A representative bioluminescent image of RLuc8 and fLuc activity in STS-treated cells 
throughout the time course is shown as well as the calculated ratiometric image, RLuc8:fLuc. (C) 
Bioluminescent measurements of RLuc8 and fLuc activity in cells treated with various doses of STS.  
The RLuc8:fLuc ratio is also shown (right axis). (D) Representative bioluminescent images of RLuc8 
and fLuc activity in cells treated with various doses of STS.  The calculated ratiometric image of 
RLuc8:fLuc is also shown. 
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over a period of 24 hours (Figure 3.7B).  The slight increase in RLuc8 and fLuc 
bioluminescence that was observed with time likely reflects cell proliferation. 
 
  Similar changes in the RLuc8:fLuc ratio were seen regardless of whether the 
coding sequences for fLuc and RLuc8 were interchanged, relative to the IRES sequence 
(Figure 3.8).  Further, it should be noted that similar bioluminescent measurements were 
obtained from live and lysed cells.  All measurements of fLuc and RLuc8 activity that are 
shown were acquired using the in vitro assay kit, Dual-Glo (Promega). 
 
  
 
 
Figure 3.7. Analysis of RLuc8:fLuc ratio as a function of cell number and time.  (A) RBS-HeLa cells 
were plated at various cell densities and the RLuc8:fLuc ratio was measured.  (B) For a fixed cell 
seeding density, the RLuc8 and fLuc bioluminescent signal that was elicited by RBS-HeLa cells (PBS-
treated) was detected over the course of 24 hrs (left axis) and the RLuc8:fLuc ratio was calculated at 
each time point (right axis). 
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To determine the extent of PCD in STS-treated RBS-HeLa cells, TUNEL assays 
for DNA fragmentation and Caspase-3/7 Glo assays for caspase-3 activation were 
performed.    As shown in Figure 3.9A, the percent of DNA fragmentation over the 
course of 24 hours with 10 µM STS treatment rises, while untreated control cells exhibit 
no such increase.  Additionally, caspase-3 activation rises initially (up to 8 hours) but 
then decreases at later time points under the same conditions; untreated control cells 
show little increase in caspase-3 activation (Figure 3.9B).  RBS-HeLa cells treated with a 
dosage range of STS (0 – 50 µM) for 6 hours experience an increase in percent DNA 
fragmentation with increasing dose (Figure 3.9C), and an increase in caspase-3 activation 
(Figure 3.9D). 
Figure 3.8. Response of reverse RBS-HeLa cells to STS.  Reverse RBS-HeLa cells were treated with PBS 
or 10 µM STS for 24 hours and characterized by measurements of RLuc8:fLuc bioluminescence.  
Statistical significance: * (p<0.01). 
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Figure 3.9. Commercial PCD assays on STS-treated RBS-HeLa cells.  (A) A TUNEL assay for DNA 
fragmentation was performed at various times during the course of 10 µM STS or PBS (untreated control) 
treatment.  (B) A Caspase-3/7 Glo assay was performed at various times during the course of 10 µM STS 
or PBS (untreated control ) treatment.  (C) A TUNEL assay for DNA fragmentation was performed after 6 
hours of 0 – 50 µM STS treatment.  (D) A Caspase-3/7 Glo assay was performed after 6 hours of 0 – 50 
µM STS treatment. 
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3.4 Discussion 
 Preliminary studies on the stabilities of wild-type bioluminescent proteins 
demonstrated that both RLuc and fLuc exhibit decreased bioluminescence under PCD-
inducing conditions.  Additionally, caspase-3 activity is markedly elevated under the 
same conditions, indicative of PCD.  The disparity between high caspase-3 activity and 
nearly completely diminished fLuc and RLuc bioluminescence suggests that the 
utilization of these proteins in sensors for PCD must be done with caution.  
These observations led us to investigate methods of increasing the stabilities of 
fLuc and RLuc.  The application of PBT, a chemical reported to increase the stability of 
fLuc by preventing its intracellular degradation(23), abrogated the decrease in fLuc 
bioluminescence in HeLa cells treated with STS.  However, the usage of this chemical 
may not translate well into in vivo models.  HeLa cells expressing mutant luciferases, 
fLuc5 and RLuc8, and treated with STS also demonstrated increases in stability, 
compared to wild-type luciferases.   
These results led to the hypothesis that if a stable and unstable luciferase were 
incorporated into one sensor, the resulting bioluminescence ratio (stable 
bioluminescence:unstable bioluminescence) could be used to report on the extent of 
intracellular stress associated with PCD.  RLuc8 was chosen as the stable luciferase for 
the sensor because it remained the most stable out of all of the proteins tested.  Wild-type 
fLuc was chosen as the unstable luciferase for the sensor because its emission wavelength 
(~600 nm) is better suited for in vivo imaging.  Additionally, each of these enzymes 
utilizes a different substrate, effectively simplifying the distinction between the 
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bioluminescence of fLuc and RLuc8.  The sensor incorporating RLuc8 and fLuc was 
termed the Ratiometric Bioluminescent Sensor, or RBS. 
 Studies involving STS-treated RBS-HeLa cells indicated that fLuc activity was 
rapidly lost, while RLuc8 exhibited significantly prolonged functionality.  Accordingly, 
the bioluminescent ratio (RLuc8 activity):(fLuc activity) correlated well with TUNEL 
and Caspase-3/7 Glo assay results, indicating that the RBS could provide information on 
cells undergoing PCD. 
 The RLuc8 and fLuc coding sequences flanked an IRES site in the final plasmid 
construct of the RBS in order to allow for protein translation from a single, bicistronic 
mRNA(28, 29).  In having both genes under the control of a single (CMV) promoter and 
expressed as a single mRNA, the RLuc8:fLuc ratio at the transcript level is unaffected by 
altered promoter activity.  However, previous studies have shown that in healthy cells, 
proteins translated from sequences downstream of the IRES site can be expressed at 
lower levels compared with upstream sequences(30).  Therefore, to ensure that the 
position of the fLuc and RLuc8 coding sequence with respect to the IRES sequence (i.e., 
before or after the IRES sequence) was not responsible for the observed correlation 
between the ratio RLuc8:fLuc  and cellular stress, the coding sequences for fLuc and 
RLuc8 were interchanged.  It was found that similar changes in the RLuc8:fLuc ratio 
were seen regardless of the position of each luciferase relative to the IRES sequence. 
 Additionally, the RLuc8:fLuc ratios remained unchanged in untreated cells 
regardless of cell number or incubation time.  This highlights the potential transitional 
use of the RBS, from high-throughput screening where very small samples are used all 
the way to animal models, where large numbers of cells are usually necessary. 
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 There was an interesting disparity present between caspase-3 activity and percent 
DNA fragmentation when cells were treated with 10 µM STS over a time course of 24 
hours.  The caspase-3 activity peaked at 8 hours, while the percent DNA fragmentation 
continued to increase.  Even though caspase-3 activation is considered to be absolutely 
necessary for apoptosis to occur(1), a hallmark trait for cells undergoing any type of PCD 
is increased DNA fragmentation(31).  Given that the RBS seems to correlate better with 
the TUNEL assay for DNA fragmentation, it is expected that it will be able to monitor 
various biochemically and morphologically distinct pathways that lead to PCD. 
 While the discrepancy between RLuc8 and fLuc bioluminescence in cells 
undergoing PCD is quite explicit, the mechanism behind this difference remained 
unknown.  There have been various reports indicating that the proteasome plays an 
essential role in PCD(32-34) and that calpain(16, 17) and cathepsin(18, 19) protease 
activity is upregulated during PCD. Additionally, increases in ROS that can occur in cells 
undergoing PCD broach the possibility of potentially damaging oxidative modifications 
to proteins(20-22).  In the subsequent determination of the RBS mechanism, the roles of 
these proteases and ROS, among others were investigated.   
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Chapter 4: The RBS mechanism relies on hydrogen peroxide 
4.1 Abstract 
 The molecular processes involved in PCD are undoubtedly complicated, however 
it is generally accepted that protein degradation is readily involved in this phenomenon.  
Given the complex nature of the cytosol, there are naturally many avenues that can 
eventually lead to protein degradation.  Some of the most prominent mechanisms for 
protein degradation involve the proteasome, caspases, lysosomal proteases and 
oxidatively damaging reactive oxygen species (ROS).  In this chapter, comprehensive 
inhibition/scavenging studies were performed to determine the cause of the disparity seen 
between fLuc and RLuc8 in the RBS.  It was shown that this disparity stems from H2O2-
mediated oxidative damage that preferentially affected fLuc over RLuc8. 
4.2 Introduction 
 Intracellular proteases play various, sometimes complicated, roles in the process 
of programmed cell death (see (1), for review).  The 26S proteasome is a proteolytic 
complex that is present in all mammalian cell types and is responsible for most of the 
protein degradation that occurs in cells.  Proteins that are covalently conjugated to 
ubiquitin are targeted for rapid proteolysis by the proteasome(2).  Ubiquitin production 
has been shown to increase in γ-irradiated thymocytes (3) and proteasome inhibition can 
result in abrogation of apoptosis (4, 5).   
 Calpains are cytosolic proteins that depend on Ca
2+
 for activation(6).  They 
typically degrade cytoskelatal proteins(7-9), but do not cleave a specific target sequence 
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within proteins(10).  Increases in intracellular Ca
2+
 during apoptosis have previously been 
reported (11, 12) and calpains have been shown to be active during apoptosis in many 
different cell types(13-15).  Additionally, calpain inhibitors have reportedly resulted in 
the inhibition of apoptosis in response to certain apoptotic stimuli(16, 17). 
 Cathepsins are cysteine, zinc and aspartyl proteases that are present primarily in 
lysosomes and endosomes, but have been shown to be secreted into the cytosol under 
certain conditions(18, 19).  Additionally, damage to lysosomal membranes via hydroxyl 
radicals (
•
OH) can result in the release of cathepsins into the cytosol(20, 21).  Cathepsin 
B and D mRNA and protein levels have been shown to be upregulated in cells 
undergoing apoptosis(22, 23) and inhibition studies have shown that when these 
proteases are inhibited, apoptosis may also be inhibited(24, 25).  Following synthesis, 
cathepsins need to be proteolytically processed(26, 27); further, they may be activated in 
a cascade-like manner(25), similar to caspases, as it has been reported that cathepsin B is 
directly cleaved by cathepsin D to become activated(28, 29). 
 Perhaps the most thoroughly characterized proteases involved in programmed cell 
death are the caspase family of proteases (see (30) for review).  Caspases are defined by 
the specific amino acids sequences they cleave(31) and caspase-3 is required in order for 
a cell to fully complete the apoptotic process(32). 
 In addition to proteases, ROS can contribute to the degradation or damage of 
proteins in dying cells.  The superoxide radical (O2
•-
) does not cause much damage on its 
own(33), but it can react with other radicals (
•
OH)(34) or intracellular iron, leading to the 
production of 
•
OH which is highly reactive.  The hydroxyl radical (
•
OH) is generally 
considered to be the most powerful oxidizing species in biological systems; the oxidative 
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attack of protein backbones is initiated by the 
•
OH-dependent abstraction of the α-
hydrogen atom of an amino acid residue to form a carbon-centered radical(35).  Once a 
carbon-centered radical is formed, it can give rise to protein cross-links, peptide-bond 
cleavage (via diamide or α-amidation pathways), or direct oxidation of amino acids(35)  
The direct oxidation of lysine, arginine, proline and threonine residues may result in the 
formation of carbonyl derivatives (e.g. semialdehydes)(36, 37).  Hydrogen peroxide 
(H2O2) is a powerful oxidizing agent that can directly and indirectly modify many amino 
acids (see (38) for review), often creating hydroxyl- or carbonyl-derivatives.  While the 
effect of protein oxidation can vary, it has been shown in some cases that oxidation can 
destabilize a protein’s native structure and result in the impairment of protein function 
and activity loss(39, 40).   
In this chapter, after eliminating mRNA as a source of RLuc8 and fLuc activity 
discrepancy, we employed a series of inhibition studies on the aforementioned proteases 
and ROS on RBS-HeLa cells treated with STS.  We have found that the disparity in fLuc 
and RLuc8 activity is likely directly related to intracellular H2O2 levels.   
4.3 Results 
Quantitative RT-PCR revealed that the relative expression of fLuc and RLuc8 
mRNA within RBS-HeLa cells did not significantly change regardless of whether being 
treated with STS or PBS (Figure 4.1A).  In contrast, Western blot analysis revealed that 
fLuc protein levels decreased over the time course of STS treatment, while RLuc8 protein 
levels remained relatively stable (Figure 4.1B).  Notably, some fLuc staining was 
observed at higher than expected molecular weights at later time points, particularly at 24 
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hours.  Based on these findings, we began to investigate various cellular pathways 
involved in protein degradation and/or modification.   
  
To investigate pathways related to protein degradation and modification, a 
comprehensive series of inhibition studies were performed.  It was expected that certain 
inhibitors would rescue fLuc activity, resulting in a decrease in the RLuc8:fLuc ratio in 
STS-treated RBS-HeLa cells.  Since the proteasome is a prominent source of intracellular 
protein degradation, it was naturally one of the first molecular entities we investigated for 
the inhibition studies. Three proteasome inhibitors were tested, and all three inhibit the 
chymotryptic, peptidylglutamic peptidase and tryptic proteasome activity of the 
proteasome.  MG-132 acts as a ‘suicide substrate’(41), epoxomicin covalently binds to 
and modifies specific proteasomal subunits(42) and lactacystin covalently binds to and 
irreversibly modifies all β-subunits of the proteasome(43).  When the proteasome 
inhibitors were employed (Figure 4.2A), the RLuc8:fLuc ratio increased, i.e.  fLuc 
Figure 4.1. Assessment of mRNA and protein levels in STS-treated RBS-HeLa cells.  (A) Normalized 
RLuc8 and fLuc mRNA levels in RBS-HeLa cells treated with PBS (control, C) or 10 µM STS (STS) for 
24 hours.  mRNA levels were determined by qRT-PCR. (B) Western blot of RBS-HeLa cells treated with 
PBS (-) or 10 µM STS (+) over a time course of 24 hours.  β-actin is shown as a loading control. 
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activity was even further reduced relative to RLuc8.  The efficacy of the proteasome 
inhibitors was confirmed by performing analogous studies with Proteasome-GLO (Figure 
4.2B).   
 
Next, inhibitors for various proteases associated with apoptosis and lysosomal 
degradation were evaluated, namely calpain Inhibitor III (inhibits calpains), Pepstatin A 
(inhibits aspartyl proteases), ammonium chloride (inhibits phagosome-lysosome fusion), 
and z-vad-fmk (pan caspase inhibitor).  As shown in figure 4.3A, none of these 
inhibitors significantly affected the RLuc8:fLuc ratio of STS-treated cells.  The efficacy 
of the various protease inhibitors was confirmed by appropriate commercial assays 
(Figure 4.3B).  As noted in Chapter 2, in lieu of a control assay for ammonium chloride 
Figure 4.2. RBS response to proteasome inhibition.  (A) RBS-HeLa cells were pretreated with PBS 
(control), 20 µM MG-132, 10 µM Epoxomicin or 10 µM Lactacsytin for 1 hour before the addition of 10 
µM STS or PBS for 24 hours.  RLuc8 and fLuc bioluminescence measurements were taken and the 
RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in 
(A) for 1 hour prior to the addition of 10 µM STS for 24 hours.  Proteasome activity was assayed using 
Proteasome-Glo and the inhibited bioluminescence values were normalized to uninhibited controls. 
Statistical significance: **p<0.01. 
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effectively inhibiting lysosome-phagosome fusion, we direct the reader to a seminal 
paper regarding this phenomenon in HeLa cells(44). 
 
Once the proteasome and various proteases were shown to have insignificant 
effects on the mechanism responsible for the increase in the RLuc8:fLuc ratio in STS-
treated cells, focus was shifted to three oxygen byproducts associated with oxidative 
stress: superoxide (O2
•-
), hydroxyl radical (
•
OH) and hydrogen peroxide (H2O2).  Three 
O2
•-
 scavengers were tested - Tiron, TEMPOL (both cell-permeable O2
•-
 scavengers) and 
MnTMPyP (a cell-permeable superoxide dismutase (SOD) mimetic) - for their ability to 
reduce the RLuc8:fLuc ratio by rescuing fLuc activity.  Figure 4.4A indicates that none 
Figure 4.3. RBS response to various protease inhibitors.  (A) RBS-HeLa cells were pretreated with PBS 
(control), 100 µM Calpain Inhibitor III, 100 µM Pepstatin A, 1 mM ammonium chloride or 1 µM z-vad-
fmk for 1 hour before the addition of 10 µM STS or PBS for 24 hours.  RLuc8 and fLuc bioluminescence 
measurements were taken and the RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with 
PBS or the inhibitors mentioned in (A) for 1 hour prior to the addition of 10 µM STS for 24 hours.  
Protease activity was assayed using appropriate commercial assays and the inhibited values were 
normalized to uninhibited controls. Statistical significance: **p<0.01. 
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of these scavengers had any significant effect on the RLuc8:fLuc ratio.  The efficacy of 
the O2
•-
 scavengers was confirmed by performing a dihydroethidium assay (Figure 4.4B). 
 
Next, three 
•
OH scavengers/inhibitors, namely mannitol (specific 
•
OH scavenger), 
deferoxamine (DFO, iron chelator) and tetraethylenepentamine (TEPA, copper chelator) 
were examined.  The two metal chelators, alone and in combination, were used to 
effectively reduce the amounts of metals available for the Fenton reaction (Fe
2+
 + H2O2 
→ Fe
3+
 + 
•
OH  + OH
−
).  Interestingly, none of the 
•
OH scavengers/inhibitors 
significantly affected the RLuc8:fLuc ratio observed in STS-treated cells (Figure 4.5A).  
The effective reduction of intracellular 
•
OH following the addition of each 
Figure 4.4. RBS response to O2·- scavengers.  (A) RBS-HeLa cells were pretreated with PBS (control), 10 
mM Tiron, 10 mM TEMPOL or 100 µM MnTMPyP for 1 hour before the addition of 10 µM STS or PBS 
for 24 hours.  RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc ratio is 
reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in (A) for 1 hour prior 
to the addition of 10 µM STS for 24 hours.  O2
•-
 scavenging capability was tested using a dihydroethidium 
assay and inhibited values were normalized to uninhibited controls. Statistical significance: *p<0.05, 
**p<0.01. 
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scavenger/inhibitor was confirmed by a decrease in hydroxyphenyl fluorescein 
fluorescence (Figure 4.5B).   
 
The next group of inhibitors/scavengers that was examined was associated with 
reducing intracellular H2O2 levels: catalase (scavenger), allopurinol (xanthine oxidase 
(XO) inhibitor), and acetylsalicylic acid (aspirin, cyclooxygenase (COX) inhibitor).  
Catalase converts H2O2 to water, allopurinol inhibits XO, an enzyme that catalyzes the 
oxidation of hypoxanthine and xanthine, creating H2O2 as a byproduct, and aspirin 
inhibits COX enzymes, which possess peroxidase activity.  The addition of all three of 
these reagents resulted in significant reduction (p<0.01) in the RLuc8:fLuc ratio, as seen 
in Figure 4.6A. A reduction in intracellular H2O2 following the addition of each 
inhibitor/scavenger was confirmed by a decrease in CM-H2DCFDA fluorescence (Figure 
Figure 4.5. RBS response to ·OH scavengers.  (A) RBS-HeLa cells were pretreated with PBS (control), 
100 mM Mannitol, 50 µM DFO, 50 µM TEPA or 50 µM DFO + 50 µM TEPA for 1 hour before the 
addition of 10 µM STS or PBS for 24 hours.  RLuc8 and fLuc bioluminescence measurements were taken 
and the RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors 
mentioned in (A) for 1 hour prior to the addition of 10 µM STS for 24 hours.  
•
OH scavenging capability 
was tested using a hydroxyphenyl fluorescein assay and inhibited values were normalized to uninhibited 
controls. Statistical significance: *p<0.05. 
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4.6B). Given these results, catalase, allopurinol and aspirin were subjected to additional 
dosing studies and a Western blot to further characterize their behavior. 
 
 The final ROS-related inhibitor tested was uric acid, a peroxynitrite (ONOO-) 
scavenger.  When RBS-HeLa cells were pretreated with 1 mM uric acid for one hour 
prior to 10 µM STS for 24 hours, a slight but insignificant increase in the RLuc8:fLuc 
ratio was exhibited compared to cells without this pretreatment (Figure 4.7).  As there are 
currently no commercial assays available that specifically detect ONOO- only, we 
referred to previously published reports indicating that this concentration of uric acid 
effectively reduced intracellular ONOO-(45-47). 
 
 
Figure 4.6. RBS response to H2O2 related scavengers.  (A) RBS-HeLa cells were pretreated with PBS 
(control), 50 U/mL catalase, 100 µM allopurinol or 1 mM aspirin for 1 hour before the addition of 10 µM 
STS or PBS for 24 hours.  RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc 
ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in (A) for 1 
hour prior to the addition of 10 µM STS for 24 hours.  H2O2 scavenging capability was tested using 
appropriate commercial assays and inhibited values were normalized to uninhibited controls. Statistical 
significance: *p<0.05, **p<0.01. 
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Catalase, allopurinol and aspirin were explored further since they had the greatest 
effect on the RLuc8:fLuc ratio of RBS-HeLa cells treated with STS.  RBS-HeLa cells 
were pretreated with increasing doses of catalase (Figure 4.8A), allopurinol (Figure 4.8B) 
or aspirin (Figure 4.8C) for 1 hour prior to the addition of 10 µM STS.  After a 24 hour 
incubation period with the various H2O2 inhibitors/scavengers and STS, the 
bioluminescent ratio was measured.  It was found that each inhibitor/scavenger 
effectively reduced the RLuc8:fLuc ratio in a dose-dependent manner.  A Western blot 
was also performed (using the same pretreatment conditions from Figure 4.6A) to 
directly determine the effect of the various H2O2 inhibitors/scavengers on bioluminescent 
protein levels.  Consistent with the observed recovery in fLuc activity, STS treated RBS-
HeLa cells that were pretreated with catalase, allopurinol, and aspirin exhibited higher 
levels of fLuc protein (Figure 4.8D, column 3-5) compared to cells treated with STS in 
the absence of inhibitor (i.e. PBS, column 2).   
Figure 4.7. RBS response to an ONOO- scavenger, uric acid. (A) RBS-HeLa cells were pretreated 
with PBS (Control) or 1 mM uric acid for 1 hour before the addition of 10 µM STS or PBS for 24 
hours.  RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc ratio is 
reported after normalization to PBS/PBS treated controls. 
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Having shown that inhibitors/scavengers of H2O2 affected the signal elicited by 
the RBS, additional studies were performed that dealt with H2O2 more directly.  First, 
RBS-HeLa cells that were treated with 10 µM STS for up to 24 hours were analyzed for 
H2O2 production using the Amplex Red assay.  Figure 4.9A shows that the intracellular 
H2O2 concentration increased nearly three-fold under these conditions, compared with 
PBS-treated controls.  The H2O2 levels in RBS-HeLa cells also increased with STS dose 
(6 hour incubation, Figure 4.9B).  These trends mirror the increase in the RLuc8:fLuc 
ratio that was observed with the RBS (Figure 4.1).  To further evaluate the effect of H2O2 
Figure 4.8. Dose response and Western blot analysis of STS-treated cells to H2O2-related scavengers.  
RBS-HeLa cells were pretreated with a dosage range of (A) catalase, (B) allopurinol, or (C) aspirin for 1 
hour prior to 24 hours of 10 µM STS.  The RLuc8:fLuc ratio was calculated and reported.  (D) Western 
blot on RBS-HeLa cells pretreated for 1 hour with PBS, 50 U/mL catalase, 100 µM allopurinol or 1 mM 
aspirin (columns 2-5) before 10 µM STS for 24 hours.  β-actin is shown as a loading control. 
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on the RBS, we investigated the response of RBS-HeLa cells to 1 mM H2O2 in serum, for 
incubation times ranging from 0 to 24 hours.  Interestingly, it was found that the 
bioluminescent ratio increased dramatically, reaching levels that were drastically higher 
than what was observed previously with STS treatment (Figure 4.9C).  Treating RBS-
HeLa cells with a range of exogenous H2O2 concentrations for 6 hours also resulted in a 
more striking increase of RLuc8:fLuc when compared with the STS dosage study (Figure 
4.9D).  Additionally, it was found that exposing purified RLuc8 and fLuc proteins to the 
HX-XO reaction led to a significant increase (p<0.01) in the RLuc8:fLuc ratio over all 
controls.  These findings suggest that the RBS may be specifically responsive to 
intracellularly produced H2O2 alone, and not other upstream or downstream reactions 
involving other oxygen radicals or enzymes.   
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Figure 4.9. Analysis of intracellular H2O2, exogenous application of H2O2, and the hypoxanthine-xanthine 
oxidase reaction.  RBS-HeLa cells treated with (A) 10 µM STS over a course of 24 hours or (B) a dosage 
range of STS for 6 hours were assayed for H2O2 concentrations using the Amplex Red Hydrogen 
Peroxide/Peroxidase assay.  RBS-HeLa cells were treated with (C) 5 mM H2O2 in serum over a course of 
24 hours or (D) a dosage of H2O2 for 6 hours and the normalized RLuc and fLuc bioluminescence 
measurements (left axis) and the RLuc8:fLuc ratio (right axis) were determined.  (E) RBS-HeLa cells were 
subjected to PBS (Control) or the HX-XO reaction (50 µM HX, 25 mU/mL XO) for 24 hours.  The 
RLuc8:fLuc ratio was calculated and reported. (F) Purified RLuc8 and fLuc proteins were treated in vitro 
with PBS (Control), 50 µM HX, 25 mU/mL XO or 50 µM HX + 25 mU/mL XO for 4 hours.  The 
RLuc8:fLuc ratio was calculated and reported. 
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To investigate whether reductions in the level of H2O2, specifically through the 
use of allopurinol pretreatment, protected STS-treated RBS-HeLa cells from cell death, a 
TUNEL assay was performed.  As can be seen in Figure 4.10A, allopurinol had no effect 
on DNA fragmentation levels, indicating that it had no effect on cell death.  
Bioluminescence measurements from HeLa cells pretreated with allopurinol before STS 
indicated a significant (p<0.01) decrease in the RLuc8:fLuc ratio compared to cells 
pretreated with PBS (Figure 4.10B).  A CM-H2DCFDA assay was performed to assess 
intracellular H2O2 levels under the same conditions, and as shown in Figure 4.10C, these 
levels were significantly reduced (p<0.01) by allopurinol pretreatment compared to PBS 
pretreatment.   These results provide further support that changed in the RLuc8:fLuc ratio 
that are observed in apoptotic cells are likely mediated by H2O2. 
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In order to obtain a more definitive understanding of the role of H2O2 in the 
mechanism of the RBS, we exposed purified RLuc8 and fLuc to increasing 
concentrations of H2O2 (0, 1, 5 and 10 mM) for 2 hours.  Each well contained 650 nM 
Figure 4.10. Summary of RBS-HeLa responses to allopurinol pretreatment.  RBS-HeLa cells were 
pretreated with either PBS or 100 µM allopurinol for 1 hour prior to PBS or 10 µM STS for 24 hours.  (A) 
DNA fragmentation levels from a TUNEL assay.  (B) RLuc8:fLuc bioluminescence ratios from fLuc and 
RLuc8 bioluminescence measurements. (C) Intracellular H2O2 levels as measured by CM-H2DCFDA.  For 
(B) and (C), measurements were normalized to PBS/PBS controls.  Statistical significance: *(p<0.05), 
**(p<0.01). 
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fLuc or 650 nM RLuc8.  Aliquots from each reaction were removed every 30 minutes 
and subjected to SDS-PAGE.  When fLuc was treated with H2O2, protein levels 
decreased with increasing time and dose, compared to untreated controls as can be seen 
in Figure 4.11 (first lane of each panel).  Smearing of the fLuc band is seen from 30-90 
minutes for 5 and 10 mM H2O2, indicative of possible degradation.  In the case of RLuc8 
treated with H2O2, little change was observed over either time or dose (Figure 4.11, 
second lane of each panel).   
 
 
 
 
 
 
 
 
 
During the same study, aliquots from each reaction were removed and analyzed 
for bioluminescence.  A dose and time dependent decrease in fLuc bioluminescence was 
demonstrated when fLuc was treated with H2O2 (Figure 4.12A), while RLuc8 
Figure 4.11. Response of purified fLuc and RLuc8 proteins to H2O2 visualized with SDS-PAGE.  
Proteins (650 nM fLuc or 650 nM RLuc8) were treated with 0-10 mM H2O2 for up to 120 minutes.  
Every 30 minutes, aliquots were removed and subjected to SDS-PAGE. For every panel, Lane 1: fLuc, 
Lane 2: RLuc8. 
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bioluminescence remained quite stable under the same conditions (Figure 4.12B).  The 
resulting RLuc8:fLuc ratio is presented in Figure 4.12C, and this ratio increases over both 
time and dose.   
  
When fLuc was treated with H2O2, fLuc bioluminescence appeared to decay at a 
faster rate than protein levels for all H2O2 concentrations tested.  For example, 
bioluminescence values were less than 1% of control values after 120 minutes (Figure 
4.12A), but fLuc protein levels were clearly higher when compared to control (Figure 
4.11).  These observations indicate that H2O2 may have oxidatively modified or damaged 
the fLuc proteins, rendering them inactive, prior to degradation/protein loss.   
  A possible mechanism causing the modification and subsequent degradation of 
fLuc is protein carbonylation, as this modification can damage/inactivate enzymes and 
Figure 4.12. Bioluminescence response of purified fLuc and RLuc8 proteins to H2O2.  Proteins (650 nM 
fLuc or 650 nM RLuc8) were treated with 0-10 mM H2O2 for up to 120 minutes.  Every 30 minutes, 
aliquots were removed and subjected to bioluminescence measurements using Dual-Glo. (A) 
Bioluminescence measurements of fLuc treated with 0-10 mM H2O2 for up to 120 minutes. (B) 
Bioluminescence measurements of RLuc8 treated with 0-10 mM H2O2.  (C) Bioluminescence ratios 
(RLuc8:fLuc) of measurements from (A) and (B).   
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serve as a trigger for protein degradation (see (48) for review).   Proteins can become 
carbonylated directly through oxidative attack on amino acid side chains as well as 
indirectly through reaction with lipid radicals, carbohydrate radicals and nucleic acid 
radicals(38).  Interestingly, a recent study has suggested that protein carbonylation caused 
by lipid radicals is actually more common than carbonylation caused by direct amino acid 
side chain oxidative attack(49).  Our studies on RBS-HeLa cells treated with STS for 24 
hours have shown increased protein carbonylation compared to PBS treated control cells 
as shown in Figure 4.13A.  The carbonylation assay uses DNP antibodies to detect 
protein carbonyls that have been derivatized to DNP using DNPH.  Lanes 1 and 3 
represent RBS-HeLa cells treated with PBS or STS and a derivatization control solution, 
while lanes 2 and 4 represent PBS or STS and DNPH treated cells.  A marked increase 
can be seen in carbonylated proteins between lanes 2 and 4. 
 To further investigate carbonylation levels specifically in fLuc and RLuc8, 
purified samples of these proteins were treated with either PBS or 5 mM H2O2 for 2 hours 
and then subjected to the same carbonylation assay.  As seen in Figure 4.13B, fLuc 
proteins treated with H2O2 exhibit a striking increase in carbonylation levels compared to 
PBS-treated controls (lanes 3 and 1, respectively).  In contrast, very little difference in 
carbonylation is seen between PBS- and H2O2-treated RLuc8 proteins (lanes 2 and 4, 
respectively).  Further, the relatively higher levels of carbonylation seen in PBS-treated 
fLuc proteins (lane 1) compared to PBS-treated RLuc8 proteins (lane 2) may explain the 
decrease in fLuc bioluminescence seen in PBS-treated fLuc in Figure 4.12A at the 120 
minute time point. 
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Figure 4.13. Analysis of protein carbonylation in STS-treated RBS-HeLa cells and H2O2-treated 
fLuc and RLuc8 proteins.  (A) Proteins from RBS-HeLa cells treated with PBS (columns 1 and 2) 
or STS (columns 3 and 4) were extracted and treated with Derivatization-Control solution (C, 
columns 1 and 3) or DNPH (columns 2 and 4).  The resulting proteins were subsequently analyzed 
by Western blot.  (B) Purified fLuc and RLuc8 proteins were treated with either PBS (columns 1 
and 2) or 5 mM H2O2 for 2 hours.  After treatment with DNPH, the samples were analyzed by 
Western blot. 
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4.4 Discussion 
Quantitative RT-PCR and western blot analyses were performed to determine 
whether changes in RNA or protein levels were responsible for the loss of fLuc activity, 
but not RLuc8 activity.  Previous studies have shown that oxidative stress can trigger the 
degradation of both mRNA (50) and proteins(38).  If RNA was degraded, we would 
expect to see a drastic difference in the relative level of fLuc and RLuc8 mRNA 
expression after STS treatment, compared with PBS-treated controls; however, this was 
not the case.    In contrast, western blot analysis revealed that the fLuc protein levels 
decreased over time, while the RLuc8 protein levels remained relatively stable.  
Additionally, several higher molecular weight bands were observed after fLuc staining at 
the later time points, introducing the possibility of protein cross-linking and/or post-
translational modification.  These results indicated that ‘activation’ of the RBS can be 
attributed to the susceptibility of the bioluminescent proteins themselves to cellular 
stresses.   
To explicate the root cause responsible for the loss in fLuc activity in STS-treated 
cells and the corresponding increase in the RLuc8:fLuc ratio, systematic 
inhibition/scavenger studies were performed to individually silence key pathways known 
to cause protein degradation/modification.  It was expected that certain inhibitors would 
rescue fLuc activity, resulting in a decrease in the RLuc8:fLuc ratio in STS-treated RBS-
HeLa cells.  Since the proteasome is a prominent source of intracellular protein 
degradation, it was naturally one of the first molecular entities we investigated for the 
inhibition studies. Surprisingly, employment of the proteasome inhibitors MG-132, 
epoxomicin and lactacystin did not rescue fLuc activity and actually demonstrated an 
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increase in the RLuc8:fLuc ratio.  These results provided strong evidence that enhanced 
proteasomal degradation was not responsible for the loss of fLuc activity in STS-treated 
cells.  Since proteasome inhibitors have previously been shown to increase intracellular 
ROS levels(51-54) these findings hinted at ROS as a potential cause for the loss of fLuc 
activity.   
Next, various proteases associated with the apoptotic and lysosomal pathways 
were inhibited to examine their effects on the RBS sensor.  None of the inhibitors tested 
(Calpain Inhibitor III, Pepstatin A, ammonium chloride and z-vad-fmk) significantly 
affected the RLuc8:fLuc ratio, indicating the unlikelihood of the related proteases’ 
involvement in the RBS mechanism.  While the increase in the RLuc8:fLuc ratio 
observed upon use of the Calpain Inhibitor III on untreated (–STS) cells requires further 
exploration, one possible explanation may involve the decrease of intracellular 
antioxidant glutathione (GSH) levels and the associated increase in oxidative stress that 
has been shown to occur with the addition of this inhibitor(55). 
After eliminating the proteasome and various proteases as primary candidates 
responsible for the increase in the RLuc8:fLuc ratio in STS-treated cells, we began 
examining the effects of  scavengers for oxygen byproducts to determine the role of 
oxidative stress on the RBS.  The three O2
•-
 scavengers that were tested (Tiron, TEMPOL 
and MnTMPyP) showed no significant change in the RLuc8:fLuc ratio, concluding that 
O2
•-
 alone is likely not responsible for the trends observed in STS-treated RBS-HeLa 
cells.  This was somewhat expected given the short half-life of O2
•-
 and its function as a 
precursor to other oxidizing agents. The three scavengers/inhibitors of 
•
OH (mannitol, 
DFO and TEPA) also did not significantly reduce the RLuc8:fLuc ratio in STS treated 
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RBS-HeLa cells, effectively eliminating the likelihood that 
•
OH as a direct contributor to 
the loss in fLuc activity.  It may be argued that the slight increase in RLuc8:fLuc ratio 
that was observed following the addition of TEPA to the RBS-HeLa cells could be a 
result of excess H2O2 buildup from the prevention of the Fenton reaction, however further 
studies are warranted especially since the combination of DFO + TEPA did not yield an 
additive effect.  In contrast to the previous inhibition studies, all three 
inhibitors/scavengers of H2O2 tested (catalase, allopurinol and aspirin), yielded a 
significant reduction (p<0.01) in the RLuc8:fLuc ratio, suggesting that fLuc activity can 
be recovered in STS-treated RBS-HeLa cells through removal of H2O2.  It should be 
noted that catalase cannot cross cell membranes, but our results are consistent with 
previous studies reporting that extracellularly added catalase is effective at removing 
intracellular H2O2 (56, 57).   
The final ROS investigated was ONOO-, by employing uric acid, an intracellular 
antioxidant that scavenges and becomes nitrosated by ONOO-(58).  Pretreatment of RBS-
HeLa cells with 1 mM uric acid prior to 10 µM STS for 24 hours had no effect on the 
RLuc8:fLuc ratio.  Interestingly, ONOO- has been reported to deplete intracellular GSH 
levels(59); therefore it would be expected that the scavenging of ONOO- by uric acid 
would alleviate this depletion, effectively reducing ROS and the RLuc8:fLuc ratio.  
However, the RLuc8:fLuc ratio did not decrease with uric acid pretreatment, suggesting 
that GSH may not be a primary target for ONOO-. 
Dosing studies of the three H2O2 related inhibitors on STS-treated RBS-HeLa 
cells revealed a reduction in the RLuc8:fLuc ratio in a dose-dependent manner, 
confirming that fLuc activity could be recovered by reducing H2O2 levels in STS-treated 
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cells.  Additionally, a Western blot performed on STS-treated RBS-HeLa pretreated with 
each inhibitor/scavenger resulted in the rescue of fLuc protein levels when compared to 
STS treatment alone.  Therefore, H2O2 inhibitors/scavengers were able to significantly 
reduce the degradation and/or modification of fLuc.  The increase in H2O2 levels of STS-
treated RBS-HeLa cells over time further supports the intrinsic involvement of H2O2 on 
the RBS mechanism, as does the striking increase in the RLuc8:fLuc ratio of these cells 
when treated directly with H2O2 in serum. 
Since the highest level of fLuc rescue was seen when RBS-HeLa cells were 
pretreated with allopurinol, an XO inhibitor, an additional cellular assay was performed 
with HX and XO added to the media of RBS-HeLa cells.  Here, the RLuc8:fLuc ratio 
also increased significantly (p<0.01) after 24 hours.  While it has been thought that this 
reaction produces the superoxide anion in addition to H2O2, recent studies have shown 
that H2O2 is the dominant oxidant produced in this reaction(60).  The magnitude of the 
increase was above that of STS treatment, but lower than H2O2 treatment, which was 
expected given that this reaction is expected to produce H2O2 more directly than STS but 
is obviously not as harsh as direct H2O2 application.   
Additionally, it was found that exposing purified RLuc8 and fLuc proteins to the 
HX-XO reaction led to a significant increase (p<0.01) in the RLuc8:fLuc ratio over all 
controls.  These findings suggest that the RBS may be specifically responsive to 
intracellularly produced H2O2 alone, and not other upstream or downstream reactions 
involving other oxygen radicals or enzymes.   
Interestingly, when RBS-HeLa cells were pretreated with allopurinol for 1 hour 
prior to STS, no change in DNA fragmentation levels were seen.  In parallel assays, this 
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pretreatment significantly reduced both the RLuc8:fLuc ratio and intracellular H2O2 level 
compared to cells pretreated with PBS.  The correlation between the RLuc8:fLuc ratio 
and intracellular H2O2 levels supports the notion that the RBS is specifically responsive 
to H2O2 and not other processes associated with cell death.  Further, the inability of 
allopurinol to affect cell death suggests that H2O2 production is a consequence of cell 
death, not a catalyst for cell death. 
To investigate the specific effects of H2O2 on fLuc and RLuc8, these proteins 
were treated with 0-10 mM H2O2.  SDS-PAGE gels and bioluminescence measurements 
of each reaction were obtained throughout the course of 120 minutes and it was found 
that fLuc bioluminescence and protein levels decreased when it was treated alone, while 
both of these metrics remained relatively stable for RLuc8 under the same conditions.  
Interestingly, fLuc bioluminescence appeared to decay more rapidly than fLuc protein 
levels at all H2O2 concentrations tested.  These observations indicate that H2O2 may have 
oxidatively modified or damaged the fLuc proteins, rendering them inactive, prior to 
degradation/protein loss.    
It is hypothesized that H2O2 may differentially affect the proteins of the RBS 
through protein carbonylation prior to degradation, as an increase in this phenomenon 
was seen in STS treated cells versus PBS treated cells.  Additionally, purified fLuc 
proteins exhibited higher levels of carbonylation versus RLuc8 when treated with H2O2.   
Protein carbonylation is irreversible(61), can cause protein aggregates to form(62, 63) 
and targets the damaged proteins for degradation(64). 
 In summary, we have shown that the bioluminescent ratio (RLuc8 activity):(fLuc 
activity) could be used to report on the extent of intracellular stress.  Through various 
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inhibition assays, it has been determined that the likely candidate causing the discrepancy 
between fLuc and RLuc8 activity in STS-treated cells is H2O2.  The specific affect that 
H2O2 has on fLuc compared to RLuc8 has yet to be determined.  An initial theory 
involved specific amino acid modifications on the proteins by H2O2.  For example, H2O2 
can modify certain amino acids, including but not limited to methionine (M), cysteine 
(C), histidine(H), tyrosine (Y) and phenylalanine (F), (see(38), for review), often creating 
hydroxyl- or carbonyl-derivatives.  The proposed active site for fLuc is 244H-H-Glycine-
F-247 (65) while the proposed active site for rLuc is a catalytic triad composed of 
aspartic acid (D) 120, glutamic acid (E) 144, and H285(66).  Given that both of these 
active sites contain amino acids that are commonly oxidatively modified, it is not clear 
whether the differential sensitivity of fLuc and RLuc8 to H2O2 can be attributed to this 
alone. 
We have determined that the RBS has the potential to relay important information 
regarding hydrogen peroxide in HeLa cells undergoing cell death.  Given that caspases 
did not influence the RBS (Figure 3A), we anticipate that the RBS may be quite useful in 
studies examining caspase-independent cell death, especially since these pathways 
generally involve an increase in ROS (67, 68).  Caspase-independent cell death has 
recently been garnering attention in terms of cancer drug development since anticancer 
drug resistance and tumorigenesis have been linked to the ability of certain cancers to 
circumvent caspase activation(69, 70).  It is envisioned that the in vitro findings 
presented here will correlate well with in vivo work, potentially opening doors for 
advances in therapeutic and antioxidant research. 
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Chapter 5: The RBS can detect caspase-dependent PCD in 
multiple cell lines using multiple inducers 
5.1 Abstract 
 Many imaging sensors currently utilized to investigate PCD rely on the cleavage 
of the amino acid sequence DEVD by caspase-3.  However, caspase-3 activity is 
transiently activated and thus does not always directly correlate with the extent of cell 
death.  Further, since caspase-7 can also cleave DEVD, PCD sensors based on caspase-3 
activity may lead to ambiguous findings and inaccurate conclusions.  In this chapter, we 
show RBS measurements consistently correlate with the extent of cell death, even in 
cases where caspase-3 probes fail.  The RBS was used to detect PCD in MCF7 and 
293T/17 cells treated with STS and in HeLa cells treated with DOX and Cpt to 
demonstrate the robustness of this approach. 
5.2 Introduction 
According to the American Cancer Society, cancer remains one of the most 
devastating diseases in the United States with over 500,000 deaths and 1.5 million new 
cases in 2009.  Although great strides have been made in the pursuit of cancer 
therapeutics, the vast array of cancer phenotypes makes it an elusive target for definitive 
cures.  As a result, there remains much to be discovered in terms of improving treatment.  
Many therapies that have been developed to treat cancer involve inducing 
apoptosis, a type of programmed cell death (PCD), that is mechanistically characterized 
by a proteolytic cascade involving caspases (See (1) for comprehensive review).  
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Accordingly, a variety of sensors have been developed to image and monitor apoptosis, 
or more specifically caspase activity, to further assist in the discovery, development, and 
evaluation of apoptosis-inducing agents.  Most of these sensors are based on fluorescence 
resonance energy transfer (FRET) or ground-state quenching, whereby removal of an 
acceptor fluorophore or quenching moiety, respectively, following cleavage of a caspase-
specific recognition sequence results in detectable change in fluorescence(2-11). 
Bioluminescence is an appealing alternative to fluorescence due to its sensitivity, 
cost-effectiveness, simplicity, virtually non-existent background signals, high-throughput 
screening potential and ability to acquire temporal information in cells and in live animal 
models.  Recently, several bioluminescent sensors for apoptosis have also been 
developed.  In general, these sensors have utilized the cleavage of the caspase-3 
recognition sequence, DEVD, as a catalyst for luciferin (substrate) recognition(12, 13), 
removal of steric hindrance(14), or protein fragment complementation(15).  However, 
many drugs that induce PCD act through a caspase-independent mechanism (see (16) for 
review), which would render caspase-specific sensors futile.  Another confounding factor 
in regarding sensors for caspase-3 is that caspase-7 recognizes and cleaves the same 
amino acid sequence (DEVD) as caspase-3.  Thus, sensors designed specifically for 
caspase-3 activity as a biomarker for apoptosis may not accurately report on intracellular 
mechanisms associated with cell death or the extent of cell death when used alone. 
We have previously determined that the RBS is activated in HeLa cells 
undergoing apoptosis and that the response correlates with intracellular H2O2 levels.  In 
this chapter, we show that the RBS also functions in MCF7 and 293T/17 cell lines treated 
with STS and in HeLa cells treated with doxorubicin (DOX) and camptothecin (Cpt), two 
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drugs known to induce apoptosis in HeLa cells(17, 18).  The capability of the RBS to 
detect PCD induced in multiple cell types and with different drugs demonstrates its 
versatility and robustness. 
 
5.3 Results 
 When RBS-MCF7 cells were treated with the apoptosis inducing drug 
staurosporine (STS) for 6 hours, the fLuc bioluminescence decreased by up to 90% in a 
dose-dependent manner.  In contrast, the RLuc8 bioluminescence was much less sensitive 
to the treatment, only decreasing by 20% at the maximum dosage (Figure 5.1A).  The 
resulting bioluminescent ratio RLuc8:fLuc increased accordingly with dosage.  It was 
previously shown in Chapter 4, with purified bioluminescent proteins and in living cells, 
that changes in the ratio RLuc8:fLuc correlate with the level of H2O2.  Consistent with 
this assessment, the intracellular H2O2 levels in MCF7 cells also increased with STS 
dose, as determined by a CM-H2DCFDA assay (Figure 5.1B).  To confirm that the STS 
treatment was causing apoptosis, two cell death assays were performed in parallel.  As 
can be seen in Figures 5.1C and 5.1D, both caspase 3/7 activity and DNA fragmentation, 
well-known hallmarks of apoptosis(19, 20), increased under the same treatment 
conditions.    
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Figure 5.1. Response of RBS-MCF7 cells to increasing STS dosage.  RBS-MCF7 cells were treated with a 
dosage range of STS (0-50 µM) for 6 hours. (A) Bioluminescent measurements of RLuc8 and fLuc were 
acquired for each STS concentration after 6 hours (left axis). The RLuc8:fLuc ratio was subsequently 
calculated for each STS concentration (right axis).  (B) Intracellular H2O2 levels were assessed using CM-
H2DCFDA at each STS concentration.  (C) A Caspase 3/7 Glo assay was performed to measure caspase 
activity at each STS concentration.  (D) A TUNEL assay for DNA fragmentation was performed at each 
STS concentration. 
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As described in Chapter 4, fLuc bioluminescence in STS-treated RBS-HeLa cells 
can be rescued by pretreatment with allopurinol, resulting in a corresponding reduction in 
the ratio RLuc8:fLuc.  Allopurinol is a xanthine oxidase (XO) inhibitor that is known to 
reduce the intracellular level of H2O2(21). To investigate the effects of this pretreatment 
on RBS-MCF7 cells, 100 µM of allopurinol was added to the cells one hour before 
treatment with 1 µM STS for 6 hours.  As expected, this resulted in a significant decrease 
in the RLuc8:fLuc ratio (p < 0.05) compared to STS treatment alone (Figure 5.2A).  
Interestingly, pretreatment with allopurinol had no effect on cell death, as shown by 
unchanged caspase 3/7 activity and DNA fragmentation in Figures 5.2B and 5.2C.  
However, a significant (p < 0.05) decrease in intracellular H2O2 was seen when MCF7 
cells were pretreated with allopurinol before the addition of STS (Figure 5.2D).   
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Figure 5.2. Response of STS-treated RBS-MCF7 cells to allopurinol pretreatment.  RBS-MCF7 cells were 
pretreated with 100 µM allopurinol for 1 hour prior to 1 µM STS for 6 hours (A) RLuc8:fLuc ratios were 
acquired for cells exposed to PBS pretreatment followed by PBS as drug treatment (i.e. PBS/PBS), 
PBS/STS or Allo/STS.  (B) Caspase 3/7 activity was acquired for cells exposed to PBS/PBS, PBS/STS or 
Allo/STS.   (C) TUNEL assays for DNA fragmentation were performed on cells exposed to PBS/PBS, 
PBS/STS or Allo/STS.  (D) Intracellular H2O2 measurements were acquired for cells exposed to PBS/PBS, 
PBS/STS or Allo/STS.  In all studies (except TUNEL assays, which provide an absolute measure of cell 
death), measurements were normalized to control (0 µM STS). Statistical significance: * (p<0.05), ** 
(p<0.01). 
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The STS treatment studies were expanded over a time course of 24 hours using 10 
µM STS on RBS-MCF7 cells.  As shown in Figure 5.3A, the RLuc8:fLuc ratio increased 
dramatically over this time course while the PBS treated controls exhibited little change. 
Consistent with the RBS measurements, the intracellular H2O2 levels continually 
increased from 0 to 24 hours with STS treatment and exhibited little change with only 
PBS treatment (Figure 5.3B).   
Interestingly, caspase activity did not continuously increase with time following 
the addition of STS, but rather reached a peak at the 6 hour time point and returned to 
control values by 24 hours (Figure 5.3C).  In contrast, the TUNEL assay revealed that 
cell death remained elevated for the entire 24 hours after STS treatment (Figure 5.3D).   
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The versatility of the RBS was tested further in 293T/17 cells.  When RBS-
293T/17 cells were treated with a dosage range of STS (0-50 µM) for 6 hours, fLuc 
bioluminescence decreased and RLuc8 bioluminescence remained relatively stable with 
increasing dosage (Figure 5.4A, left axis); thus an increase in the RLuc8:fLuc ratio was 
Figure 5.3. Response of RBS-MCF7 to treatment with PBS (untreated control) or 10 µM STS over the 
course of 24 hours.  (A) Bioluminescent measurements of RLuc8 and fLuc were acquired at various times 
following treatment with STS or PBS (left axis) and the RLuc8:fLuc ratios were subsequently calculated 
(right axis). (B) Intracellular H2O2 levels were measured during the course of treatment. (C) Caspase 
activity measurements were acquired at various time points.  (D) The percent DNA fragmentation was 
determined at various time points using a TUNEL assay.  In all studies (except TUNEL assays, which 
provide an absolute measure of cell death), measurements were normalized to control (time = 0). 
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observed (Figure 5.4A, right axis).  Under the same treatment conditions, a rise in 
intracellular H2O2 was exhibited (Figure 5.4B). The two control assays for cell death 
revealed that caspase-3 activity increased (Figure 5.4C) along with DNA fragmentation 
(Figure 5.4D), indicating that increasing STS dosage led to a corresponding increase in 
PCD. 
Figure 5.4. Response of 293T/17 cells to increasing STS dosage.  RBS-293T/17 cells were treated with a 
dosage range of STS (0-50 µM) for 6 hours. (A) Bioluminescence measurements of RLuc8 and fLuc were 
acquired for each STS concentration after 6 hours (left axis). The RLuc8:fLuc ratio was subsequently 
calculated for each STS concentration (right axis).  (B) Intracellular H2O2 levels were assessed using CM-
H2DCFDA at each STS concentration.  (C) A Caspase 3/7 Glo assay was performed to measure caspase 
activity at each STS concentration.  (D) A TUNEL assay for DNA fragmentation was performed at each 
STS concentration. 
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The effects of 10 µM STS over the course of 24 hours were also examined in 
RBS 293T/17 cells.  As expected, the RLuc8:fLuc ratio increased with time, as shown in 
Figure 5.5A, while the PBS treated control remained unchanged.  Similarly, intracellular 
H2O2 (Figure 5.5B) levels increased when treated with 10 µM STS for up to 24 hours 
compared to PBS treated controls.  The two control assays for cell death indicated that 
caspase-3 activity increased (Figure 5.5C) and DNA fragmentation (Figure 5.5D), also 
increased with time. 
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Similar to RBS-MCF7 and RBS-HeLa cells, RLuc8:fLuc ratio and intracellular 
H2O2 levels in STS-treated RBS-293T/17 cells (10 µM STS for 24 hours) could be 
significantly reduced (p<0.05) by the application of 100 µM allopurinol for one hour 
Figure 5.5. Response of RBS-293T/17 to treatment with PBS (untreated control) or 10 µM STS over the 
course of 24 hours.  (A) Bioluminescent measurements of RLuc8 and fLuc were acquired at various times 
following treatment with STS or PBS (left axis) and the RLuc8:fLuc ratios were subsequently calculated 
(right axis). (B) Intracellular H2O2 levels were measured during the course of treatment. (C) Caspase 
activity measurements were acquired at various time points.  (D) The percent DNA fragmentation was 
determined at various time points using a TUNEL assay.  In all studies (except TUNEL assays, which 
provide an absolute measure of cell death), measurements were normalized to control (time = 0). 
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prior to STS, as shown in Figure 5.6A and 5.6B, respectively.  These results further 
support the notion that the PCD detection of the RBS is related to H2O2 levels.  
 
Further investigation of the capabilities of the RBS involved treating RBS-HeLa 
cells with doxorubicin (DOX) and camptothecin (Cpt).  RBS-HeLa cells treated with 1 
µM DOX exhibited an increase in the RLuc8:fLuc ratio over the time course of 48 hours, 
compared to control (Figure 5.7A).  In addition, intracellular H2O2 levels also increased 
in DOX-treated cells compared to controls (Figure 5.7B). The application of 10 µM Cpt 
for up to 48 hours elicited similar results for the RLuc8:fLuc ratio (Figure 5.7C) and 
intracellular H2O2 levels (Figure 5.7D).   
 
 
Figure 5.6. Effect of allopurinol on PBS (-STS) and STS treated RBS-293T/17 cells.  100 µM                                      
allopurinol or PBS was added to the cells for 1 hour prior to PBS or 10 µM STS application for 24 hours. 
(A) RLuc8 and fLuc bioluminescence measurements were obtained and the RLuc8:fLuc ratio is calculated 
and reported.  (B) Intracellular H2O2 levels were measured using CM-H2DCFDA.  For both assays, values 
were normalized to PBS/PBS treated controls.  Statistical significance: *(p<0.05). 
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When RBS-HeLa cells were treated with 1 µM DOX over a time course of 48 
hours, caspase-3 activity increased, compared to PBS treated control (Figure 5.8A).  
Under the same treatment conditions, DNA fragmentation percentage increased 
predominantly from 24 to 48 hours (Figure 5.8B).  The application of 10 µM Cpt on 
Figure 5.7. Effects of DOX and Cpt on RBS-HeLa cells.  RBS-HeLa cells were treated with PBS (i.e. 
untreated control), 1 µM DOX or 10 µM Cpt over the time course of 48 hours.  RLuc8 and fLuc 
bioluminescence measurements were taken at various time points following treatment with (A) DOX or (C) 
Cpt or PBS and the RLuc8:fLuc ratio was calculated.  Intracellular H2O2 levels were measured in cells 
treated with (B) DOX, (D) Cpt or PBS.  All reported values were normalized to time 0. 
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RBS-HeLa cells for 48 hours yielded a similar increase in caspase-3 activity (Figure 
5.8C).  The percent of DNA fragmentation increased earlier in the Cpt treated cells 
(Figure 5.8D) compared to DOX-treated cells, but the kinetic profile was similar between 
24 and 48 hours. 
Figure 5.8. Response of commercial cell death assays in RBS-HeLa cells treated with DOX or Cpt.  
Caspase activity measurements were taken at various time points using Caspase-3/7 Glo after (A) 1 µM 
DOX , (C) 10 µM Cpt or PBS treatment on RBS-HeLa cells.  Values were normalized to PBS (untreated) 
control at time 0.  TUNEL assays for DNA fragmentation were performed on cells treated with (B) DOX, 
(D) Cpt, or PBS.  In all studies (except TUNEL assays, which provide an absolute measure of cell death), 
measurements were normalized to control (time = 0). 
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To investigate the role of H2O2 in the mechanism of the RBS in HeLa cells treated 
with DOX and Cpt, RBS-HeLa cells were pretreated with 100 µM allopurinol for 1 hour 
prior to drug treatment.  Allopurinol pretreatment prior to 1 µM DOX application yielded 
a significant (p<0.05) decrease in the RBS ratio compared to PBS pretreated control 
(Figure 5.9A).  Intracellular H2O2 levels also decreased significantly (p<0.01) with 
allopurinol pretreatment before DOX application (Figure 5.9B).  Similar significant 
decreases (p<0.01) in the RLuc8:fLuc ratio and intracellular H2O2 levels were 
demonstrated in RBS-HeLa cells treated with allopurinol prior to 10 µM Cpt (Figure 
5.9C and 5.9D, respectively).   
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5.4 Discussion 
It was shown in chapter 3 that the RBS is responsive to cell death induced by STS 
in HeLa cells.  To begin to investigate the span of cell types in which the RBS could 
Figure 5.9. Response of DOX and Cpt treated RBS-HeLa cells to allopurinol pretreatment.  RBS-HeLa 
cells were treated with PBS or 100 µM allopurinol for 1 hour prior to 1 µM DOX or 10 µM Cpt for 48 
hours.  RLuc8 and fLuc bioluminescence measurements were taken at various time points following 
treatment with (A) DOX or (C) Cpt and the RLuc8:fLuc ratio was calculated.  Intracellular H2O2 levels 
were measured in cells treated with (B) DOX, (D) Cpt or PBS.  All reported values were normalized 
PBS/PBS treated controls. 
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function, RBS-MCF7 and RBS-293T/17 cells were also subjected to STS dosage and 
time course studies.  The RBS exhibited an increase in the RLuc8:fLuc ratio in both cell 
lines with an increase in STS dosage (6 hour treatment); additionally, the RLuc8:fLuc 
ratio increased with time in RBS-MCF7 and RBS-293T/17 cells treated with 10 µM STS 
for up to 24 hours.  Corresponding assays for cell death demonstrated that both cell lines 
were undergoing PCD under these conditions, which was expected based on previous 
reports of STS inducing PCD in MCF7 (22) and 293T/17 cells(23).  The ability of the 
RBS to relay information on cell death in MCF7 and 293T/17 cells in addition to HeLa 
cells indicates its versatility and potential for utilization over a wide range of cellular 
research endeavors. 
Similar to HeLa cells, when MCF7 and 293T/17 cells are treated with STS, cell 
death was accompanied by an increase in H2O2.  These findings suggest that H2O2 levels 
are increased in a wide range of cell lines as a consequence of STS-induced PCD, 
consistent with previous reports(24, 25).  As shown in chapter 4, the RLuc8:fLuc ratio 
can be reduced in STS-treated RBS-HeLa cells by pretreatment with allopurinol, and this 
reduction is due to the rescue of functional fLuc protein levels.  Allopurinol, a xanthine 
oxidase (XO) inhibitor(21), prevents the oxidation of xanthine or hypoxanthine by XO, 
thereby reducing production of the dominant oxidant of H2O2(26).  The treatment of 
RBS-MCF7 cells with allopurinol for 1 hour prior to STS effectively reduced the RBS 
ratio and intracellular H2O2 levels, while leaving caspase-3 activity and DNA 
fragmentation unchanged.  The correlation between the decrease in intracellular H2O2 and 
the reduction in the RLuc8:fLuc ratio further supports the notion that the RBS is 
specifically responsive to H2O2 during cell death.  However, the inability of allopurinol to 
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affect the extent of cell death suggests that H2O2 production is a consequence of cell 
death, not a catalyst for cell death. 
The STS time course studies on RBS-MCF7 cells introduced an interesting 
disparity between caspase-3 activity and DNA fragmentation, RBS ratio and intracellular 
H2O2 levels; namely, caspase-3 activity returned to near-control levels while the 
remaining three parameters continued to increase.  These results highlight how the use of 
caspase-3 activity as a biomarker for cell death could potentially lead to ambiguous 
findings, due to the transient nature of its activation.  Here, the RBS may hold an 
advantage over traditional cell death assays, since it is capable of detecting cell death 
when caspase activity assays cannot and it possesses real-time detection ability.  
Additionally, the RBS can be used for in vivo assays, an ability that is not characteristic 
of the TUNEL assay.  The correlation between the TUNEL assay and the RBS, even in 
the absence of caspase activity, suggests that the RBS may be able to provide insight on 
cells undergoing caspase-independent PCD. This would not be entirely surprising 
considering that many previous studies have shown that caspase-independent cell death 
pathways can involve ROS(27-32). 
Inducing caspase-dependent cell death (apoptosis) in tumor cells remains a topic 
of interest regarding cancer therapeutics, and DOX and Cpt are two well-established 
therapeutics (see (33, 34) for reviews, respectively).  The overall increasing trend in 
RLuc8:fLuc ratio, DNA fragmentation and H2O2 levels following DOX- and Cpt-
treatment suggests that the RBS will likely detect cell death under a vast array of 
induction methods.  Many other drugs have also been shown to result in an increase in 
H2O2 levels.  For example, it has been shown that murine epidermal cells treated with 
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vanadate undergo apoptosis and exhibit an increase in intracellular H2O2 cells(35).  Also, 
apoptosis induced by erbstatin (36), vinblastine and inostamycin (37) in human small cell 
lung carcinoma cells is accompanied by increased intracellular H2O2 levels.   
In summary, we have determined that the RBS is capable of detecting PCD in 
multiple cell lines using multiple inducers.  It is envisioned that the RBS will prove to be 
useful for investigations of any death-inducing conditions that are accompanied by an 
increase in H2O2 levels.  Given that the RBS does not rely on caspases for its 
functionality, it is hypothesized that it may perform well during instances of caspase-
independent PCD as well. 
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Chapter 6: The RBS can detect caspase-independent PCD 
through pathways involving ROS production, Bcl-2 
downregulation and mitochondrial membrane 
permeabilization 
6.1 Abstract 
 A variety of cancer phenotypes possess the ability to evade caspase activation and 
this can result in both tumorigenesis and anticancer drug resistance, especially if the 
drugs are designed to induce caspase-dependent PCD.  Accordingly, the development of 
drugs that induce caspase-independent PCD has been garnering much attention in the 
scientific community.  It is envisioned that the ability to monitor caspase-independent 
PCD through molecular imaging would undoubtedly lead to both novel and improved 
cancer therapeutics.  In this chapter, we show that the RBS is capable of detecting 
caspase-independent PCD induced by different compounds that act through distinct 
pathways.  
6.2 Introduction 
 
While caspase-3 activation is considered a gold-standard for the identification of 
cells undergoing programmed cell death (PCD), caspase-independent PCD has recently 
been attracting attention in regards to cancer drug development.  Anticancer drug 
resistance and tumorigenesis have been linked to the ability of certain cancer types to 
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evade caspase activation(1, 2).  Thus, it is envisioned that cancer therapeutics that induce 
caspase-independent PCD could have widespread impact.   
In one study, caspase-independent PCD was induced in HeLa cells treated with 
sodium selenite (SSe)(3).  Here, it was deduced that p53 and p38 were activated 
independently of caspases through an oxidative stress mediated process.  It has also been 
shown that resveratrol induces caspase-independent PCD in MCF7 cells through Bcl-2 
downregulation, mitochondrial membrane permeabilization and ROS production without 
caspase 3 activation, PARP cleavage or cytochrome c release(4).  In another study, 
various microtubule stabilizing agents (MSAs) induced caspase-independent PCD in non-
small cell lung carcinoma (NSCLC) cells and it was found that cathepsin B played a 
pivotal role(5).  Additionally, paclitaxel, a type of MSA(6), has been shown to induce 
caspase-independent PCD in ovarian cancer cells through an apoptosis inducing factor 
(AIF) mechanism(7).  Other groups have reported caspase-independent PCD in arsenic 
trioxide-treated myeloma cells(8), vitamin D-treated breast cancer cells(9, 10), and 
flavopiridol-treated glioma cells(11). 
The therapeutic need for agents that induce caspase-independent PCD gives rise 
to the necessity of assays that can detect this phenomenon.  Additionally, current studies 
involving these types of agents will likely warrant assays that can be extended to animal 
models.  Currently, not all PCD sensors rely on caspase activity as a metric for PCD.  The 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, first 
developed in 1992(12), detects DNA strand breaks after terminal deoxynucleotidyl 
transferase (TdT) incorporates labeled dUTP at break sites; DNA fragmentation is a 
hallmark of cells undergoing PCD(13).  CytoTox Glo is a bioluminescent assay that 
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measures the activity of certain intracellular proteases (dead-cell proteases) that are 
released from cells with compromised membranes.  Additionally, assays that measure the 
reduction of various tetrazolium salts, such as MTT(14), XTT(15) and WST-1(16), by 
intracellular dehydrogenases active only in living cells are commonly used.  However, it 
is important to note that these reduction assays are actually a measure of cell viability as 
opposed to cell death.  Although all of these assays clearly have utility in measuring PCD 
in cell culture, most of them are not appropriate for real-time imaging/detection and/or 
imaging in animal models of disease.  These limitations arise from the need for cell lysis, 
the use of membrane impermeable substrates, and/or the use of green fluorescent dyes, 
which are generally masked by autofluorescence in vivo.    
Notably, many instances of caspase-independent PCD involve an increase in the 
intracellular level of reactive oxygen species (ROS)(1-3, 17). Therefore, imaging agents 
that specifically detect ROS could potentially be used to identify cells undergoing 
caspase-independent cell death.  In this chapter, we show that the RBS is able to detect 
caspase-independent PCD with inducers that involve distinct pathways, and that this 
detection corresponds with intracellular H2O2 levels. 
6.3 Results 
 
To test the hypothesis that the RBS may be able to provide insight into cells 
undergoing caspase-independent PCD, RBS-HeLa cells were treated with sodium selenite 
(SSe). This compound has been shown to induce caspase-independent PCD in HeLa cells 
through oxidative stress mediated activation of p53 and p38(3).  When RBS-HeLa cells 
were treated with a dosage range of SSe for 24 hours, the RLuc8:fLuc ratio increased 
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(Figure 6.1A), while caspases 3 and 7 remained relatively inactive (Figure 6.1B).  Under 
the same conditions, the intracellular H2O2 levels also rose appreciably (Figure 6.1C).  
Additionally, to examine whether or not SSe caused cell death, a TUNEL assay was 
performed.  As seen in Figure 6.1D, DNA fragmentation increased with SSe treatment.   
 
Figure 6.1. Response of RBS-HeLa cells to increasing doses of sodium selenite.  Sodium selenite (SSe) 
was added to RBS-HeLa cells at a concentration range of 0-55 µM for 24 hours.  (A) RLuc8:fLuc ratios 
were calculated for treated RBS-HeLa cells.  (B) Caspase activity in treated RBS-HeLa cells was measured 
using Caspase 3/7 Glo.  (C) Intracellular H2O2 measurements in treated RBS-HeLa cells were obtained 
using CM-H2DCFDA.  (D) A TUNEL assay for DNA fragmentation was performed on treated RBS-HeLa 
cells.  In all studies (except TUNEL assays, which provide an absolute measure of cell death), 
measurements were normalized to control (0 µM SSe). 
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Parallel studies were performed on RBS-MCF7 cells using SSe; the pathway in 
which SSe induces PCD in MCF7 cells remains unknown, however it has been shown to 
decrease viability in these cells(18).  With increasing SSe dosage (0 – 55 µM), the 
RLuc8:fLuc ratio of the RBS increased (Figure 6.2A), caspase-3 activation was not 
observed (Figure 6.2B), and intracellular H2O2 and DNA fragmentation levels (Figure 
6.2C and 6.2D, respectively) increased.  
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Figure 6.2. Response of RBS-MCF7 cells to increasing doses of sodium selenite.  Sodium selenite (SSe) 
was added to RBS-MCF7 cells at a concentration range of 0-55 µM for 48 hours.  (A) Bioluminescent 
measurements of RLuc8 and fLuc were acquired at each SSe concentration and the RLuc8:fLuc ratios were 
subsequently calculated.   (B) A Caspase 3/7 Glo assay was performed to measure caspase activity at each 
SSe concentration.  (C) Intracellular H2O2 levels were assessed using CM-H2DCFDA at each SSe 
concentration.  (D) A TUNEL assay for DNA fragmentation was performed at each STS concentration.  In 
all studies (except TUNEL assays, which provide an absolute measure of cell death), measurements were 
normalized to control (0 µM SSe). 
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To further examine the detection of caspase-independent PCD by the RBS, 
resveratrol was used as a cell death inducer in RBS-MCF7 cells.  Resveratrol has been 
shown to induce caspase-independent PCD in MCF7 cells through Bcl-2 downregulation, 
mitochondrial membrane permeabilization and ROS production without caspase 3 
activation, PARP cleavage or cytochrome c release(4).   As shown in Figure 6.3A, when 
RBS-MCF7 cells were treated with increasing dosages of resveratrol for 24 hours, the 
RLuc8:fLuc ratio increased.  Similarly to the SSe studies, caspases remained relatively 
inactive while intracellular H2O2 and DNA fragmentation levels increased (Figure 6.3B-
D).   
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Figure 6.3. Response of RBS-MCF7 cells to increasing doses of resveratrol.  Resveratrol (Res) was added 
to RBS-MCF7 cells at a concentration range of 0-1000 µM for 24 hours.  (A) RLuc8:fLuc ratios were 
calculated for treated RBS-MCF7 cells.  (B) Caspase activity in treated RBS-MCF7 cells was measured 
using Caspase 3/7 Glo.  (C) Intracellular H2O2 measurements in treated RBS-MCF7 cells were obtained 
using CM-H2DCFDA.  (D) A TUNEL assay for DNA fragmentation was performed on treated RBS-MCF7 
cells.  In all studies (except TUNEL assays, which provide an absolute measure of cell death), 
measurements were normalized to control (0 µM Res). 
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As with previous studies with cell death inducers, allopurinol was used as an 
inhibitor of xanthine oxidase in order to reduce intracellular H2O2 on both RBS-HeLa and 
RBS-MCF7 cells treated with 55 µM SSe and RBS-MCF7 cells treated with 1 mM Res.  
RBS-HeLa cells pretreated with 100 µM allopurinol for 1 hour prior to 55 µM SSe 
treatment for 24 hours exhibited significant decreases (p<0.05) in both RLuc8:fLuc ratio 
and intracellular H2O2 levels (Figure 6.4A and 6.4B, respectively), compared to PBS 
pretreated controls.  Similarly, when RBS-MCF7 cells were pretreated with 100 µM STS 
for 1 hour before the addition of 55 µM SSe, there was a significant (p<0.05) decrease in 
the RLuc8:fLuc ratio and intracellular H2O2 levels compared to PBS pretreated controls 
after 48 hours, as seen in Figure 4C and 4D, respectively.    Finally, Res-treated RBS-
MCF7 cells that were subjected to allopurinol pretreatment also demonstrated significant 
(p<0.01) reductions in both RLuc8:fLuc (Figure 6.4E) and intracellular H2O2 levels 
(Figure 6.4F) after 24 hours.  
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Figure 6.4. Effect of allopurinol on RBS-HeLa and RBS-MCF7 cells treated with SSe and RBS-MCF7 
cells treated with Res.  PBS or 100 µM allopurinol was added to cells for 1 hour prior to drug treatment.  
RLuc8 and fLuc bioluminescence measurements were acquired and the RLuc8:fLuc ratios were calculated 
and reported for (A) RBS-HeLa cells treated with 55 µM SSe for 24 hours, (C) RBS-MCF7 cells treated 
with 55 µM SSe for 48 hours, (E) RBS-MCF7 cells treated with 1 mM Res.  Intracellular H2O2 levels were 
determined using CM-H2DCFDA for (B) RBS-HeLa cells treated with 55 µM SSe for 24 hours, (D) RBS-
MCF7 cells treated with 55 µM SSe for 48 hours, (F) RBS-MCF7 cells treated with 1 mM Res.  All 
reported values were normalized to untreated controls.  Statistical significance: *(p<0.05), **(p<0.01). 
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When RBS-HeLa cells were pretreated with allopurinol for one hour prior to 55 
µM SSe treatment for 24 hours, the extent of PCD remained unchanged compared to PBS 
pretreatment according to the DNA fragmentation levels reported by the TUNEL assay 
(Figure 6.5A).  DNA fragmentation percentage remained unchanged between PBS and 
allopurinol pretreated RBS-MCF7 cells after the application of 55 µM SSe for 48 hours 
(Figure 6.5B).  Additionally, allopurinol pretreatment conferred no rescue from cell death 
when RBS-MCF7 cells were treated with 1 mM Res, compared to PBS pretreated control 
(Figure 6.5C). 
Figure 6.5. Extent of DNA fragmentation in RBS cells pretreated with allopurinol prior to the addition of 
SSe or Res.  PBS or 100 µM allopurinol was used as a pretreatment for 1 hour prior to adding (A) PBS or 
55 µM SSe to RBS-HeLa cells for 24 hours, (B) PBS or 55 µM SSe to RBS-MCF7 cells for 48 hours, or 
(C) PBS or 1 mM Res to RBS-MCF7 cells for 24 hours.  Statistical significance: *(p<0.01). 
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6.4 Discussion 
 
Given the disparities seen in previous chapters where caspase-3 activity levels did 
not exhibit the same trends as DNA fragmentation levels, it was hypothesized that the 
RBS could be used to detect caspase-independent PCD.  When both RBS-HeLa and 
RBS-MCF7 cells were treated with SSe, the RLuc8:fLuc ratio, percent DNA 
fragmentation and intracellular H2O2 levels increased while caspase-3/7 activity levels 
remained relatively unchanged.  The increase in DNA fragmentation along with the lack 
of appreciable caspase activation show that SSe induces caspase-independent PCD and 
that this form of cell death can be detected by the RBS sensor in HeLa and MCF7 cells.   
Resveratrol application to RBS-MCF7 cells produced results comparable to RBS-
HeLa and RBS-MCF7 cells treated with SSe, further attesting to the impact the RBS may 
have on caspase-independent PCD research.  Given the reported effects of resveratrol on 
the mitochondria and the associated increase in ROS(4), the RBS may be particularly 
useful in studies investigating the targeting of this organelle in cancer therapy(19).  In 
fact, many compounds that target the mitochondria for this purpose create excessive 
amounts of ROS(20-24). 
When cells were pretreated with allopurinol for one hour prior to SSe (RBS-HeLa 
and RBS-MCF7) or resveratrol (RBS-MCF7), the RLuc8:fLuc ratios were significantly 
decreased (p<0.05 for SSe, p<0.01 for resveratrol) compared to cells pretreated with 
PBS.  As shown in previous chapters, this decrease corresponds to a decrease in 
intracellular H2O2.  These results provide strong evidence that the RBS is specifically 
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responsive to the increasing H2O2 levels in SSe/Resveratrol-treated cells.  However, even 
though the RBS is specifically responsive to intracellular H2O2 in cells treated with SSe 
and Res, allopurinol pretreatment did not protect these cells from undergoing PCD, 
according to the TUNEL assay.  Previously, it was reported that these inducers trigger 
PCD through ROS in some manner; however, it is likely that H2O2 is not the catalyst 
since its removal does not prevent PCD, even in cases of caspase-independent cell death. 
This suggests that increasing H2O2 levels are a consequence of cell death.  In spite of 
these results, we still believe that the RBS will prove to be an informative tool in studies 
investigating caspase-independent PCD, given that we and others have shown increases 
in intracellular H2O2 levels in wide varieties of cell types and death inducing 
conditions(25-27). 
Extensive testing of the RBS across different cell lines and with multiple cell 
death inducers has shown that the RBS may be a useful tool in the investigation of cancer 
therapeutics that focus on either caspase-dependent or caspase-independent PCD.  The 
consistent correlation between the RLuc8:fLuc ratio and intracellular H2O2 concentration, 
along with the reduction in the RLuc8:fLuc ratio by allopurinol strongly indicate that the 
RBS detects multiple types of PCD through an ROS (or more specifically, H2O2) 
dependent manner.  This is not entirely surprising, given the reported increases in ROS in 
both caspase-dependent and caspase-independent PCD(1-3, 17, 28).  The intracellular 
H2O2 trends reported here under all cell death inducing conditions tested suggest that the 
RBS will likely perform well in a wide range of PCD-inducing conditions. 
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Chapter 7: The RBS detects programmed cell death in vivo 
7.1 Abstract 
 In regards to optical imaging modalities for in vivo research endeavors 
investigating cancer therapeutics, bioluminescence imaging (BLI) is an attractive choice 
given its simplicity, cost-effectiveness, sensitivity and spatiotemporal imaging abilities.  
There are currently only a few bioluminescent sensors designed to detect PCD, and of 
these, none can specifically detect caspase-independent PCD.  Anticancer drug resistance 
and tumorigenesis have been attributed to the evasion of caspase activation, making 
caspase-independent PCD a new target for cancer therapeutic development.  In this 
chapter, we show that the RBS, which has previously been shown to detect caspase-
dependent and –independent PCD, can detect PCD in murine tumor models, and that this 
detection is related to intracellular levels of H2O2. 
7.2 Introduction 
 Bioluminescence imaging (BLI) has emerged as a powerful molecular imaging 
tool to investigate diverse cellular processes non-invasively and in real-time.  While its in 
vitro utility should not be discounted, its ability to relay physiological information in 
animal models makes it an attractive choice for many research endeavors.  The optical 
properties of some bioluminescent proteins allow for depths of up to a few centimeters to 
be imaged in vivo(1, 2).  The emission wavelength of fLuc is ~600 nm, making it less 
likely to be attenuated in animal tissue.  Cancer cells expressing fLuc have been imaged 
in rat colon(1) and mouse lungs(2), illustrating the potential of BLI to image beyond 
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superficial depths in animal models.  Also, the intrinsically low bioluminescence of 
tissues allows for greater signal-to-background ratios, as opposed to fluorescence, for 
example, where the autofluorescence of tissues causes unwanted background signal, 
effectively reducing this ratio.   
 In addition to its cost-effectiveness, robustness and simplicity, BLI has recently 
proven to be quite useful in high-throughput screening (HTS) assays(3-5).  An advantage 
of using BLI in HTS assays is that lead compounds can be applied to in vivo models that 
utilize the same bioluminescent cellular targets originally tested, thus accelerating the 
translation from bench to clinic.  HTS assays have been employed to identify compounds 
that induce programmed cell death (PCD) in many types of cancer cells including 
retinoblastoma(6), lymphoma(7) and breast cancer stem cells (8), a subpopulation of 
tumor cells that have been shown to drive tumor growth/recurrence (see (9) for review) 
and are resistant to many cancer treatments(10).  It is envisioned that bioluminescent 
probes that detect PCD through cellular and in vivo HTS assays could improve the cancer 
therapeutic milieu. 
 Several bioluminescent sensors for PCD have been developed recently and they 
all target caspase-3, a protease critical for certain manifestations of PCD(11).  In general, 
these sensors have utilized the cleavage of the caspase-3 recognition sequence, DEVD, as 
a catalyst for luciferin (substrate) recognition(12, 13), removal of steric hindrance(14), or 
protein fragment complementation(15).  However, tumorigenesis and anticancer drug 
resistance have been attributed to the ability of cancer cells to evade caspase activation 
and thus caspase-dependent PCD(16, 17).  This phenomenon has led to the investigation 
of therapeutics that induce caspase-independent cell death, for example sodium 
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selenite(18), resveratrol(19) and various microtubule stabilizing agents(20, 21).  The lack 
of caspase activity here deems the aforementioned sensors ineffective in research efforts 
involving this mechanism of PCD. 
 We have shown previously that the Ratiometric Bioluminescent Sensor (RBS) is 
capable of detecting caspase-dependent and caspase-independent PCD in multiple cell 
lines.  Additionally it was shown that the response level of the RBS was directly related 
to intracellular hydrogen peroxide (H2O2) levels.  In this chapter, we show that the RBS 
is capable of detecting PCD in murine tumor models of cervical cancer and that this 
detection correlates with H2O2 levels. 
7.3 Results 
To investigate the capability of the RBS to provide information on cell death in 
vivo, RBS-HeLa tumor xenografts were grown in nude mice (n = 3 per group).  Tumors 
were initially treated with PBS or Allopurinol as an inhibitor, followed by PBS or STS 1 
hour later.  As seen in Figure 7.1A, control mice that were treated with PBS as an 
inhibitor and PBS as treatment (PBS/PBS) exhibited little change in RLuc8 
bioluminescence after 24 hours (top panel).  Similarly, the fLuc bioluminescence also did 
not change significantly in PBS/PBS-treated mice (Figure 7.1A, bottom panel).  In 
contrast, in PBS/STS-treated mice, the RLuc8 bioluminescence remained stable (Figure 
7.1B, top panel), but the fLuc bioluminescence was significantly diminished after 24 
hours (Figure 7.1B, bottom panel).  When mice were treated with inhibitor alone 
(Allo/PBS), the tumors again exhibited little change in RLuc8 bioluminescence (Figure 
7.1C, top panel), but there was a slight increase in fLuc bioluminescence (Figure 7.1C, 
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bottom panel) after 24 hours.  Finally, when mice were treated with the inhibitor and the 
cell death inducer (Allo/STS), tumors showed little change in bioluminescence for RLuc8 
(Figure 7.1D, top panel) and fLuc (Figure 7.1D, bottom panel).   
 
The bioluminescence values were quantified for each group of animals and the 
RLuc8:fLuc ratio values are reported in Figure 7.2.  Consistent with previous cell culture 
studies, the ratio increased significantly (p < 0.01) between the PBS/PBS and PBS/STS 
groups.  The RLuc8:fLuc ratio decreased slightly from the PBS/PBS groups to the 
Allo/PBS groups; however, the change was not statistically significant. A significant 
Figure 7.1. Assessment of RBS performance in vivo.  Female nude mice bearing RBS-HeLa tumor 
xenografts were imaged prior to and 24 hours after the following inhibitor/drug treatment regiment: 
(A) PBS/PBS, (B) PBS/STS, (C) Allo/PBS, and (D) Allo/STS.  Inhibitors were administered 1 hour 
prior to drug treatment. 
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reduction in the RLuc8:fLuc ratio (p < 0.05) was observed between the PBS/STS and 
Allo/STS groups.   
 
 
 
 
 
 
7.4 Discussion 
 The RBS was tested for its ability to detect PCD in murine tumor models using 
STS.  RBS-HeLa tumors were subjected to one of four conditions: PBS/PBS, PBS/STS, 
Allopurinol/PBS or Allopurinol/STS.  The inhibitor (or control of PBS) was administered 
1 hour prior to drug treatment (or control of PBS).  Representative bioluminescence 
images of each treatment for RLuc8 and fLuc mimicked in vitro results when the same 
cell line (HeLa) and treatment (STS) was investigated (Chapter 3).  The fLuc 
bioluminescence was noticeably diminished in the PBS/STS tumor, while the RLuc8 
bioluminescence remained stable.  Additionally, when tumors were pretreated with 
Figure 7.8. Quantitative analysis of RBS in live animals.  RLuc8 and fLuc bioluminescence counts were 
obtained from mice bearing RBS-HeLa tumor xenografts and treated with PBS/PBS, PBS/STS, Allo/PBS, 
and Allo/STS.  All images were analyzed using Living Image Software.  Following background 
subtraction, the RLuc8:fLuc ratios were calculated and normalized to day 1 values.  Statistical significance: 
* (p<0.05), ** (p<0.01). 
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allopurinol before STS, little change in either signal was observed after 24 hours.  
Interestingly, in the tumors pretreated with allopurinol prior to PBS, an increase in fLuc 
bioluminescence was observed after 24 hours that was not seen with RLuc8.  This could 
be attributed to elevated levels of H2O2 within the hypoxic cores of tumors (see (22) for 
review); after 24 hours of allopurinol treatment, H2O2 levels may be reduced, thus 
restoring the bioluminescence of fLuc.  The quantification of the bioluminescence images 
revealed that the RLuc8:fLuc ratio was significantly increased in the PBS/STS group 
compared to PBS/PBS (p<0.01) and that this ratio was significantly decreased in the 
Allo/STS group compared to PBS/STS (p<0.01).  These results were somewhat expected, 
given the past performance of the RBS in PCD-inducing conditions, both with and 
without allopurinol.  These results provide evidence that the RBS is capable of detecting 
PCD in vivo in an H2O2-related manner. 
 We have shown in this body of work that the RBS detects PCD in vitro and in 
vivo.  Taken together, it is envisioned that the same RBS could be used in HTS assays to 
screen for PCD-inducing drugs, in vitro assays to validate lead compounds and in vivo 
assays to ensure efficacy with minimal toxicity, which would be necessary prior to 
clinical trials.  The in vivo imaging capability of the RBS would potentially allow for a 
more streamlined transition from the initial screen to animal models, given that it has 
been shown to function both in vitro and in vivo. 
 In addition to screens for PCD-inducing compounds, the RBS could be utilized in 
HTS assays that try to identify antioxidant compounds.  An example of this involves the 
burgeoning area of cancer stem cells (CSCs).  This subset of cells within a tumor are 
often resistant to chemotherapeutics (10) and ionizing radiation(23, 24).  This resistance 
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in mammary CSCs has recently been attributed to the lower ROS levels present in these 
cells compared to non-tumorigenic cells(25), since ROS are essential elements involved 
in ionization-mediated PCD(26, 27).  To increase intracellular ROS levels of the 
mammary CSCs, a glutathione (GSH)-depleting agent has been used to decrease 
intracellular levels of the antioxidant GSH.  After GSH depletion, the mammary CSCs 
exhibited higher ROS levels, and thus higher radiosensitization compared to cells with 
normal GSH levels(25).  It can be imagined that the RBS would prove to be useful in 
screens of other compounds that possess the capability of increasing or decreasing 
intracellular antioxidant levels in this system. 
 In summary, we have shown that the RBS is capable of detecting PCD in a 
murine tumor model.  Inhibition studies using allopurinol demonstrated that the RBS is 
likely responsive to intracellular H2O2 levels.  Thus it is envisioned that the RBS may be 
a useful tool in research endeavors involving caspase-dependent or caspase-independent 
PCD as a target for cancer therapeutics. 
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Chapter 8: Overall discussion, future directions and 
concluding remarks 
 
8.1 Overall Discussion 
8.1.1 Development of the Ratiometric Bioluminescent Sensor (RBS) and its response 
to cellular stress in HeLa cells 
Many optical imaging sensors designed to report on PCD are based on the 
specific proteolytic cleavage of the amino acid sequence DEVD by caspase-3, the 
cysteine-aspartic protease that is required for apoptotis(1).  However, caspases are not the 
only proteases that are active during PCD; it has been shown that calpains(2, 3) and 
cathepsins(4, 5) are upregulated during this process.  Additionally, damaging oxidative 
modifications may result from increases in ROS(6-8) that can occur during PCD(9-11).  
Thus, information garnered from fluorescent(12-21) and bioluminescent(22-25) sensors 
for PCD must be scrutinized carefully, given the many opportunities for damage and/or 
modification. 
In order to investigate the sensitivity of bioluminescent proteins during PCD, we 
began by examining the effects of staurosporine (STS), a PCD-inducing drug(26) that has 
also been shown to increase intracellular ROS(9), on HeLa cells transiently expressing 
fLuc or RLuc.  Throughout 24 hours of 1 µM STS treatment, both fLuc and RLuc 
exhibited decreased bioluminescence while a parallel assay indicated that caspase-3 
activity was markedly increased over the same time period.  The disparity between 
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diminished fluc/RLuc bioluminescence and elevated caspase-3 activity confirmed that the 
utilization of these proteins in sensors for PCD must be done with caution, as signals 
would not only reflect caspase activity, but also other degradation/modification 
mechanisms within the cell. 
These observations led us to investigate methods of increasing the stabilities of 
fLuc and RLuc.  The implementation of phenylbenzothiazole (PBT), a chemical reported 
to increase the stability of fLuc by preventing its intracellular degradation(27), abrogated 
the decrease in fLuc bioluminescence previously seen in STS-treated cells.  While 
initially promising, certain limitations prevented PBT from being examined further.  
First, it was unknown whether this chemical would interfere with other intracellular 
proteins or exogenously applied PCD-inducing compounds.  Second, the use of PBT may 
not have translated well into in vivo models due to issues related to administration and 
pharmacokinetics.  Additionally, PBT derivatives have been reported to exhibit anti-
tumor activity(28), which would undoubtedly interfere with both in vitro and in vivo 
assays related to PCD.  Thus, we investigated two luciferase mutants that have been 
reported to exhibit increased stability under various stress conditions, fLuc5(29) and 
RLuc8(30).  The bioluminescence of fLuc5 remained more stable compared to wild-type 
fLuc when transiently expressed in STS-treated HeLa cells.  RLuc8 also exhibited 
improved stability when compared to RLuc under the same conditions, and was the more 
stable of the two variants tested. 
These results led to the hypothesis that if a stable and unstable luciferase were 
incorporated into one sensor, the resulting bioluminescence ratio (stable 
bioluminescence:unstable bioluminescence) could be used to report on the extent of PCD 
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and potentially specific molecular processes associated with PCD (e.g., oxidative stress).  
RLuc8 was chosen as the stable luciferase element because it possessed the greatest 
bioluminescence stability when expressed in HeLa cells undergoing PCD.  Wild-type 
fLuc was chosen as the unstable luciferase element.  Notably, each of these enzymes 
utilizes a different substrate, effectively simplifying the distinction between the 
bioluminescence of fLuc and RLuc8.  The sensor incorporating RLuc8 and fLuc was 
termed the Ratiometric Bioluminescent Sensor, or RBS. 
Preliminary examination of the RBS using STS-treated HeLa cells demonstrated 
that the RLuc8:fLuc ratio, derived from fLuc and RLuc8 bioluminescence measurements, 
correlated well with both caspase activation and DNA fragmentation, two hallmarks of 
cells undergoing PCD(1, 31).  Representative images from STS-treated RBS-HeLa cells 
exemplified similar trends to the recorded fLuc and RLuc8 bioluminescence 
measurements and ratios.  These results suggested that the RBS was capable of detecting 
PCD in STS-treated HeLa cells.   
When RBS-HeLa cells were plated at a range of 0 – 20,000 cells/well of a 96-well 
tissue culture plate, the recorded RLuc8:fLuc ratio was shown to be independent of cell 
number.  Additionally, there was virtually no increase in the RLuc8:fLuc ratio observed 
in RBS-HeLa cells that were incubated (untreated) over a period of 24 hours.  These 
results highlight the potential transitional use of the RBS, from high-throughput screening 
where very small samples are used all the way to animal models, where large numbers of 
cells are usually necessary. 
While these initial studies regarding the RBS and its response to PCD induction 
were promising, the mechanism behind the disparity in fLuc and RLuc8 activity had yet 
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to be determined.  An initial theory involved the use of the IRES sequence in the plasmid 
DNA vector encoding the RBS.  This sequence was incorporated into the plasmid such 
that it was flanked by RLuc8 and fLuc (RLuc8-IRES-fLuc) in order to allow for protein 
translation from a single, bicistronic mRNA(32, 33), effectively eliminating any 
unwanted effects related to altered promoter activity.  Since it has been reported that in 
healthy cells, proteins translated from sequences downstream of the IRES site can be 
expressed at lower levels compared with upstream sequences(34), a ‘reverse RBS’ sensor 
was created (fLuc-IRES-RLuc8) to determine the effects of the positioning of fLuc and 
RLuc8 relative to the IRES sequence.  HeLa cells expressing this sensor exhibited an 
increase in the RLuc8:fLuc ratio when treated with STS.  While this ratio was 
considerably higher than that of the ‘normal’ RBS, this can likely be attributed to the 
transient expression of the ‘reverse’ sensor compared to the stable expression of the 
‘normal’ sensor, specifically the accelerated loss of fLuc activity owing to, the lack of 
genomic integration of the ‘reverse’ RBS plasmid would lead to its dilution through cell 
division and/or degradation. 
After the elimination of the IRES sequence as a source of the explicit differential 
between fLuc and RLuc8 activity, the mechanism behind this difference remained 
unknown.  There have been various reports indicating that the proteasome(35, 36) and 
calpain(2, 3) and cathepsin(4, 5) proteases can play significant roles in PCD. 
Additionally, increases in ROS that can occur in cells undergoing PCD broach the 
possibility of potentially damaging oxidative modifications to proteins(6-8) and/or 
RNA(37).  In the subsequent determination of the RBS mechanism, the roles of these 
proteases and ROS, among others, were investigated.   
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8.1.2 The RBS mechanism relies on ROS, particularly H2O2 
 In order to determine the mechanism behind the bioluminescence disparity 
between fLuc and RLuc8 in the RBS in cells undergoing PCD, an RT-PCR study was 
first performed to assess fLuc and RLuc8 mRNA levels in STS treated cells compared to 
PBS treated cells.  This assay revealed that the relative expression of these mRNAs 
within RBS-HeLa cells did not significantly change regardless of PBS or STS treatment.  
In contrast, Western blot analysis demonstrated that fLuc protein levels decreased over 
the time course of STS treatment, while RLuc8 protein levels remained relatively stable.  
Interestingly, some fLuc staining was observed at higher than expected molecular 
weights at later time points, which could be indicative of protein cross-links or 
posttranslational modifications.  Taken together, these results suggested that the 
mechanism of the RBS involved the bioluminescent proteins themselves, rather than 
mRNA levels. 
Next, various inhibition/scavenging studies were performed on targets known to 
play roles in PCD.  It was expected that certain inhibitors would rescue fLuc activity, 
resulting in a decrease in the RLuc8:fLuc ratio in STS-treated RBS-HeLa cells.  Given 
that the proteasome is responsible for the majority of intracellular protein degradation, it 
was naturally one of the first targets of the inhibition study.  The employment of the 
proteasome inhibitors MG-132, epoxomicin and lactacystin on STS-treated RBS-HeLa 
cells did not rescue fLuc activity and actually caused a slight increase in the RLuc8:fLuc 
ratio.  In the case of epoxomicin, this slight increase was statistically significant 
compared to uninhibited controls.  This result is potentially indicative of increased PCD, 
an effect that has been reported to occur during proteasome inhibition using 
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epoxomicin(35).  Proteasome inhibition has also been shown to increase intracellular 
ROS levels(9, 38-40), possibly implicating ROS in the RBS mechanism.  Nonetheless, 
these results provided strong evidence that enhanced proteasomal degradation was not 
likely responsible for the RBS mechanism.   
The next group of inhibitors focused on various proteases that are associated with 
PCD through various mechanisms: calpains, cathepsins and caspases.  When STS-treated 
RBS-HeLa cells were pretreated with Calpain Inhibitor III, the RLuc8:fLuc ratio was not 
significantly affected compared to PBS pretreated controls.  These results suggested that 
calpains were not involved in the mechanism of the RBS.  Interestingly, an increase in 
the ratio was seen in RBS-HeLa cells treated with PBS following Calpain Inhibitor III.  
This inhibitor has been shown to decrease the levels of intracellular antioxidant 
glutathione (GSH) levels, effectively increasing intracellular ROS(41), again potentially 
implicating ROS in the RBS mechanism. 
Two inhibitors for cathepsins were employed: Pepstatin A (inhibits aspartyl 
proteases) and ammonium chloride (inhibits phagosome-lysosome fustion(42)).  Neither 
of these inhibitors significantly affected the RLuc8:fLuc ratios in STS-treated RBS-HeLa 
cells and hence they were discounted from the mechanism of the RBS.   
Arguably, the most thoroughly characterized proteases involved in PCD are the 
caspase family of proteases (see (43) for review).  To inhibit caspase activity during STS 
treatment of RBS-HeLa cells, the pan-caspase inhibitor z-vad-fmk was employed, and 
surprisingly the use of this inhibitor did not affect the RLuc8:fLuc ratio.  These results 
suggested that caspases did not play a significant role in the disparity between fLuc and 
RLuc8 activity in STS-treated cells. 
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 In addition to proteases, various ROS can contribute to the modification, damage 
or degradation of proteins in dying cells.  Three superoxide (O2
•-
) scavengers, Tiron, 
TEMPOL and MnTMPyP, were tested for their ability to reduce the RLuc8:fLuc ratio in 
STS treated cells.  None of these scavengers had any significant effect on the RLuc8:fLuc 
ratio which led us to conclude that O2
•-
 alone is not responsible for the trends observed in 
STS-treated RBS-HeLa cells.  This was somewhat expected given the short half-life of 
O2
•-
 and its function as a precursor to other oxidizing agents.  However, even though the 
O2
•-
 scavenging abilities of TEMPOL, Tiron and MnTMPyP were confirmed to be 
statistically significant by using a dihydroethidium assay, the intracellular levels of O2
•- 
appeared to be reduced by only ~50%.  Therefore, further studies on the effects O2
•-
 in 
regards to the RBS mechanism may be warranted.  Initial experiments could involve the 
use of other O2
•-
 scavengers, such as SOD transgenes(44). 
 Peroxynitrite (ONOO-) is formed as a result of the reaction between O2
•-
 and 
nitric oxide (NO)(45) and specific amino acid residues (methionine, cysteine, tyrosine 
and tryptophan) are vulnerable to modification by ONOO-(6).  To scavenge ONOO-, the 
scavenger uric acid was used as a pretreatment on STS-treated RBS-HeLa cells.  A slight, 
but insignificant, increase in the RLuc8:fLuc ratio was observed compared to PBS-
pretreated controls which suggested that ONOO- does not play a dominant role in the 
mechanism of the RBS.  Even though there currently exists no commerical assays to 
detect ONOO-, numerous studies have shown that acid is an effective scavenger of 
ONOO-(46-48). 
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The agents mannitol, a specific scavenger of 
•
OH, deferoxamine (DFO), an iron 
chelator, and tetraethylenepentamine (TEPA), a copper chelator, were utilized to examine 
the effects of 
•
OH on the RLuc8:fLuc ratio of RBS-HeLa cells treated with STS.  
Carbon-centered radical formation via hydroxyl radicals (
•
OH) serves to initiate the 
oxidative attack of protein radicals(6).  This carbon-centered radical can give rise to 
protein cross-links, peptide-bond cleavage or direct oxidation of amino acids(6).  The two 
metal chelators, alone and in combination, were used to reduce the amounts of metals 
available for the Fenton reaction (Fe
2+
 + H2O2  Fe
3+
 + 
•
OH + OH
-
).  None of these 
compounds significantly reduced the RLuc8:fLuc ratio, and these results effectively 
eliminated the likelihood that 
•
OH as a direct contributor to the loss in fLuc activity.  It 
may be argued that the slight increase in the RLuc8:fLuc ratio that was observed with 
TEPA could be a result of excess H2O2 buildup from the prevention of the Fenton 
reaction, however further studies are warranted since the combination of DFO + TEPA 
did not yield an additive effect.  Additionally, it remains unclear as to the effect of metal 
chelation on the Fenton reaction.  It has been reported that iron chelation can serve both 
antioxidant(49) and prooxidant(50) functions.   
Hydrogen peroxide (H2O2) is a powerful oxidizing agent that can directly and 
indirectly modify many amino acids, often creating hydroxyl- or carbonyl-derivatives 
(see (51) for review).  It has been shown that this oxidation can destabilize a protein’s 
native structure and result in activity loss(8, 52).  The H2O2 inhibitors/scavengers 
catalase, allopurinol and aspirin were tested for their ability to reduce the RLuc8:fLuc 
ratio in STS-treated RBS-HeLa cells.  The pretreatment of RBS-HeLa cells with these 
reagents prior to STS treatment conferred a significant reduction (p<0.01) in the 
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RLuc8:fLuc ratio.  These findings suggested that fLuc activity could be recovered in 
STS-treated RBS-HeLa cells through removal of H2O2.  It should be noted that catalase 
cannot cross cell membranes, but our results are consistent with previous studies 
reporting that extracellularly added catalase is effective at removing intracellular 
H2O2(53, 54). 
When STS-treated RBS-HeLa cells were subjected to increasing dosages of 
catalase, allopurinol and aspirin, the RLuc8:fLuc ratio decreased in a dose-dependent 
manner.  These results confirmed that fLuc activity could be recovered by reducing H2O2 
levels in STS-treated cells.  Additionally, Western blot analysis indicated that fLuc 
protein levels in STS-treated RBS-HeLa cells were rescued slightly when pretreated with 
each inhibitor compared to PBS-pretreated controls.  Therefore, H2O2 
inhibitors/scavengers were able to reduce the degradation of fLuc in STS-treated RBS-
HeLa cells.   
 Given that the inhibitors/scavengers of H2O2 significantly affected the 
RLuc8:fLuc ratio, additional studies were performed that dealt with H2O2 more directly.  
Intracellular H2O2 levels were measured in STS-treated RBS-HeLa cells over a time 
course of 24 hours and over a dosing range of 0-50 µM.  In both cases intracellular H2O2 
levels increased up to nearly three-fold.  Additionally, when RBS-HeLa cells were treated 
directly with H2O2 in fully supplemented culture medium, the RLuc8:fLuc ratios 
exhibited striking increases.  These results further supported the intrinsic involvement of 
H2O2 in the RBS mechanism. 
 It may be argued that the concentrations of H2O2 used in both the cellular and in 
vitro assays was too high to be biologically relevant.  However, recent studies 
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investigating oxidative stress have employed similar concentrations of H2O2(55, 56).  
Nonetheless, an immunohistochemical analysis of RLuc8 and fLuc proteins in control 
and STS-treated cells may provide insight into any preferential localization of these 
proteins to sites of increased ROS (e.g. peroxisomes) during cell death.  Peroxisomes 
contain ROS and enzymes that generate these species, e.g., xanthine oxidase (see (57) for 
review), thus it can be envisioned that localization of proteins to this organelle could be a 
source excessive ROS exposure that would subsequently modify/damage fLuc. 
 The highest level of fLuc rescue in STS-treated RBS-HeLa cells was exhibited 
when allopurinol, an XO inhibitor, was employed as a pretreatment.  Therefore, RBS-
HeLa cells were subjected to an HX-XO reaction, which has been shown to produce 
H2O2 as the dominant oxidant(58). After 24 hours, a significant (p<0.01) increase in the 
RLuc8:fLuc ratio was observed.  The magnitude of this increase was above that seen with 
STS treatment, but lower than with direct H2O2 treatment, which was expected given that 
this reaction produces H2O2 more directly than STS, but is obviously not as harsh as 
direct H2O2 application.  When purified RLuc8 and fLuc proteins were subjected to the 
HX-XO reaction, the RLuc8:fLuc ratio increased significantly (p<0.01).  These findings 
suggested that the RBS may be specifically responsive to intracellularly produced H2O2 
alone, and not other upstream or downstream reactions involving other ROS or enzymes. 
 We recently measured the amount of H2O2 generated by the HX-XO system we 
employed and it was determined that the concentration was ~5 µM.  However, when both 
RBS-HeLa cells and pure fLuc and RLuc8 proteins were subjected to 5 µM H2O2, no 
differences in the RLuc8:fLuc ratio or activity were observed.  This could be explained 
by degradation of the acutely applied H2O2 at the initial time points of the assays, as 
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opposed to the chronic generation of H2O2 via the HX-XO reaction.  Alternatively, the 
XO enzyme itself contains 4 iron atoms.  The reaction of both O2
•-
 and H2O2 with iron 
can generate damaging 
•
OH, potentially leading to protein crosslinks, peptide bond 
cleavage and amino acid modifications(6).   
 When RBS-HeLa cells were pretreated with allopurinol prior to STS, no changes 
in DNA fragmentation levels were observed.  However, in parallel assays, this 
pretreatment significantly (p<0.01) decreased both the RLuc8:fLuc ratio and intracellular 
H2O2 levels.  This correlation supported earlier findings that the RBS is specifically 
responsive to H2O2 during cell death and not other degradation pathways associated with 
PCD. Further, the ability of allopurinol to reduce H2O2 levels without affecting cell death 
implicated H2O2 production as a consequence of, rather than a catalyst for, cell death. 
 In order to obtain a more definitive understanding of the role of H2O2 in the RBS 
mechanism, purified RLuc8 and fLuc proteins were exposed to a range of H2O2 
concentrations.  Analysis of both SDS-PAGE and bioluminescence measurements 
indicated that when the proteins were treated with H2O2, fLuc bioluminescence and 
protein levels decreased, while RLuc8 bioluminescence and protein levels remained 
relatively stable over the time course for all doses tested.  Additionally, smearing of the 
fLuc protein was observed for most H2O2 concentrations, indicative of possible 
modifications or degradation. Interestingly, fLuc bioluminescence appeared to decay 
more rapidly and to a greater extent than fLuc protein levels at all concentrations tested.  
These observations indicate that H2O2 may have oxidatively modified or damaged the 
fLuc proteins, rendering them inactive, prior to degradation/protein loss.  This conclusion 
would also support the Western blot analysis where fLuc protein levels were rescued by 
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the H2O2 inhibitors/scavengers.  Since oxidatively modified/damaged proteins are often 
targets for proteasomal degradation(59, 60), it can be hypothesized that the H2O2 
inhibitors scavengers prevented oxidative modifications of fLuc that would normally 
trigger proteasomal degradation of the protein. 
 H2O2 may modify the fluc protein through carbonylation; protein carbonylation is 
irreversible(61), can cause protein aggregates to form(51, 62) and targets damaged 
proteins for degradation(63).  When STS-treated RBS-HeLa cells were analyzed for 
protein carbonylation, a substantial increase in this phenomenon was seen when 
compared to PBS treated controls.  Furthermore, when H2O2-treated purified fLuc and 
RLuc8 proteins were subjected to the carbonylation assay, fLuc became extensively more 
carbonylated versus RLuc8, compared to PBS-treated controls.  These results implicated 
protein carbonylation as one of the potential modifications to fLuc in STS-treated RBS-
HeLa cells, especially since it has been shown that H2O2 can cause protein 
carbonylation(51).   
 Investigation into the crystal structures of fLuc and RLuc8 may provide insight 
into the activity disparity between fLuc and RLuc8 in stressed cells as well.  Given that 
certain amino acid residues, namely lysine, arginine, proline, methionine, cysteine and 
tyrosine are preferentially oxidatively modified(6, 64, 65), the relative locations of these 
residues (i.e. on the surface or buried) might explain the differential in oxidative 
modifications leading to fLuc protein activity loss. 
 While the precise mechanism behind the ROS-mediated activity of the RBS has 
yet to be determined, we have shown that it is primarily responsive to intracellular H2O2 
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levels.  Thus, it is envisioned that the RBS will be useful as a sensor for PCD, since many 
instances of PCD are accompanied by ROS production(11, 66-74). 
8.1.3 The RBS can detect caspase-dependent PCD in multiple cell lines using 
multiple inducers 
Many therapies that have been developed to treat cancer involve inducing 
apoptosis, a type of PCD, that is mechanistically characterized by a proteolytic cascade 
involving caspases (See (43) for comprehensive review).  Accordingly, a variety of 
sensors have been developed to image and monitor apoptosis, or more specifically 
caspase-3 activity, to further assist in the discovery, development, and evaluation of 
apoptosis-inducing agents.  These sensors detect caspase-3 by the recognition and 
cleavage of the amino acid sequence DEVD and are either fluorescent(12-21) or 
bioluminescent(22-25) in nature.  However, we have shown caspase-3 activity is not 
always elevated in apoptotic cells (Chapter 3).  Another confounding factor in regarding 
sensors for caspase-3 is that caspase-7 recognizes and cleaves the same amino acid 
sequence (DEVD) as caspase-3.  Thus, sensors designed specifically for caspase-3 
activity as a biomarker for apoptosis may not accurately report on the extent of cell death. 
As shown in chapter 3, the RBS is responsive to cell death induced by STS in 
HeLa cells.  To begin to investigate the span of cell types in which the RBS could 
function, RBS-MCF7 cells were treated with a dosage range of STS (0 – 50 µM) for 6 
hours.  Here, fLuc bioluminescence decreased by up to 90% while RLuc8 remained 
relatively insensitive to the treatment and only decreasing by 20%.  Accordingly, the 
RLuc8:fLuc ratio increased with increasing STS dose.  Additionally, intracellular H2O2 
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levels, caspase-3 activity and DNA fragmentation levels all increased with STS dosage in 
RBS-MCF7 cells, consistent with the notion that the RBS detects PCD through a H2O2-
related mechanism.  When RBS-293T/17 cells were treated with the same STS dosage 
range for 6 hours, increases were also seen in the RLuc8:fLuc ratio, intracellular H2O2 
levels, caspase-3 activity and DNA fragmentation levels.  The ability of the RBS to relay 
information on cell death in MCF7 and 293T/17 cells in addition to HeLa cells indicates 
its versatility and potential for utilization over a wide range of cellular research 
endeavors. 
The treatment of RBS-MCF7 and 293T/17 cells with allopurinol for 1 hour prior 
to 10 µM STS for 6 hours effectively reduced the RBS ratio and intracellular H2O2 levels, 
while leaving caspase-3 activity and DNA fragmentation unchanged.  The trends in 
RLuc8:fLuc ratio and intracellular H2O2 reduction with allopurinol pretreatment further 
supported the theory that the RBS is specifically responsive to H2O2 during cell death.  
Also, these results further confirm that H2O2 elevation is a consequence of cell death, 
rather than a catalyst for cell death in STS-treated RBS-MCF7 cells.  
The STS studies on RBS-MCF7 cells were expanded to a time course of 24 hours 
using 10 µM STS.  Under these conditions, the RLuc8:fLuc ratio increased dramatically 
compared to PBS-treated controls.  The intracellular H2O2 levels also increased under this 
conditions while the caspase-3 activity actually peaked at the 6 hour time point and 
returned to control levels by 24 hours.  The TUNEL assay revealed that DNA 
fragmentation remained elevated throughout the entire time course.  These results 
introduced an interesting disparity between caspase-3 activity and DNA fragmentation, 
RBS ratio and intracellular H2O2 levels; namely, caspase-3 activity returned to near-
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control levels while the remaining three parameters remained elevated.  These results 
highlighted how the use of caspase-3 activity as a biomarker for cell death could 
potentially lead to ambiguous findings, due to the transient nature of its activation.  Here, 
the RBS may hold an advantage over traditional cell death assays, since it is capable of 
detecting cell death when caspase activity assays cannot and possesses real-time and in 
vivo capabilities that are not characteristic of the TUNEL assay.  Additionally, the 
correlation between the TUNEL assay and the RBS, even in the absence of caspase 
activity, suggests that the RBS may be able to provide insight on cells undergoing 
caspase-independent PCD. This would not be entirely surprising considering that many 
previous studies have shown that caspase-independent cell death pathways can involve 
ROS(11, 68, 69, 74-76).   
Even though caspase-independent PCD research is gaining in popularity, caspase-
dependent cell death remains a prominent area of interest regarding cancer therapeutics, 
whether by inducing PCD on their own(77-79) or in combination with other drugs(80, 
81).  Two drugs that induce apoptosis in HeLa cells are doxorubicin (DOX, (82)) and 
camptothecin (Cpt, (83)).  When RBS-HeLa cells were treated with 1 µM DOX or 10 µM 
Cpt over the course of 48 hours, the RLuc8:fLuc ratio increased compared to PBS-treated 
controls.  In addition, the intracellular H2O2 levels increased compared to untreated 
control and the RLuc8:fLuc ratio was significantly decreased when the cells were 
pretreated with 100 µM allopurinol (DOX, p<0.05, Cpt, p<0.01).  Parallel caspase 
activity and DNA fragmentation assays indicated that PCD was occurring under DOX 
and Cpt treatment.  The overall increasing trend in RLuc8:fLuc ratio, DNA fragmentation 
and H2O2 levels following DOX- and CPT-treatment suggests that the RBS will likely 
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detect cell death under a vast array of induction methods, since many are accompanied by 
an increase in H2O2 levels.  For example, it has been shown that murine epidermal cells 
treated with vanadate undergo apoptosis and exhibit an increase in intracellular H2O2 
cells(84).  Similarly, apoptosis induced by erbstatin(85), vinblastine and inostamycin(86) 
in human small cell lung carcinoma cells is also accompanied by increased intracellular 
H2O2 levels.   
While the ability of the RBS to detect caspase-dependent PCD should not be 
discounted, it would be interesting to determine whether it would be responsive in 
oxidatively stressed cells that are not undergoing PCD.  This could be accomplished by 
treating RBS-cells with tumor necrosis factor (TNF) alpha or various antioxidant 
inhibitors.  Additionally, expressing the RBS in immune cells, such as neutrophils, that 
exhibit a characteristic ‘oxidative burst’ may provide more insight into the response of 
the RBS to oxidative stress induction.   
8.1.4 The RBS can detect caspase-independent PCD through pathways involving 
ROS production, Bcl-2 downregulation and mitochondrial membrane 
permeabilization 
 Anticancer drug resistance and tumorigenesis have been attributed to the ability of 
certain cancers to evade caspase activation(87, 88).  It is envisioned that cancer 
therapeutics that induce PCD through a caspase-independent mechanism could have 
widespread impact.  The therapeutic need for agents that induce caspase-independent 
PCD gives rise to the necessity of assays that can detect this phenomenon; thus, the RBS 
was examined for its potential to report on caspase-independent PCD. 
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 When RBS-HeLa cells were treated with a dosage range (0-55 µM) of sodium 
selenite (SSe), a compound that has been shown to induce caspase-independent PCD in 
HeLa cells through oxidative stress mediated activation of p53 and p38(89), the 
RLuc8:fLuc ratio increased.  Under the same conditions, caspase-3 remained relatively 
inactive, while intracellular H2O2 and DNA fragmentation levels increased.  RBS-MCF7 
cells were subjected to the same SSe dosage conditions for 48 hours.  The exact pathway 
by which SSe induces caspase-independent PCD in MCF7 cells is unknown, however it 
has been shown to decrease viability in this cell type(90).  Similarly to RBS-HeLa cells, 
the RLuc8:fLuc ratio, intracellular H2O2 levels and DNA fragmentation levels increased, 
while caspase activity remained unchanged, as the SSe dosage increased.  In both of these 
studies, the increase in DNA fragmentation along with the lack of appreciable caspase 
activity show that SSe induces caspase-independent PCD and that it can be detected by 
the RBS.  Also, the correlation between levels of intracellular H2O2 and the RLuc8:fLuc 
ratio suggested that the RBS was responsive to H2O2 in these instances of PCD. 
 To further investigate the detection of caspase-independent PCD by the RBS, 
resveratrol was used as a PCD inducer in RBS-MCF7 cells.  Resveratrol has been shown 
to induce PCD in MCF7 cells through Bcl-2 downregulation, mitochondrial membrane 
permeabilization and ROS production without caspase-3 activation, PARP cleavage or 
cytochrome c release(91).  With increased resveratrol dosage (0-1 mM), the RLuc8:fLuc 
ratio increased, while caspase activity remained unchanged.  Additionally, intracellular 
H2O2 and DNA fragmentation levels increased as the resveratrol dose increased.  Taken 
together, the studies that used SSe and Res further attested to the impact the RBS may 
have on research endeavors involving caspase-independent PCD.  The RBS may be 
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particularly useful in studies involving the targeting of mitochondria in cancer therapy, 
given the reported effects of resveratrol on the mitochondria and the associated increase 
in ROS(91).  In fact, many compounds that target the mitochondria for this purpose 
generate excessive amounts of ROS(92-96).   
 To examine the role of H2O2 in these caspase-independent PCD processes, 
allopurinol was used as an inhibitor for one hour prior to the application of SSe (RBS-
HeLa and RBS-MCF7) and resveratrol (RBS-MCF7).  RBS-HeLa and RBS-MCF7 cells 
pretreated with 100 µM allopurinol for 1 hour prior to treatment with 55 µM SSe 
exhibited significant decreases (p<0.05) in the RLuc8:fLuc ratio and intracellular H2O2 
levels, compared to cells pretreated with PBS.  Similarly, allopurinol pretreatment for 1 
hour prior to 1 mM resveratrol application for 24 hours on RBS-MCF7 cells conferred 
significant (p<0.01) reductions in the RLuc8:fLuc ratio and levels of intracellular H2O2.  
These results provided strong evidence that the RBS is specifically responsive to the 
increasing H2O2 levels seen in SSe/resveratrol-treated cells.   
 Allopurinol pretreatment did not protect either of the cell types from PCD 
compared to PBS pretreatment, as indicated by a TUNEL assay.  Previous reports have 
indicated that the mechanisms of PCD induced by SSe and resveratrol involve ROS in 
some manner(89, 91); however, it is unlikely that H2O2 is the catalyst because its removal 
does not prevent PCD.  These results suggested that increasing levels of H2O2 are thus a 
consequence of cell death.   
 We have shown through extensive testing of multiple compounds on multiple cell 
lines that the RBS may be a useful tool in the development and testing of cancer 
therapeutics designed to induce caspase-independent PCD.  There was a consistent 
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correlation between the RLuc8:fLuc ratio and levels of intracellular H2O2.  Further, the 
RLuc8:fLuc ratio was reduced in drug-treated cells when pretreated with allopurinol.  
The trends reported here suggest that the RBS will likely perform well in a wide range of 
PCD-inducing conditions. 
8.1.5 The RBS detects programmed cell death in vivo 
 We have acquired evidence that the RBS is capable of detecting caspase-
dependent and caspase-independent PCD in multiple cell lines.  Additionally it was 
shown that the response level of the RBS was directly related to intracellular H2O2 levels.  
To test the in vivo imaging capability of the RBS, a murine tumor model was employed. 
 Nude mice bearing RBS-HeLa tumors (n = 3 per group) were imaged at time 0 
hours to obtain fLuc and RLuc8 bioluminescence images.  Immediately following the 
second imaging session, tumors were treated with either PBS or allopurinol as inhibitors 
for one hour prior to PBS or STS administration.  After 24 hours, the animals were 
imaged again.  The animals treated with PBS as an inhibitor and as a drug treatment 
(PBS/PBS) exhibited little change in either RLuc8 or fLuc bioluminescence after 24 
hours.  The group treated with PBS followed by STS (PBS/STS) retained RLuc8 
bioluminescence after 24 hours, while fLuc bioluminescence diminished considerably.  
When tumors were treated with allopurinol followed by PBS (Allo/PBS), the RLuc8 
bioluminescence did not change and fLuc demonstrated a slight increase in 
bioluminescence after 24 hours.  Finally, STS treatment following allopurinol 
pretreatment (Allo/STS) conferred little change in RLuc8 bioluminescence and a slight 
decrease in fLuc bioluminescence after 24 hours.  Following bioluminescence image 
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quantification, it was found that the RLuc8:fLuc ratio increased significantly (p<0.01) for 
the PBS/STS group compared to the PBS/PBS control.  Additionally, the ratio 
significantly decreased (p<0.05) for the Allo/STS group compared to the PBS/STS group.  
These results indicated that the RBS was capable of detecting PCD in vivo.  
 After 24 hours, the tumors treated with Allo/STS exhibited an increase in fLuc 
bioluminescence that was not observed with RLuc8.  This could be attributed to the 
elevated levels of H2O2 within the hypoxic cores of tumors (see (97) for review).  
Intrinsically high levels of H2O2 levels within these tumors were likely reduced after 24 
hours of allopurinol treatment, thus restoring fLuc bioluminescence. 
  In summary, we have shown that the RBS is capable of detecting PCD in vivo 
through a murine tumor model.  Using allopurinol as an inhibitor demonstrated that the 
RBS is likely responsive to intracellular H2O2 levels.  Together with previous in vitro 
results, it is envisioned that the RBS will be a useful tool in research endeavors involving 
caspase-dependent and caspase-independent cell death. 
 
8.2 Future Directions 
 Intracellular H2O2 levels are generally accepted to lie in the nM-µM range, 
depending on health status.  However, the levels of exogenously applied H2O2 in our 
studies were in the mM range. Thus, this concentration discrepancy should be further 
examined.  When we treated both RBS-HeLa cells and purified proteins with the HX-XO 
reaction, we also observed that fLuc activity decreased significantly, while the RLuc8 
activity remained stable.  Interestingly, when the H2O2 concentration generated by this 
 198 
HX-XO reaction was measured using Amplex Red, it was found to be ~5 µM.  The HX-
XO reaction generates H2O2 in a continuous manner, until the compounds are exhausted.  
Conversely, the exogenously applied H2O2 could be degraded over time, which could 
account for the mM levels of H2O2 used to activate the RBS.  It has been shown that 
exogenously applied H2O2 can decrease by ~67% after 20 minutes in fully supplemented 
cell culture medium(98).  To explore this further, additional studies could be performed 
to more accurately quantify H2O2 levels as a function of time during both the HX-XO 
reaction and acute H2O2 application on both cells and purified proteins. 
 The SDS-PAGE and bioluminescence assays performed on purified proteins 
demonstrated that, when treated with H2O2, the fLuc protein exhibited activity loss at a 
higher rate and to a greater extent than protein degradation.  This suggests that the 
oxidative modification of the fLuc protein may be primarily responsible for its activity 
loss and that degradation only occurs at a later stage.  This would be consistent with 
current observations that oxidatively modified/damaged proteins are targeted for 
proteasomal degradation(59, 60, 99).  In order to further examine these processes, a 
Western blot could be performed on PBS and STS-treated RBS-cells that were pretreated 
with PBS or proteasome inhibitors.  It would be expected that the inhibitor pretreated 
STS-treated RBS-cells would exhibit higher fLuc protein levels even if cells under the 
same treatment conditions exhibited low bioluminescence activity. These blots may also 
reveal altered band staining accounting for damage/modification.  The lysates from these 
cells could also be subjected to a protein carbonylation assay to assess the levels of 
carbonyl-derivative formation.  Presumably, these proteins would be carbonylated, but 
not degraded due to proteasome inhibition.  To specifically investigate carbonylation 
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levels of fLuc and RLuc8 in these cells, the carbonylation assay could be performed on 
immunoprecipitated fLuc and RLuc8 proteins. 
While many commercial assays for ROS are unable to be used in animal models 
of disease, they often possess high in vitro sensitivity.  To improve the sensitivity of the 
RBS, additional luciferases (e.g. gaussia, cbRed, cbGreen) or randomly mutated fLuc 
could be examined for their sensitivity to inactivation in stressed cells.  It also may be 
worthwhile to investigate fLuc variants that are engineered to be even less stable than 
wild-type fLuc.  For example, a fLuc variant containing a ‘PEST’ sequence from mouse 
ornithine decarboxylase targets the protein for proteolytic degradation, effectively 
reducing its half-life to less than 1 hour, compared to ~3.5 hours for wild-type fLuc(100).  
The use of this fLuc variant in the RBS could result in a faster stress response given the 
higher rate of protein turnover.   
Intriguingly, the wild-type fLuc sequence from the popular pGL3 basic vector 
(also used in this dissertation) was actually engineered to remove a peroxisomal targeting 
sequence(101) (discovered to be the C-terminal sequence -Ser-Lys-Leu(102)).  It was 
thought the peroxisomal targeting of fLuc could interfere with normal cell functions, 
contribute to its degradation and/or reduce cofactor availability.  With the exception of 
interfering with basic cellular processes, the remaining two consequences could prove to 
be beneficial in the context of the RBS. 
 Additionally, many in vivo assays for PCD in regards to cancer therapeutic 
development occur over many weeks.  Thus if the wild-type fLuc of the RBS was 
replaced with a slightly more stable variant of fLuc, the resulting sensor may prove to be 
more useful in studies of this nature.  We have shown that the fLuc variant, fLuc5, 
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exhibits improved stability over wild-type fLuc, but not to the extent of RLuc8.  
Although further testing is warranted, the combination of fLuc5 and RLuc8 could 
improve upon the functional lifespan of the RBS. 
Even though RLuc8 is 4 times brighter than native RLuc, its emitted wavelength 
of light (480 nm) is greatly attenuated in animal tissue, resulting in low bioluminescence 
signal measurements during in vivo imaging studies.  The RBS sensor may be improved 
by incorporating red-shifted luciferase variants.  Recently, a variant of RLuc8 was 
developed, RLuc8.6, that exhibits a red-shifted bioluminescence compared to both wild-
type RLuc and RLuc8(103).  It is envisioned that this variant could be utilized in the RBS 
in two ways.  First, it could be combined with wild-type fLuc to create essentially a red-
shifted RBS, wherein the bioluminescence signals from fLuc and RLuc8.6 would be 
distinguished by their different substrates, but the RLuc8.6 would likely exhibit less 
signal attenuation in vivo.  A second RBS variant could involve wild-type RLuc and 
RLuc8.6.  In this case, emission filters would be absolutely required in order to 
distinguish the bioluminescence signals from each enzyme as they catalyze the same 
substrate, coelenterazine.  However, the need for only one substrate 
administration/imaging session could save considerable time, reagents and financial 
resources. 
 
 8.3 Concluding remarks 
This body of work involved the development, characterization and 
implementation of an ROS-responsive Ratiometric Bioluminescent Sensor (RBS).  It was 
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hypothesized that the RBS could serve as a metric for intracellular stresses involved in 
PCD, as many instances of PCD are associated with elevated levels of ROS.  While the 
exact mechanism behind the disparity in bioluminescence activity between RLuc8 and 
fLuc has yet to be elucidated, we have shown that ROS, namely H2O2, play a significant 
role.  The RBS was implemented in various models of PCD, both in vitro and in vivo and 
proved to be responsive in any instances of PCD that involved increased ROS levels.  It 
is envisioned that the RBS could prove to be quite useful in research endeavors 
investigating PCD, and its related molecular processes (e.g. oxidative stress).  Ultimately, 
the RBS could have widespread impact in the development, evaluation and/or 
improvement of therapeutics intended to combat many, often devastating pathologies 
related to these molecular processes, such as cancer, Alzheimer’s disease, autoimmune 
disorders, type-2 diabetes and AIDS. 
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